WO2021165847A1 - Purification of saccharides - Google Patents

Purification of saccharides Download PDF

Info

Publication number
WO2021165847A1
WO2021165847A1 PCT/IB2021/051330 IB2021051330W WO2021165847A1 WO 2021165847 A1 WO2021165847 A1 WO 2021165847A1 IB 2021051330 W IB2021051330 W IB 2021051330W WO 2021165847 A1 WO2021165847 A1 WO 2021165847A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
kda
micron
minutes
polysaccharide
Prior art date
Application number
PCT/IB2021/051330
Other languages
English (en)
French (fr)
Inventor
Wei Chen
Ling Chu
Nishith Merchant
Justin Keith Moran
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Priority to CA3171864A priority Critical patent/CA3171864A1/en
Priority to IL295713A priority patent/IL295713A/en
Priority to BR112022015796A priority patent/BR112022015796A2/pt
Priority to KR1020227032647A priority patent/KR20220144393A/ko
Priority to CN202180021155.1A priority patent/CN115362177A/zh
Priority to AU2021224078A priority patent/AU2021224078B2/en
Priority to MX2022010355A priority patent/MX2022010355A/es
Priority to EP21711029.5A priority patent/EP4107192A1/en
Priority to US17/799,992 priority patent/US20230085173A1/en
Publication of WO2021165847A1 publication Critical patent/WO2021165847A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D21/00—Separation of suspended solid particles from liquids by sedimentation
    • B01D21/01—Separation of suspended solid particles from liquids by sedimentation using flocculating agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/145—Ultrafiltration
    • B01D61/146—Ultrafiltration comprising multiple ultrafiltration steps
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the .txt file contains a sequence listing entitled "PC72592_ST25.txt” created on Janauary 29, 2021 and having a size of 34 KB.
  • the sequence listing contained in this .txt file is part of the specification and is incorporated herein by reference in its entirety.
  • the present invention relates to methods for purifying bacterial polysaccharides, in particular for removing impurities from cellular lysates of bacteria producing polysaccharides.
  • Bacterial polysaccharides in particular capsular polysaccharides, are important immunogens found on the surface of bacteria involved in various bacterial diseases. This has led to them being an important component in the design of vaccines. They have proven useful in eliciting immune responses especially when linked to carrier proteins.
  • Bacterial polysaccharides are typically produced by fermentation of the bacteria (e.g. Streptococci (e.g., S. pneumoniae, S. pyogenes, S. agalactiae or Group C & G Streptococci), Staphylococci (e.g., Staphylococcus aureus), Haemophilus, (e.g., Haemophilus influenzae), Neisseria (e.g., Neisseria meningitidis), Escherichia, (e.g., Escherichia coli) and Klebsiella (e.g., Klebsiella pneumoniae).
  • Streptococci e.g., S. pneumoniae, S. pyogenes, S. agalactiae or Group C & G Streptococci
  • Staphylococci e.g., Staphylococcus aureus
  • Haemophilus e.g.,
  • bacterial polysaccharides are produced using batch culture in complex medium, fed batch culture or continuous culture.
  • This invention provides a method for purifying a saccharide derived from bacteria from a solution comprising said saccharide and contaminants following fermentation, wherein said method comprises the following steps: (a) acid hydrolysis; (b) a first u Itrafi Itratio n/d iafiltratio n - (UFDF-1); (b) carbon filtration; (c) chromatography; and (d) a second ultrafiltration/diafiltration- (UFDF-2).
  • the method further comprises a flocculation step following the acid hydrolysis of step (a).
  • the bacteria is a gram positive bacteria.
  • the bacteria is any one of Streptococcus, Staphylococcus, Enterococci, Bacillus, Corynebacterium, Listeria, Erysipelothrix, or Clostridium.
  • the bacteria is any one of Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae, Group C & G Streptococcii or Staphylococcus aureus.
  • the bacteria is a gram negative bacteria.
  • the bacteria is any one of Haemophilus, Neisseria, Escherichia or Klebsiella. In another aspect, the bacteria is Haemophilus influenzae, Neisseria meningitidis, Escherichia coli or Klebsiella pneumoniae.
  • FIG. 1 depicts SEC-HPLC chromatograms for post released K p O-Ag in broth (top) and purified K p O-Ag (bottom) for 01 V1 variant.
  • FIG. 2 depicts SEC-HPLC chromatograms for post released K P O-Ag in broth (top) and purified K p O-Ag (bottom) for 01 V2 variant.
  • FIG. 3 depicts SEC-HPLC chromatograms for post released K p O-Ag in broth (top) and purified K p O-Ag (bottom) for 02V1 variant.
  • FIG. 4 depicts SEC-HPLC chromatograms for post released K p O-Ag in broth (top) and purified K p O-Ag (bottom) for 02V2 variant.
  • This invention provides a method for purifying a saccharide derived from bacteria from a solution comprising said saccharide and contaminants following fermentation, wherein said method comprises the following steps: (a) acid hydrolysis; (b) a first u Itrafi Itratio n/d iafiltratio n - (UFDF-1); (b) carbon filtration; (c) chromatography; and (d) a second ultrafiltration/diafiltration- (UFDF-2).
  • the method further comprises a flocculation step following the acid hydrolysis of step (a).
  • the chromatography of step (c) comprises IEX membrane chromatography or Hydrophobic Interaction Chromatography (HIC) or both.
  • the bacteria is a gram positive bacteria.
  • the bacteria is any one of Streptococcus, Staphylococcus, Enterococci, Bacillus, Corynebacterium, Listeria, Erysipelothrix, or Clostridium.
  • the bacteria is any one of Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae, Group C & G Streptococcii or Staphylococcus aureus.
  • the bacteria is a gram negative bacteria.
  • the bacteria is any one of Haemophilus, Neisseria, Escherichia or Klebsiella. In another aspect, the bacteria is Haemophilus influenzae, Neisseria meningitidis, Escherichia coli or Klebsiella pneumoniae.
  • the bacteria is Escherichia coli comprising a saccharide having a structure selected from any one of Formula 01 , Formula 01 A, Formula 01 B, Formula 01 C, Formula 02, Formula 03, Formula 04, Formula 04:K52, Formula 04:K6, Formula 05, Formula 05ab, Formula O5ao, Formula 06, Formula 06:K2; K13; K15, Formula 06:K54, Formula 07, Formula 08, Formula 09, Formula 010, Formula 011 , Formula 012, Formula 013, Formula 014, Formula 015, Formula 016, Formula 017, Formula 018, Formula 018A, Formula O18ao, Formula 018A1 , Formula 018B, Formula 018B1 , Formula 019, Formula 020, Formula 021 , Formula 022, Formula 023, Formula 023A, Formula 024, Formula 025, Formula 025a, Formula 025b, Formula 026, Formula 027, Formula 028, Formula 029, Formula 030,
  • the bacteria is Klebsiella pneumoniae comprising a saccharide having a structure selected from any one of Formula K.01.1 , Formula K.01 .2, Formula K.01.3, Formula K.01.4, Formula K.02.1 , Formula K.02.2, Formula K.02.3, Formula K.02.4, Formula K.03, Formula K.04, Formula K.05, Formula K.07, Formula K.012 or Formula K.08.
  • the methods of the invention can be used to purify bacterial polysaccharides from a solution comprising said polysaccharides together with contaminants.
  • the sources of bacterial polysaccharide to be purified according to this invention are bacterial cells, in particular pathogenic bacteria.
  • Non-limiting examples of gram-positive bacteria for use according to this invention are Streptococcus (e.g., S. pneumoniae, S. pyogenes, S. agalactiae or Group C & G Streptococci), Staphylococcus (e.g., Staphylococcus aureus), Enterococci, Bacillus, Corynebacterium, Listeria, Erysipelothrix, and Clostridium.
  • Streptococcus e.g., S. pneumoniae, S. pyogenes, S. agalactiae or Group C & G Streptococci
  • Staphylococcus e.g., Staphylococcus aureus
  • Enterococci Bacillus, Corynebacterium, Listeria, Erysipelothrix, and Clostridium.
  • Non-limiting examples of gram-negative bacteria for use with this invention include Haemophilus, (e.g., Haemophilus influenzae), Neisseria (e.g., Neisseria meningitidis), Escherichia, (e.g., Escherichia coli) and Klebsiella (e.g., Klebsiella pneumoniae).
  • Haemophilus e.g., Haemophilus influenzae
  • Neisseria e.g., Neisseria meningitidis
  • Escherichia e.g., Escherichia coli
  • Klebsiella e.g., Klebsiella pneumoniae.
  • the source of bacterial polysaccharides for use according to this invention is selected from the group consisting of Aeromonas hydrophila and other species (spp.); Bacillus anthracis; Bacillus cereus ; Botulinum neurotoxin-producing species of Clostridium ⁇ , Brucella abortus; Brucella melitensis; Brucella suis; Burkholderia mallei (formally Pseudomonas mallei) ⁇ , Burkholderia pseudomallei (formerly Pseudomonas pseudomallei) ⁇ , Campylobacter jejuni; Chlamydia psittaci; Chlamydia trachomatis, Clostridium botulinum; Clostridium pulpe; Clostridium perfringens; Coccidioides immitis; Coccidioides posadasii; Cowdria ruminantium (Headwater); Coxiella burnetii; Enterococcus f
  • a polysaccharide desired for purification may be associated with a cellular component, such as a cell wall.
  • Association with the cell wall means that the polysaccharide is a component of the cell wall itself, and/or is attached to the cell wall, either directly or indirectly via intermediary molecules, or is a transient coating of the cell wall (for example, certain bacterial strains exude capsular polysaccharides, also known in the art as 'exopolysaccharides').
  • the polysaccharide extracted from the bacteria is a capsular polysaccharide, a sub-capsular polysaccharide, or a lipopolysaccharide.
  • the polysaccharide is a capsular polysaccharide.
  • the source of bacterial capsular polysaccharide is Escherichia coli.
  • the source of bacterial capsular polysaccharide is an Escherichia coli part of the Enterovirulent Escherichia coli group (EEC Group) such as Escherichia coli - enterotoxigenic (ETEC), Escherichia coli - enteropathogenic (EPEC), Escherichia coli - 0157:H7 enterohemorrhagic (EHEC), or Escherichia coli - entero invasive (EIEC).
  • ETEC Escherichia coli - enterotoxigenic
  • EPEC Escherichia coli - enteropathogenic
  • EHEC Escherichia coli - 0157:H7 enterohemorrhagic
  • EIEC Escherichia coli - entero invasive
  • the source of bacterial capsular polysaccharide is an Uropathogenic Escherichia coli
  • the source of bacterial capsular polysaccharide is an Escherichia coli serotype selected from the group consisting of serotypes 0157:H7, 026:1-111 ,
  • the source of bacterial capsular polysaccharide is an Escherichia coli serotype selected from the group consisting of serotypes 06:K2:H1 and 018:K1 :H7. In an embodiment, the source of bacterial capsular polysaccharide is an Escherichia coli serotype selected from the group consisting of serotypes 045:K1 ,
  • the source of bacterial capsular polysaccharide is an Escherichia coli serotype O104:H4. In an embodiment, the source of bacterial capsular polysaccharide is an Escherichia coli serotype 01 :K12:H7. In an embodiment, the source of bacterial capsular polysaccharide is an Escherichia coli serotype 0127:H6. In an embodiment, the source of bacterial capsular polysaccharide is an Escherichia coli serotype 0139:H28. In an embodiment, the source of bacterial capsular polysaccharide is an Escherichia coli serotype 0128:H2.
  • the source of bacterial capsular polysaccharides is Neisseria meningitidis.
  • the source of bacterial capsular polysaccharides is N. meningitidis serogroup A (MenA), N. meningitidis serogroup W135 (MenW135), N. meningitidis serogroup Y (MenY), N. meningitidis serogroup X (MenX) or N. meningitidis serogroup C (MenC).
  • the source of bacterial capsular polysaccharides is N. meningitidis serogroup A (MenA).
  • the source of bacterial capsular polysaccharides is N.
  • the source of bacterial capsular polysaccharides is N. meningitidis serogroup Y (MenY). In an embodiment the source of bacterial capsular polysaccharides is N. meningitidis serogroup C (MenC). In an embodiment the source of bacterial capsular polysaccharides is N. meningitidis serogroup X (MenX).
  • the source of bacterial capsular polysaccharides is Klebsiella pneumoniae.
  • the source of bacterial capsular polysaccharides is K. pneumoniae serogroup 01 (01), K. pneumoniae serogroup 02 (02), K. pneumoniae serogroup 02ac (02ac), K. pneumoniae serogroup 03 (03), K. pneumoniae serogroup 04 (04), K. pneumoniae serogroup 05 (05), K. pneumoniae serogroup 07 (07), K. pneumoniae serogroup 08 (08) or K. pneumoniae serogroup 09 (09).
  • the source of bacterial capsular polysaccharides is K. pneumoniae serogroup 01 (01).
  • the source of bacterial capsular polysaccharides is K.
  • the source of bacterial capsular polysaccharides is K. pneumoniae serogroup 02ac (02ac). In an embodiment the source of bacterial capsular polysaccharides is K. pneumoniae serogroup 03 (03). In an embodiment the source of bacterial capsular polysaccharides is K. pneumoniae serogroup 04 (04). In an embodiment the source of bacterial capsular polysaccharides is K. pneumoniae serogroup 05 (05). In an embodiment the source of bacterial capsular polysaccharides is K. pneumoniae serogroup 07 (07). In an embodiment the source of bacterial capsular polysaccharides is K. pneumoniae serogroup 08 (08). In an embodiment the source of bacterial capsular polysaccharides is K. pneumoniae serogroup 09 (09).
  • the polysaccharides are produced by growing the bacteria in a medium (e.g. a solid or preferably a liquid medium).
  • a medium e.g. a solid or preferably a liquid medium.
  • the polysaccharides are then prepared by treating the bacterial cells.
  • the starting material for methods of the present invention is a bacterial culture and preferably a liquid bacterial culture (e.g. a fermentation broth).
  • the bacterial culture is typically obtained by batch culture, fed batch culture or continuous culture (see e.g. WO 2007/052168 or WO 2009/081276).
  • continuous culture fresh medium is added to a culture at a fixed rate and cells and medium are removed at a rate that maintains a constant culture volume.
  • the population of the organism is often scaled up from a seed vial to seed bottles and passaged through one or more seed fermentors of increasing volume until production scale fermentation volumes are reached.
  • the starting material may thus be the supernatant from a centrifuged bacterial culture.
  • the starting material will be prepared by treating the bacteria themselves, such that the polysaccharide is released.
  • the bacterial cells are deactivated. This is particularly the case when pathogenic bacteria are used.
  • a suitable method for deactivation is for example treatment with phenoLethanol, e.g. as described in Fattom etal. (1990) Infect Immun. 58(7):2367-74.
  • the bacterial cells may be previously deactivated or not deactivated.
  • Polysaccharides can be released from bacteria by various methods, including chemical, physical or enzymatic treatment (see e.g.; W02010151544, WO 2011/051917 or W02007084856).
  • the bacterial cells (deactivated or not deactivated) are treated in suspension in their original culture medium.
  • the process may therefore start with the cells in suspension in their original culture medium.
  • the bacterial cells are centrifuged prior to release of capsular polysaccharide.
  • the process may therefore start with the cells in the form of a wet cell paste.
  • the cells are treated in a dried form.
  • the bacterial cells are resuspended in an aqueous medium that is suitable for the next step in the process, e.g. in a buffer or in distilled water.
  • the cells may be washed with this medium prior to re-suspension.
  • the bacterial cells are treated with a lytic agent.
  • a “lytic agent” is any agent that aids in cell wall breakdown.
  • the lytic agent is a detergent.
  • the term “detergent” refers to any anionic or cationic detergent capable of inducing lysis of bacterial cells.
  • detergents for use within the methods of the present invention include deoxycholate sodium (DOC), N-lauryl sarcosine (NLS), chenodeoxycholic acid sodium, and saponins (see WO 2008/118752 pages 13 lines 14 to page 14 line 10).
  • the lytic agent used for lysing bacterial cells is DOC.
  • the lytic agent is a non-animal derived lytic agent.
  • the non-animal derived lytic agent is selected from the group consisting of decanesulfonic acid, tert-octylphenoxy 5 poly(oxyethylene)ethanols (e.g. IGEPAL CA-630, CAS #: 9002-93-1 , available from Sigma Aldrich, St. Louis, MO), octylphenol ethylene oxide condensates (e.g. TRITON X-100, available from Sigma Aldrich, St.
  • NLS N-lauryl sarcosine sodium
  • lauryl iminodipropionate sodium dodecyl sulfate, chenodeoxycholate, hyodeoxycholate, glycodeoxycholate, taurodeoxycholate, taurochenodeoxycholate, and cholate.
  • the non-animal derived lytic agent is NLS.
  • the bacterial cells are enzymatically treated such that the polysaccharide is released.
  • the bacterial cells are treated by an enzyme selected from the group consisting of lysostaphin, mutanolysin b-N- acetylglucosaminidase and a combination of mutanolysin and b- N- acetylglucosaminidase.
  • the bacterial cells are treated by a type II phosphodiesterase (PDE2).
  • PDE2 type II phosphodiesterase
  • the enzyme(s) is/are deactivated.
  • a suitable method for deactivation is, for example, heat treatment or acidic treatment.
  • the bacterial cells e.g. in suspension in their original culture medium, in the form of a wet cell paste, in a dried form or resuspended in an aqueous medium after centrifugation
  • the bacterial cells are autoclaved such that the polysaccharide is released.
  • the bacterial cells e.g. in suspension in their original culture medium, in the form of a wet cell paste, in a dried form or resuspended in an aqueous medium after centrifugation
  • the chemical treatment can be, for example, hydrolysis using base or acid (see e.g. W02007084856).
  • the bacterial cells chemical treatment is base extraction (e.g., using sodium hydroxide).
  • Base extraction can cleave the phosphodiester linkage between the capsular saccharide and the peptidoglycan backbone.
  • the base is selected from the group consisting of NaOH, KOH, LiOH, NaHC03, Na2C03, KzC03, KCN, Et3N, NH3, HzN2H2, NaH, NaOMe, NaOEt and KOtBu.
  • the reaction mixture may be neutralised. This may be achieved by the addition of an acid.
  • the reaction mixture is neutralised by an acid selected from the group consisting of HCI, H3PO4, citric acid, acetic acid, nitrous acid, and sulfuric acid.
  • the bacterial cells chemical treatment is acid treatment (e.g., sulfuric acid).
  • the acid is selected from the group consisting of HCI, H3PO4, citric acid, acetic acid, nitrous acid, and sulfuric acid.
  • the reaction mixture may be neutralised. This may be achieved by the addition of a base.
  • the reaction mixture is neutralised by a base selected from the group consisting of NaOH, KOH, LiOH, NaHC03, Na2C03, KzC03, KCN, Et3N, NH3, HzN2H2, NaH, NaOMe, NaOEt and KOtBu.
  • the methods of the invention comprise a flocculation step.
  • the inventors have found that the process is quick and simple and results in a purified polysaccharide with low contamination.
  • the solution obtained by any of the methods of section 1 .1 above is treated by flocculation.
  • the term “flocculation” refers to a process wherein colloids come out of suspension in the form of floe or flake due to the addition of a flocculating agent.
  • the flocculation step comprises adding a “flocculating agent” to a solution comprising bacterial polysaccharides together with contaminants.
  • the contaminants comprise bacterial cell debris, bacterial cell proteins and nucleic acids.
  • the contaminants comprise bacterial cell proteins and nucleic acids.
  • the flocculation step may further include adjustment of the pH, either before or after the addition of the flocculating agent.
  • the solution may be acidified.
  • the addition of the flocculating agent and/or the adjustment of the pH may be performed at a temperature adjusted to a desirable level.
  • the solution may be held for some time to allow settling of the floes prior to downstream processing.
  • a “flocculating agent” refers to an agent being capable of allowing or promoting flocculation, in a solution comprising a polysaccharide of interest together with contaminants, by causing colloids and other suspended particles to aggregate in the form of floe or flake, while the polysaccharide of interest stays in solution.
  • the flocculating agent comprises a multivalent cation.
  • the flocculating agent is a multivalent cation.
  • said multivalent cation is selected from the group consisting of aluminium, iron, calcium and magnesium.
  • the flocculating agent is a mixture of at least two multivalent cations selected from the group consisting of aluminium, iron, calcium and magnesium.
  • the flocculating agent is a mixture of at least three multivalent cations selected from the group consisting of aluminium, iron, calcium and magnesium.
  • the flocculating agent is a mixture of four multivalent cations consisting of aluminium, iron, calcium and magnesium.
  • the flocculating agent comprises an agent selected from the group consisting of alum (e.g. potassium alum, sodium alum or ammonium alum), aluminium chlorohydrate, aluminium sulphate, calcium oxide, calcium hydroxide, iron(ll) sulphate (ferrous sulphate), iron(lll) chloride (ferric chloride), polyacrylamide, modified polyacrylamides, polyDADMAC, polyethylenimine (PEI), sodium aluminate and sodium silicate.
  • alum e.g. potassium alum, sodium alum or ammonium alum
  • aluminium chlorohydrate aluminium sulphate
  • calcium oxide calcium hydroxide
  • iron(ll) sulphate iron(lll) chloride
  • ferrric chloride iron(lll) chloride
  • polyacrylamide modified polyacrylamides
  • polyDADMAC polyethylenimine
  • PEI polyethylenimine
  • sodium aluminate and sodium silicate e.g.
  • the flocculating agent is polyethylenimine (PEI).
  • the flocculating agent comprises alum.
  • the flocculating agent is alum.
  • the flocculating agent comprises potassium alum.
  • the flocculating agent comprises sodium alum.
  • the flocculating agent is sodium alum.
  • the flocculating agent comprises ammonium alum.
  • the flocculating agent is ammonium alum.
  • the flocculating agent is a mixture of agents (e.g. two, three or four agents) selected from the group consisting of alum (e.g. potassium alum, sodium alum or ammonium alum), aluminium chlorohydrate, aluminium sulphate, calcium oxide, calcium hydroxide, iron(ll) sulphate (ferrous sulphate), iron(lll) chloride (ferric chloride), polyacrylamide, modified polyacrylamides, polyDADMAC, polyethylenimine (PEI), sodium aluminate and sodium silicate.
  • the flocculating agent is selected from the group consisting of alum (e.g.
  • potassium alum sodium alum or ammonium alum
  • aluminium chlorohydrate aluminium sulphate, calcium oxide, calcium hydroxide, iron(ll) sulphate (ferrous sulphate), iron(lll) chloride (ferric chloride), polyacrylamide, modified polyacrylamides, polyDADMAC, sodium aluminate and sodium silicate.
  • the flocculating agent is a mixture of two agents selected from the group consisting of alum (e.g. potassium alum, sodium alum or ammonium alum), aluminium chlorohydrate, aluminium sulphate, calcium oxide, calcium hydroxide, iron(ll) sulphate (ferrous sulphate), iron(lll) chloride (ferric chloride), polyacrylamide, modified polyacrylamides, polyDADMAC, sodium aluminate and sodium silicate.
  • the flocculating agent is a mixture of at least three agents selected from the group consisting of alum (e.g.
  • potassium alum sodium alum or ammonium alum
  • aluminium chlorohydrate aluminium sulphate, calcium oxide, calcium hydroxide, iron(ll) sulphate (ferrous sulphate), iron(lll) chloride (ferric chloride), polyacrylamide, modified polyacrylamides, polyDADMAC, sodium aluminate and sodium silicate.
  • the flocculating agent comprises an agent selected from the group consisting of chitosan, isinglass, moringa oleifera seeds (Horseradish Tree), gelatin, strychnos potatorum seeds (Nirmali nut tree), guar gum and alginates (e.g. brown seaweed extracts).
  • the flocculating agent is selected from the group consisting of chitosan, isinglass, moringa oleifera seeds (Horseradish Tree), gelatin, strychnos potatorum seeds (Nirmali nut tree), guar gum and alginates (e.g. brown seaweed extracts).
  • the concentration of flocculating agent may depend on the agent(s) used, the polysaccharide of interest and the parameter of the flocculation step (e.g. temperature).
  • a concentration of flocculating agent of between about 0.1 and 20 % (w/v) can be used.
  • a concentration of flocculating agent of between about 0.5 and 10 % (w/v) is used.
  • a concentration of flocculating agent of between about 1 and 5 % (w/v) is used. Any number within any of the above ranges is contemplated as an embodiment of the disclosure.
  • a concentration of flocculating agent of about 0.5% (w/v), about 1.0% (w/v), about 1.5% (w/v), about 2.0% (w/v), about 2.5% (w/v), about 3.0%
  • a concentration of flocculating agent of about 1.0% (w/v), about 1.5% (w/v), about 2.0% (w/v), about 2.5% (w/v), about 3.0% (w/v), about 3.5% (w/v) or about 4.0% (w/v) is used.
  • the flocculating agent is added over a certain period of time. In some embodiments of the present invention, the flocculating agent is added over a period of between a few seconds (e.g. 1 to 10 seconds) and about one month. In some embodiments the flocculating agent is added over a period of between about 2 seconds and about two weeks. In some embodiments of the present invention, the flocculating agent is added over a period of between about 1 minute and about one week.
  • the flocculating agent is added over a period of between about 1 minute, about 5 minutes, about 10 minutes, about 15 minutes, about 20 minutes , about 25 minutes, about 30 minutes, about 35 minutes, about 40 minutes, about 45 minutes, about 50 minutes, about 55 minutes, about 60 minutes, about 65 minutes, about 70 minutes, about 80 minutes, about 85 minutes, about 90 minutes, about 95 minutes, about 100 minutes, about 110 minutes, about 120 minutes, about 130 minutes, about 140 minutes, about 150 minutes, about 160 minutes, about 170 minutes, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 11 hours, about 12 hours, about 13 hours, about 14 hours, about 15 hours, about 16 hours, about 17 hours, about 18 hours, about 19 hours, about 20 hours, about 21 hours, about 22 hours, about 23 hours or about 24 hours and about two days.
  • the flocculating agent is added over a period of between about 5 minutes, about 10 minutes, about 15 minutes, about 20 minutes, about 25 minutes, about 30 minutes, about 35 minutes, about 40 minutes, about 45 minutes, about 50 minutes, about 55 minutes, about 60 minutes, about 65 minutes, about 70 minutes, about 80 minutes, about 85 minutes, about 90 minutes, about 95 minutes, about 100 minutes, about 110 minutes, about 120 minutes, about 130 minutes, about 140 minutes, about 150 minutes, about 160 minutes, about 170 minutes, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 11 hours or about 12 hours and about one day.
  • the flocculating agent is added over a period of between about 15 minutes, about 20 minutes , about 25 minutes, about 30 minutes, about 35 minutes, about 40 minutes, about 45 minutes, about 50 minutes, about 55 minutes, about 60 minutes, about 65 minutes, about 70 minutes, about 80 minutes, about 85 minutes, about 90 minutes, about 95 minutes, about 100 minutes, about 110 minutes, about 120 minutes, about 130 minutes, about 140 minutes, about 150 minutes, about 160 minutes, about 170 minutes, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 11 hours or about 12 hours and about one day.
  • the flocculating agent is added over a period of between about 15 minutes and about 3 hours. In certain embodiments the flocculating agent is added over a period of between about 30 minutes and about 120 minutes.
  • the flocculating agent may be added over a period of about 2 seconds, about 10 seconds, about 30 seconds, about 1 minute, about 5 minutes, about 10 minutes, about 15 minutes, about 20 minutes, about 25 minutes, about 30 minutes, about 35 minutes, about 40 minutes, about 45 minutes, about 50 minutes, about 55 minutes, about 60 minutes, about 65 minutes, about 70 minutes, about 75 minutes, about 80 minutes, about 85 minutes, about 90 minutes, about 95 minutes, about 100 minutes, about 105 minutes, about 110 minutes, about 115 minutes, about 120 minutes, about 125 minutes, about 130 minutes, about 135 minutes, about 140 minutes, about 145 minutes, about 150 minutes, about 155 minutes, about 160 minutes, about 170 minutes, about 3 hours, about 3.5 hours, about 4 hours, about
  • the flocculating agent is added without agitation. In another embodiment, the flocculating agent is added under agitation. In another embodiment, the flocculating agent is added under gentle agitation. In another embodiment, the flocculating agent is added under vigorous agitation.
  • the inventors have further surprisingly noted that the flocculation is improved when performed at an acidic pH.
  • the flocculation step is performed at a pH below 7.0, 6.0, 5.0 or 4.0.
  • the flocculation step is performed at a pH between 7.0 and 1 .0.
  • the flocculation step is performed at a pH between 5.5 and 2.5, 5.0 and 2.5, 4.5 and 2.5, 4.0 and 2.5, 5.5 and 3.0, 5.0 and 3.0, 4.5 and 3.0, 4.0 and 3.0, 5.5 and 3.5, 5.0 and 3.5, 4.5 and 3.5 or 4.0 and 3.5.
  • the flocculation step is performed at a pH of about 5.5, about 5.0, about 4.5, about 4.0, about 3.5, about 3.0, about 2.5, about 2.0, about 1 .5 or about 1 .0. In an embodiment, the flocculation step is performed at a pH of about 4.0, about 3.5, about 3.0 or about 2.5. In an embodiment, the flocculation step is performed at a pH of about 3.5. Any number within any of the above ranges is contemplated as an embodiment of the disclosure.
  • said acidic pH is obtained by acidifying the solution obtained by any of the method of section 1.1 above or further clarified as disclosed at section 1.2 with an acid.
  • said acid is selected from the group consisting of HCI, H3PO4, citric acid, acetic acid, nitrous acid, and sulfuric acid.
  • said acid is an amino acid.
  • said acid is an amino acid selected from the group consisting of glycine, alanine and glutamate.
  • said acid is HCI (hydrochloric acid).
  • said acid is sulfuric acid.
  • the acid is added is without agitation.
  • the acid is added is under agitation.
  • the acid is added under gentle agitation.
  • the acid is added under vigorous agitation.
  • the solution is hold for some time to allow settling of the floes prior to downstream processing.
  • the flocculation step is performed with a settling time of between a few seconds (e.g. 2 to 10 seconds) to about 1 minute.
  • the settling time is at least about 2, at least about 3, at least about 4, at least about 5, at least about 10, at least about 15, at least about 20, at least about 25, at least about 30, at least about 35, at least about 40, at least about 45, at least about 50, at least about 55, at least about 60, at least about 65, at least about 70, at least about 75, at least about 80, at least about 85, at least about 90, at least about 95, at least about 100, at least about 105, at least about 110, at least about 115, at least about 120, at least about 125, at least about 130, at least about 135, at least about 140, at least about 145, at least about 150, at least about 155 or at least about 160 minutes.
  • the settling time is less than a week, however the settling time maybe longer.
  • the settling time is between about 1 , about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 15, about 20, about 25, about 30, about 40, about 50, about 60, about 70, about 80, about 90, about 100, about 120, about 140, about 160, about 180, about 220, about 240, about 300, about 360, about 420, about 480, about 540, about 600, about 660, about 720, about 780, about 840, about 900, about 960, about 1020, about 1080, about 1140, about 1200, about 1260, about 1320, about 1380, about 1440 minute(s), about two days, about three days, about four days, about five days or about six days and 1 week.
  • the settling time is between a few seconds (e.g.
  • the settling time is between about 2 seconds and about two weeks. In some embodiments of the present invention, the settling time is between between about 1 minute and about one week. In some embodiments the settling time is between about 1 minute, about 5 minutes, about 10 minutes, about 15 minutes, about 20 minutes , about 25 minutes, about 30 minutes, about 35 minutes, about 40 minutes, about 45 minutes, about 50 minutes, about 55 minutes, about 60 minutes, about 65 minutes, about 70 minutes, about 80 minutes, about 85 minutes, about 90 minutes, about 95 minutes, about 100 minutes, about 110 minutes, about 120 minutes, about 130 minutes, about 140 minutes, about 150 minutes, about 160 minutes, about 170 minutes, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 11 hours, about 12 hours, about 13 hours, about 14 hours, about 15 hours, about 16 hours, about 17 hours, about 18 hours, about 19 hours, about 20 hours, about 21 hours, about 22 hours, about 23 hours
  • the settling time is between about 5 minutes, about 10 minutes, about 15 minutes, about 20 minutes, about 25 minutes, about 30 minutes, about 35 minutes, about 40 minutes, about 45 minutes, about 50 minutes, about 55 minutes, about 60 minutes, about 65 minutes, about 70 minutes, about 80 minutes, about 85 minutes, about 90 minutes, about 95 minutes, about 100 minutes, about 110 minutes, about 120 minutes, about 130 minutes, about 140 minutes, about 150 minutes, about 160 minutes, about 170 minutes, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 11 hours or about 12 hours and about one day.
  • the settling time is between about 15 minutes, about 20 minutes , about 25 minutes, about 30 minutes, about 35 minutes, about 40 minutes, about 45 minutes, about 50 minutes, about 55 minutes, about 60 minutes, about 65 minutes, about 70 minutes, about 80 minutes, about 85 minutes, about 90 minutes, about 95 minutes, about 100 minutes, about 110 minutes, about 120 minutes, about 130 minutes, about 140 minutes, about 150 minutes, about 160 minutes, about 170 minutes, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 11 hours or about 12 hours and about one day.
  • the settling time is between about 15 minutes and about 3 hours. In certain embodiments the settling time is between about 30 minutes and about 120 minutes.
  • the settling time is about 2 seconds, about 10 seconds, about 30 seconds, about 1 minute, about 5 minutes, about 10 minutes, about 15 minutes, about 20 minutes, about 25 minutes, about 30 minutes, about 35 minutes, about 40 minutes, about 45 minutes, about 50 minutes, about 55 minutes, about 60 minutes, about 65 minutes, about 70 minutes, about 75 minutes, about 80 minutes, about 85 minutes, about 90 minutes, about 95 minutes, about 100 minutes, about 105 minutes, about 110 minutes, about 115 minutes, about 120 minutes, about 125 minutes, about 130 minutes, about 135 minutes, about 140 minutes, about 145 minutes, about 150 minutes, about 155 minutes, about 160 minutes, about 170 minutes, about 3 hours, about 3.5 hours, about 4 hours, about 4.5 hours, about 5 hours, about
  • the settling time is between about 5, about 10, about 15, about 20, about 25, about 30, about 60, about 90, about 120, about 180, about 220, about 240, about 300, about 360, about 420, about 480, about 540, about 600, about 660, about 720, about 780, about 840, about 900, about 960, about 1020, about 1080, about 1140, about 1200, about 1260, about 1320, about 1380 or about 1440 minute(s) and two days.
  • the settling time is between about 5 minutes and about one day. In certain embodiments the settling time is between about 5 minutes and about 120minutes.
  • the settling time may be about 5 minutes, about 10 minutes, about 15 minutes, about 20 minutes, about 25 minutes, about 30 minutes, about 35 minutes, about 40 minutes, about 45 minutes, about 50 minutes, about 55 minutes, about 60 minutes, about 65 minutes, about 70 minutes, about 75 minutes, about 80 minutes, about 85 minutes, about 90 minutes, about 95 minutes, about 100 minutes, about 105 minutes, about 110 minutes, about 115 minutes, about 120 minutes, about 125 minutes, about 130 minutes, about 135 minutes, about 140 minutes, about 145 minutes, about 150 minutes, about 155 minutes or about 160 minutes. Any number within any of the above ranges is contemplated as an embodiment of the disclosure.
  • the optional settling step is conducted without agitation. In an embodiment, the optional settling step is conducted under agitation. In another embodiment, the optional settling step is conducted under gentle agitation. In another embodiment, the optional settling step is conducted under vigorous agitation.
  • the addition of the flocculating agent, the settling of the solution and/or the adjustment of the pH is performed at a temperature between about 4°C and about 30°C.
  • the addition of the flocculating agent, the settling of the solution and/or the adjustment of the pH is performed at a temperature of about 4°C, about 5°C, about 6°C, about 7°C, about 8°C, about 9°C, about 10°C, about 11 °C, about 12°C, about 13°C, about 14°C, about 15°C, about 16°C, about 17°C, about 18°C, about 19°C, about 20°C, about 21 °C, about 22°C, about 23°C, about 24°C, about 25°C, about 26°C, about 27°C, about 28°C, about 29°C or about 30°C.
  • the addition of the flocculating agent, the settling of the solution and/or the adjustment of the pH is performed at a temperature of about 20°C.
  • the inventors have surprisingly noted that the flocculation can be further improved when performed at elevated temperature. Therefore, in a particular embodiment of the present invention, the addition of the flocculating agent, the settling of the solution and/or the adjustment of the pH is performed at temperature between about 30°C to about 95°C.
  • the addition of the flocculating agent, the settling of the solution and/or the adjustment of the pH is performed at a temperature between about 35°C to about 80°C, at temperature between about 40°C to about 70°C, at temperature between about 45°C to about 65°C, at temperature between about 50°C to about 60°C, at temperature between about 50°C to about 55°C, at temperature between about 45°C to about 55°C or at temperature between about 45°C to about 55°C.
  • the addition of the flocculating agent, the settling of the solution and/or the adjustment of the pH is performed at a temperature of about 35°C, about 36°C, about 37°C, about 38°C, about 39°C, about 40°C, about 41 °C, about 42°C, about 43°C, about 44°C, about 45°C, about 46°C, about 47°C, about 48°C, about 49°C, about 50°C, about 51 °C, about 52°C, about
  • the addition of the flocculating agent, the settling of the solution and/or the adjustment of the pH is performed at a temperature of about 50°C.
  • the addition of the flocculating agent is perfomed at any of the above mentioned temperatures. In an embodiment, the settling of the solution after the addition of the flocculating agent is performed at any of the above mentioned temperatures.
  • the adjustment of the pH is performed at any of the above mentioned temperatures.
  • the addition of the flocculating agent and the settling of the solution after the addition of the flocculating agent are performed at any of the above mentioned temperatures.
  • the addition of the flocculating agent and the adjustment of the pH are performed at any of the above mentioned temperatures.
  • the addition of the flocculating, the settling of the solution after the addition of the flocculating agent and the adjustment of the pH are performed at any of the above mentioned temperatures.
  • the flocculation step comprises adding a flocculating agent (as disclosed above) without pH adjustement.
  • the flocculation step comprises adding a flocculating agent and settling the solution (as disclosed above), without pH adjustement.
  • the flocculation step comprises adding a flocculating agent, adjusting the pH and settling the solution (as disclosed above).
  • the flocculating agent is added before adjusting the pH.
  • the pH is adjusted before adding the flocculating agent.
  • the flocculation step comprises adding a flocculating agent, settling the solution and adjusting the pH (as disclosed above).
  • the addition of flocculating agent and settling of the solution is conducted before adjusting the pH.
  • the pH is adjusted before adding the flocculating agent and settling the solution.
  • the addition of the flocculating agent and adjusting the pH is conducted before settling the solution.
  • the pH is adjusted before adding the flocculating agent and settling the solution.
  • the flocculation step comprises adding a flocculating agent, adjusting the pH and adjustment of the temperature (as disclosed above).
  • the solution may be hold for some time to allow settling of the floes prior to downstream processing.
  • the flocculated material can be separated from the polysaccharide of interest by any suitable solid / liquid separation method.
  • the suspension (as obtained at section 1.2 above) is clarified by decantation, sedimentation, filtration or centrifugation.
  • the polysaccharide-containing solution is then collected for storage and/or additional processing.
  • the suspension (as obtained at section 1.2 above) is clarified by decantation.
  • Decanters are used to separate liquids where there is a sufficient difference in density between the liquids for the floe to settle. In an operating decanter there will be three distinct zones: clear heavy liquid, separating dispersed liquid (the dispersion zone), and clear light liquid. To produce a clean solution, a small amount of solution must generally be left in the container. Decanters can be designed for continuous operation.
  • the suspension (as obtained at section 1.2 above) is clarified by sedimentation (settling).
  • Sedimentation is the separation of suspended solid particles from a liquid mixture by gravity settling into a clear fluid and a slurry of higher solids content. Sedimentation can be done in a thickener, in a clarifier or in a classifier. Since thickening and clarification are relatively cheap processes when used for the treatment of large volumes of liquid, they can be used for pre-concentration of feeds to filtering.
  • the suspension (as obtained at section 1.2 above) is clarified by centrifugation.
  • said centrifugation is continuous centrifugation.
  • said centrifugation is bucket centrifugation.
  • the polysaccharide-containing supernatant is then collected for storage and/or additional processing.
  • the suspension is centrifuged at about 1 ,000 g about 2,000 g , about 3,000 g , about 4,000 g, about 5,000 g, about 6,000 g, about 8,000 g, about 9,000 g, about 10,000 g, about 11 ,000 g, about 12,000 g, about 13,000 g, about 14,000 g, about 15,000 g, about
  • the suspension is centrifuged at about 8,000 g, about 9,000 g, about 10,000 g, about 11 ,000 g, about 12,000 g, about 13,000 g, about 14,000 g, about 15,000 g, about 16,000 g, about 17,000 g, about 18,000 g, about 19,000 g, about 20,000 g or about 25,000 g.
  • the suspension is centrifuged between about 5,000 g and about 25,000 g. In some embodiments the suspension is centrifuged between about 8,000 g and about 20,000 g. In some embodiments the suspension is centrifuged between about 10,000 g and about 15,000 g. In some embodiments the suspension is centrifuged between about 10,000 g and about 12,000 g.
  • the suspension is centrifuged during at least 2, at least 3, at least
  • centrifugation time is less than 24 hours.
  • the suspension is centrifuged during between about
  • the suspension is centrifuged during between about 5, about 10, about 15, about 20, about 25, about 30, about 60, about 90, about 120, about 180, about 240, about 300, about 360, about 420, about 480 or about 540 minutes and about 600 minutes. In certain embodiments the suspension is centrifuged during between about 5 minutes and about 3 hours. In certain the suspension is centrifuged during between about 5 minutes and about 120 minutes.
  • the suspension may be centrifuged during between about 5 minutes, about 10 minutes, about 15 minutes, about 20 minutes, about 25 minutes, about 30 minutes, about 35 minutes, about 40 minutes, about 45 minutes, about 50 minutes, about 55 minutes, about 60 minutes, about 65 minutes, about 70 minutes, about 75 minutes, about 80 minutes, about 85 minutes, about 90 minutes, about 95 minutes, about 100 minutes, about 105 minutes, about 110 minutes, about 115 minutes, about 120 minutes, about 125 minutes, about 130 minutes, about 135 minutes, about 140 minutes, about 145 minutes, about 150 minutes or about 155 minutes and about 160 minutes.
  • the suspension may be centrifuged during between about 10 minutes, about 15 minutes, about 20 minutes, about 25 minutes, about 30 minutes, about 35 minutes, about 40 minutes, about 45 minutes, about 50 minutes or about 55 minutes and about 60 minutes.
  • the suspension may be centrifuged during about 5, about 10, about 15, about 20, about 30, about 40, about 50, about 60, about 70, about 80, about 90, about 100, about 120, about 140, about 160, about 180, about 220, about 240, about 300, about 360, about 420, about 480, about 540, about 600, about 660, about 720, about 780, about 840, about 900, about 960, about 1020, about 1080, about 1140, about 1200, about 1260, about 1320, about 1380 minutes or about 1440 minutes.
  • the suspension may be centrifuged during about 5 minutes, about 10 minutes, about 15 minutes, about 20 minutes, about 25 minutes, about 30 minutes, about 35 minutes, about 40 minutes, about 45 minutes, about 50 minutes, about 55 minutes, about 60 minutes, about 65 minutes, about 70 minutes, about 75 minutes, about 80 minutes, about 85 minutes, about 90 minutes, about 95 minutes, about 100 minutes, about 105 minutes, about 110 minutes, about
  • the suspension may be centrifuged during between about 10 minutes, about 15 minutes, about 20 minutes, about 25 minutes, about 30 minutes, about 35 minutes, about 40 minutes, about 45 minutes, about 50 minutes, about 55 minutes or about 60 minutes.
  • centrifugation is continuous centrifugation.
  • the feed rate can be of between of 50-5000 ml/min, 100-4000 ml/min, 150- 3000 ml/min, 200-2500 ml/min, 250-2000 ml/min, 300-1500 ml/min, 300-1000 ml/min, 200-1000 ml/min, 200-1500 ml/min, 400-1500 ml/min, 500-1500 ml/min, 500-1000 ml/min, 500-2000 ml/min, 500-2500 ml/min or 1000-2500 ml/min.
  • the feed rate can be of about 10, about 25, about 50, about 75, about 100, about 150, about 200, about 250, about 300, about 350, about 400, about 450, about 500, about 550, about 600, about 650, about 700, about 750, about 800, about 850, about 900, about 950, about 1000, about 1050, about 1100, about 1150, about 1200, about 1250, about 1300, about 1350, about 1400, about 1450, about 1500, about 1650 about 1700, about 1800, about 1900, about 2000, about 2100, about 2200, about 2300, about 2400, about 2500, about 2600, about 2700, about 2800, about 2900, about 3000, about 3250, about 3500, about 3750 about 4000, about 4250, about 4500 or about 5000 ml/min.
  • the suspension (as obtained at section 1.2 above) is clarified by filtration.
  • filtration suspended solid particles in a liquid are removed by passing the mixture through a porous medium that retains particles and passes the clear filtrate. Filtration is performed on screens by gravity or on filters by vacuum, pressure or centrifugation. The solid can be retained on the surface of the filter medium, which is cake filtration, or captured within the filter medium, which is depth filtration.
  • the suspension (as obtained at section 1 .2 above) is clarified by microfiltration.
  • microfiltration is tangential microfiltration.
  • microfiltration is dead-end filtration (perpendicular filtration).
  • microfiltration is dead-end filtration wherein diatomaceous earth (DE), also known as DE diatomite, is used as a filter aid to facilitate and enhance the efficiency of the solid / liquid separation. Therefore in an embodiment, after flocculation, the suspension (as obtained at section 1.2 above) is clarified by dead-end microfiltration comprising diatomaceous earth (DE). DE can be impregnated (or incorporated) into to the dead-end filter as an integral part of the depth filter.
  • DE diatomaceous earth
  • the DE in another format, can be added to the flocculated solution (as obtained after section 1 .2) in powder form.
  • the DE treated flocculated solution can be further clarified by depth filtration.
  • the solution is treated by a microfiltration step wherein the filter has a nominal retention range of between about 0.01-2 micron, about 0.05-2 micron, about 0.1-2 micron, about 0.2-2 micron, about 0.3-2 micron, about 0.4-2 micron, about 0.45-2 micron, about 0.5-2 micron, about 0.6-2 micron, about 0.7-2 micron, about 0.8-2 micron, about 0.9-2 micron, about 1-2 micron, about 1 .25-2 micron, about 1 .5-2 micron, or about 1 .75-2 micron.
  • the solution is treated by a microfiltration step wherein the filter has a nominal retention range of between about 0.01-1 micron, about 0.05-1 micron, about 0.1-1 micron, about 0.2-1 micron, about 0.3-1 micron, about 0.4-1 micron, about 0.45-1 micron, about 0.5-1 micron, about 0.6-1 micron, about 0.7-1 micron, about 0.8-1 micron or about 0.9-1 micron.
  • the solution is treated by a microfiltration step wherein the filter has a nominal retention rating of about 0.01 , about 0.05, about 0.1 , about 0.2, about 0.3, about 0.4, about 0.45, about 0.5, about 0.6, about 0.7, about 0.8, about 0.9, about 1 , about 1.1 , about 1 .2, about 1 .3, about 1 .4, about 1 .5, about 1 .6, about 1 .7, about 1 .8, about 1 .9 or about 2 micron.
  • the solution is treated by a microfiltration step wherein the filter has a nominal retention rating of about 0.45 micron.
  • the solution is treated by a microfiltration step wherein the filter has a filter capacity of between 100-5000 L/m 2 , 200-5000 L/m 2 , 300-5000 L/m 2 , 400-5000 L/m 2 , 500- 5000 L/m 2 , 750-5000 L/m 2 , 1000-5000 L/m 2 , 1500-5000 L/m 2 , 2000-5000 L/m 2 , 3000-5000 L/m 2 or 4000-5000 L/m 2 ,.
  • the solution is treated by a microfiltration step wherein the filter has a filter capacity of between 100-2500 L/m 2 , 200-2500 L/m 2 , 300-2500 L/m 2 , 400-2500 L/m 2 , 500- 2500 L/m 2 , 750-2500 L/m 2 , 1000-2500 L/m 2 , 1500-2500 L/m 2 or 2000-2500 L/m 2 .
  • the solution is treated by a microfiltration step wherein the filter has a filter capacity of between 100-1500 L/m 2 , 200-1500 L/m 2 , 300-1500 L/m 2 , 400-1500 L/m 2 , 500- 1500 L/m 2 , 750-1500 L/m 2 or 1000-1500 L/m 2 .
  • the solution is treated by a microfiltration step wherein the filter has a filter capacity of between 100-1250 L/m 2 , 200-1250 L/m 2 , 300-1250 L/m 2 , 400-1250 L/m 2 , 500- 1250 L/m 2 , 750-1250 L/m 2 or 1000-1250 L/m 2 .
  • the solution is treated by a microfiltration step wherein the filter has a filter capacity of between 100-1000 L/m 2 , 200-1000 L/m 2 , 300-1000 L/m 2 , 400-1000 L/m 2 , 500- 1000 L/m 2 or 750-1000 L/m 2 .
  • the solution is treated by a microfiltration step wherein the filter has a filter capacity of between 100-750 L/m 2 , 200-750 L/m 2 , 300-750 L/m 2 , 400-750 L/m 2 or 500-750 L/m 2 .
  • the solution is treated by a microfiltration step wherein the filter has a filter capacity of between 100-600 L/m 2 , 200-600 L/m 2 , 300-600 L/m 2 , 400-600 L/m 2 or 400-600 L/m 2 .
  • the solution is treated by a microfiltration step wherein the filter has a filter capacity of between 100-500 L/m 2 , 200-500 L/m 2 , 300-500 L/m 2 or 400-500 L/m 2 .
  • the solution is treated by a microfiltration step wherein the filter has a filter capacity of about 100, about 150, about 200, about 250, about 300, about 350, about 400, about 450, about 500, about 550, about 600, about 650, about 700, about 750, about 800, about 850, about 900, about 950, about 1000, about 1050, about 1100, about 1150, about 1200, about 1250, about 1300, about 1350, about 1400, about 1450, about 1500, about 1550, about 1600, about 1650, about 1700, about 1750, about 1800, about 1850, about 1900, about
  • solid / liquid separation methods described above can be used in a standalone format or in combination of two in any order, or in combination of three in any order.
  • the polysaccharide containing solution e.g. the supernatant
  • the polysaccharide containing solution can optionally be further clarified.
  • the solution is filtrated, thereby producing a further clarified solution.
  • the filtration is applied directly to the solution obtained by any of the method of section 1.2 above. In an embodiment, the filtration is applied to the solution further clarified by the solid/liquid separation step as described at section 1 .3 above.
  • the solution is treated by a filtration step selected from the group consisting of depth filtration, filtration through activated carbon, size filtration, diafiltration and ultrafiltration. In an embodiment, the solution is treated by a diafiltration step, particularly by tangential flow filtration. In an embodiment, the solution is treated by a depth filtration step.
  • Depth filters use a porous filtration medium to retain particles throughout the medium, rather than just on the surface of the medium. Due to the tortuous and channel-like nature of the filtration medium, the particles are retained throughout the medium within its structure, as opposed to on the surface.
  • the solution is treated by a depth filtration step wherein the depth filter design is selected from the group consisting of cassettes, cartridges, deep bed (e.g. sand filter) and lenticular filters.
  • the depth filter design is selected from the group consisting of cassettes, cartridges, deep bed (e.g. sand filter) and lenticular filters.
  • the solution is treated by a depth filtration step wherein the depth filter has a nominal retention range of between about 0.01-100 micron, about 0.05-100 micron, about 0.1-100 micron, about 0.2-100 micron, about 0.3-100 micron, about 0.4-100 micron, about 0.5-100 micron, about 0.6-100 micron, about 0.7-100 micron, about 0.8-100 micron, about 0.9- 100 micron, about 1-100 micron, about 1.25-100 micron, about 1.5-100 micron, about 1.75-100 micron, about 2-100 micron, about 3-100 micron, about 4-100 micron, about 5-100 micron, about 6-100 micron, about 7-100 micron, about 8-100 micron, about 9-100 micron, about 10- 100 micron, about 15-100 micron, about 20-100 micron, about 25-100 micron, about 30-100 micron, about 40-100 micron, about 50-100 micron or about 75-100 micron.
  • the solution is treated by a depth filtration step wherein the depth filter has a nominal retention range of between about 0.01-75 micron, about 0.05-75 micron, about 0.1-75 micron, about 0.2-75 micron, about 0.3-75 micron, about 0.4-75 micron, about 0.5- 75 micron, about 0.6-75 micron, about 0.7-75 micron, about 0.8-75 micron, about 0.9-75 micron, about 1-75 micron, about 1 .25-75 micron, about 1 .5-75 micron, about 1 .75-75 micron, about 2- 75 micron, about 3-75 micron, about 4-75 micron, about 5-75 micron, about 6-75 micron, about 7-75 micron, about 8-75 micron, about 9-75 micron, about 10-75 micron, about 15-75 micron, about 20-75 micron, about 25-75 micron, about 30-75 micron, about 40-75 micron or about 50- 75 micron.
  • the solution is treated by a depth filtration step wherein the depth filter has a nominal retention range of between about 0.01-50 micron, about 0.05-50 micron, about 0.1-50 micron, about 0.2-50 micron, about 0.3-50 micron, about 0.4-50 micron, about 0.5- 50 micron, about 0.6-50 micron, about 0.7-50 micron, about 0.8-50 micron, about 0.9-50 micron, about 1-50 micron, about 1 .25-50 micron, about 1 .5-50 micron, about 1 .75-50 micron, about 2- 50 micron, about 3-50 micron, about 4-50 micron, about 5-50 micron, about 6-50 micron, about 7-50 micron, about 8-50 micron, about 9-50 micron, about 10-50 micron, about 15-50 micron, about 20-50 micron, about 25-50 micron, about 30-50 micron, about 40-50 micron or about 50- 50 micron.
  • the solution is treated by a depth filtration step wherein the depth filter has a nominal retention range of between about 0.01-25 micron, about 0.05-25 micron, about 0.1-25 micron, about 0.2-25 micron, about 0.3-25 micron, about 0.4-25 micron, about 0.5- 25 micron, about 0.6-25 micron, about 0.7-25 micron, about 0.8-25 micron, about 0.9-25 micron, about 1-25 micron, about 1 .25-25 micron, about 1 .5-25 micron, about 1 .75-25 micron, about 2- 25 micron, about 3-25 micron, about 4-25 micron, about 5-25 micron, about 6-25 micron, about 7-25 micron, about 8-25 micron, about 9-25 micron, about 10-25 micron, about 15-25 micron or about 20-25 micron.
  • the solution is treated by a depth filtration step wherein the depth filter has a nominal retention range of between about 0.01-10 micron, about 0.05-10 micron, about 0.1-10 micron, about 0.2-10 micron, about 0.3-10 micron, about 0.4-10 micron, about 0.5- 10 micron, about 0.6-10 micron, about 0.7-10 micron, about 0.8-10 micron, about 0.9-10 micron, about 1-10 micron, about 1 .25-10 micron, about 1 .5-10 micron, about 1 .75-10 micron, about 2- 10 micron, about 3-10 micron, about 4-10 micron, about 5-10 micron, about 6-10 micron, about 7-10 micron, about 8-10 micron or about 9-10 micron.
  • the solution is treated by a depth filtration step wherein the depth filter has a nominal retention range of between about 0.01-8 micron, about 0.05-8 micron, about 0.1-8 micron, about 0.2-8 micron, about 0.3-8 micron, about 0.4-8 micron, about 0.5-8 micron, about 0.6-8 micron, about 0.7-8 micron, about 0.8-8 micron, about 0.9-8 micron, about 1-8 micron, about 1.25-8 micron, about 1.5-8 micron, about 1.75-8 micron, about 2-8 micron, about 3-8 micron, about 4-8 micron, about 5-8 micron, about 6-8 micron or about 7-8 micron.
  • the depth filter has a nominal retention range of between about 0.01-8 micron, about 0.05-8 micron, about 0.1-8 micron, about 0.2-8 micron, about 0.3-8 micron, about 0.4-8 micron, about 0.5-8 micron, about 0.6-8 micron, about 0.7-8 micron, about 0.8-8 micron, about 0.9-8 micron, about 1-8 micron
  • the solution is treated by a depth filtration step wherein the depth filter has a nominal retention range of between about 0.01-5 micron, about 0.05-5 micron, about 0.1-5 micron, about 0.2-5 micron, about 0.3-5 micron, about 0.4-5 micron, about 0.5-5 micron, about 0.6-5 micron, about 0.7-5 micron, about 0.8-5 micron, about 0.9-5 micron, about 1-5 micron, about 1.25-5 micron, about 1.5-5 micron, about 1.75-5 micron, about 2-5 micron, about 3-5 micron or about 4-5 micron.
  • the solution is treated by a depth filtration step wherein the depth filter has a nominal retention range of between about 0.01-2 micron, about 0.05-2 micron, about 0.1-2 micron, about 0.2-2 micron, about 0.3-2 micron, about 0.4-2 micron, about 0.5-2 micron, about 0.6-2 micron, about 0.7-2 micron, about 0.8-2 micron, about 0.9-2 micron, about 1-2 micron, about 1.25-2 micron, about 1.5-2 micron, about 1.75-2 micron, about 2-2 micron, about 3-2 micron or about 4-2 micron.
  • the solution is treated by a depth filtration step wherein the depth filter has a nominal retention range of between about 0.01-1 micron, about 0.05-1 micron, about 0.1-1 micron, about 0.2-1 micron, about 0.3-1 micron, about 0.4-1 micron, about 0.5-1 micron, about 0.6-1 micron, about 0.7-1 micron, about 0.8-1 micron or about 0.9-1 micron.
  • the solution is treated by a depth filtration step wherein the depth filter has a nominal retention range of between about 0.05-50 micron, 0.1 -25 micron 0.2-10, micron 0.1-10 micron, 0.2-5 micron or 0.25-1 micron.
  • the solution is treated by a depth filtration step wherein the depth filter has a filter capacity of 1-2500 L/m 2 , 5-2500 L/m 2 , 10-2500 L/m 2 , 25-2500 L/m 2 , 50-2500 L/m 2 , 75-2500 L/m 2 , 100-2500 L/m 2 , 150-2500 L/m 2 , 200-2500 L/m 2 , 300-2500 L/m 2 , 400-2500 L/m 2 , 500-2500 L/m 2 , 750-2500 L/m 2 , 1000-2500 L/m 2 , 1500-2500 L/m 2 or 2000-2500 L/m 2 .
  • the depth filter has a filter capacity of 1-2500 L/m 2 , 5-2500 L/m 2 , 10-2500 L/m 2 , 25-2500 L/m 2 , 50-2500 L/m 2 , 75-2500 L/m 2 , 100-2500 L/m 2 , 150-2500 L/m 2 , 200-2500 L/
  • the solution is treated by a depth filtration step wherein the depth filter has a filter capacity of 1 -1000 L/m 2 , 5-1000 L/m 2 , 10-1000 L/m 2 , 25-1000 L/m 2 , 50-1000 L/m 2 , 75-1000 L/m 2 , 100-1000 L/m 2 , 150-1000 L/m 2 , 200-1000 L/m 2 , 300-1000 L/m 2 , 400-1000 L/m 2 , 500-1000 L/m 2 or 750-1000 L/m 2 .
  • the solution is treated by a depth filtration step wherein the depth filter has a filter capacity of 1-750 L/m 2 , 5-750 L/m 2 , 10-750 L/m 2 , 25-750 L/m 2 , 50-750 L/m 2 , 75- 750 L/m 2 , 100-750 L/m 2 , 150-750 L/m 2 , 200-750 L/m 2 , 300-750 L/m 2 , 400-750 L/m 2 or 500-750 L/m 2 .
  • the depth filter has a filter capacity of 1-750 L/m 2 , 5-750 L/m 2 , 10-750 L/m 2 , 25-750 L/m 2 , 50-750 L/m 2 , 75- 750 L/m 2 , 100-750 L/m 2 , 150-750 L/m 2 , 200-750 L/m 2 , 300-750 L/m 2 , 400-750 L/m 2 or 500-750 L/m 2 .
  • the solution is treated by a depth filtration step wherein the depth filter has a filter capacity of 1-500 L/m 2 , 5-500 L/m 2 , 10-500 L/m 2 , 25-500 L/m 2 , 50-500 L/m 2 , 75- 500 L/m 2 , 100-500 L/m 2 , 150-500 L/m 2 , 200-500 L/m 2 , 300-500 L/m 2 or 400-500 L/m 2 .
  • the solution is treated by a depth filtration step wherein the depth filter has a filter capacity of 1-400 L/m 2 , 5-400 L/m 2 , 10-400 L/m 2 , 25-400 L/m 2 , 50-400 L/m 2 , 75- 400 L/m 2 , 100-400 L/m 2 , 150-400 L/m 2 , 200-400 L/m 2 or 300-400 L/m 2 .
  • the solution is treated by a depth filtration step wherein the depth filter has a filter capacity of 1-300 L/m 2 , 5-300 L/m 2 , 10-300 L/m 2 , 25-300 L/m 2 , 50-300 L/m 2 , 75- 300 L/m 2 , 100-300 L/m 2 , 150-300 L/m 2 or 200-300 L/m 2 .
  • the solution is treated by a depth filtration step wherein the depth filter has a filter capacity of 1-200 L/m 2 , 5-200 L/m 2 , 10-200 L/m 2 , 25-200 L/m 2 , 50-200 L/m 2 , 75- 200 L/m 2 , 100-200 L/m 2 or 150-200 L/m 2 .
  • the solution is treated by a depth filtration step wherein the depth filter has a filter capacity of 1 -100 L/m 2 , 5-100 L/m 2 , 10-100 L/m 2 , 25-100 L/m 2 , 50-100 L/m 2 or 75-100 L/m 2 .
  • the solution is treated by a depth filtration step wherein the depth filter has a filter capacity of 1-50 L/m 2 , 5-50 L/m 2 , 10-50 L/m 2 or 25-50 L/m 2 .
  • the solution is treated by a depth filtration step wherein the feed rate is between 1 -1000 LMH (liters/m 2 /hour), 10-1000 LMH, 25-1000 LMH, 50-1000 LMH, 100-1000 LMH, 125-1000 LMH, 150-1000 LMH, 200-1000 LMH, 250-1000 LMH, 300-1000 LMH, 400- 1000 LMH, 500-1000 LMH, 600-1000 LMH, 700-1000 LMH, 800-1000 LMH or 900-1000 LMH.
  • the feed rate is between 1 -1000 LMH (liters/m 2 /hour), 10-1000 LMH, 25-1000 LMH, 50-1000 LMH, 100-1000 LMH, 125-1000 LMH, 150-1000 LMH, 200-1000 LMH, 250-1000 LMH, 300-1000 LMH, 400- 1000 LMH, 500-1000 LMH, 600-1000 LMH, 700-1000 LMH, 800-1000 LMH or 900-1000 LMH.
  • the solution is treated by a depth filtration step wherein the feed rate is between 1 -500 LMH, 10-500 LMH, 25-500 LMH, 50-500 LMH, 100-500 LMH, 125-500 LMH, 150-500 LMH, 200-500 LMH, 250-500 LMH, 300-500 LMH or 400-500 LMH.
  • the solution is treated by a depth filtration step wherein the feed rate is between 1-400 LMH, 10-400 LMH, 25-400 LMH, 50-400 LMH, 100-400 LMH, 125-400 LMH, 150-400 LMH, 200-400 LMH, 250-400 LMH or 300-400 LMH.
  • the solution is treated by a depth filtration step wherein the feed rate is between 1 -250 LMH, 10-250 LMH, 25-250 LMH, 50-250 LMH, 100-250 LMH, 125-250 LMH, 150-250 LMH or 200-250 LMH.
  • the solution is treated by a depth filtration step wherein the feed rate is about 1 , about 2, about 5, about 10, about 25, about 50, about 60, about 70, about 80, about 90, about 100, about 110, about 120, about 130, about 140, about 150, about 160, about 170, about 180, about 190, about 200, about 210, about 220, about 230, about 240 about 250, about
  • the solution obtained i.e. the filtrate
  • the solution obtained can optionally be further clarified.
  • the solution is subjected to microfiltration.
  • microfiltration is dead-end filtration (perpendicular filtration).
  • microfiltration is tangential microfiltration.
  • the solution is treated by a microfiltration step wherein the filter has a nominal retention range of between about 0.01-2 micron, about 0.05-2 micron, about 0.1-2 micron, about 0.2-2 micron, about 0.3-2 micron, about 0.4-2 micron, about 0.45-2 micron, about 0.5-2 micron, about 0.6-2 micron, about 0.7-2 micron, about 0.8-2 micron, about 0.9-2 micron, about 1-2 micron, about 1 .25-2 micron, about 1 .5-2 micron, or about 1 .75-2 micron.
  • the solution is treated by a depth filtration step wherein the filter has a nominal retention range of between about 0.01-1 micron, about 0.05-1 micron, about 0.1-1 micron, about 0.2-1 micron, about 0.3-1 micron, about 0.4-1 micron, about 0.45-1 micron, about 0.5-1 micron, about 0.6-1 micron, about 0.7-1 micron, about 0.8-1 micron or about 0.9-1 micron. Any number within any of the above ranges is contemplated as an embodiment of the disclosure.
  • the solution is treated by a microfiltration step wherein the filter has a nominal retention rating of about 0.01 , about 0.05, about 0.1 , about 0.2, about 0.3, about 0.4, about 0.45, about 0.5, about 0.6, about 0.7, about 0.8, about 0.9, about 1 , about 1.1 , about 1 .2, about 1 .3, about 1 .4, about 1 .5, about 1 .6, about 1 .7, about 1 .8, about 1 .9 or about 2 micron.
  • the solution is treated by a microfiltration step wherein the filter has a nominal retention rating of about 0.45 micron.
  • the solution is treated by a microfiltration step wherein the filter has a filter capacity of between 100-5000 L/m 2 , 200-5000 L/m 2 , 300-5000 L/m 2 , 400-5000 L/m 2 , 500- 5000 L/m 2 , 750-5000 L/m 2 , 1000-5000 L/m 2 , 1500-5000 L/m 2 , 2000-5000 L/m 2 , 3000-5000 L/m 2 or 4000-5000 L/m 2 ,.
  • the solution is treated by a microfiltration step wherein the filter has a filter capacity of between 100-2500 L/m 2 , 200-2500 L/m 2 , 300-2500 L/m 2 , 400-2500 L/m 2 , 500- 2500 L/m 2 , 750-2500 L/m 2 , 1000-2500 L/m 2 , 1500-2500 L/m 2 or 2000-2500 L/m 2 .
  • the solution is treated by a microfiltration step wherein the filter has a filter capacity of between 100-1500 L/m 2 , 200-1500 L/m 2 , 300-1500 L/m 2 , 400-1500 L/m 2 , 500- 1500 L/m 2 , 750-1500 L/m 2 or 1000-1500 L/m 2 .
  • the solution is treated by a microfiltration step wherein the filter has a filter capacity of between 100-1250 L/m 2 , 200-1250 L/m 2 , 300-1250 L/m 2 , 400-1250 L/m 2 , 500- 1250 L/m 2 , 750-1250 L/m 2 or 1000-1250 L/m 2 .
  • the solution is treated by a microfiltration step wherein the filter has a filter capacity of between 100-1000 L/m 2 , 200-1000 L/m 2 , 300-1000 L/m 2 , 400-1000 L/m 2 , 500- 1000 L/m 2 or 750-1000 L/m 2 .
  • the solution is treated by a microfiltration step wherein the filter has a filter capacity of between 100-750 L/m 2 , 200-750 L/m 2 , 300-750 L/m 2 , 400-750 L/m 2 or 500-750 L/m 2 .
  • the solution is treated by a microfiltration step wherein the filter has a filter capacity of between 100-600 L/m 2 , 200-600 L/m 2 , 300-600 L/m 2 , 400-600 L/m 2 or 400-600 L/m 2 .
  • the solution is treated by a microfiltration step wherein the filter has a filter capacity of between 100-500 L/m 2 , 200-500 L/m 2 , 300-500 L/m 2 or 400-500 L/m 2 .
  • the solution is treated by a microfiltration step wherein the filter has a filter capacity of about 100, about 150, about 200, about 250, about 300, about 350, about 400, about 450, about 500, about 550, about 600, about 650, about 700, about 750, about 800, about 850, about 900, about 950, about 1000, about 1050, about 1100, about 1150, about 1200, about 1250, about 1300, about 1350, about 1400, about 1450, about 1500, about 1550, about 1600, about 1650, about 1700, about 1750, about 1800, about 1850, about 1900, about
  • the solution obtained i.e. the filtrate
  • the solution obtained can optionally be further clarified by Ultrafiltration and/or Dialfiltration.
  • Ultrafiltration is a process for concentrating a dilute product stream.
  • UF separates molecules in solution based on the membrane pore size or molecular weight cutoff (MWCO).
  • the solution e.g. the filtrate obtained at section 1 .5 or 1 .6 above
  • the solution is treated by ultrafiltration.
  • the solution is treated by ultrafiltration and the molecular weight cut off of the membrane is in the range of between about 5 kDa -1000 kDa. In an embodiment the molecular weight cut off of the membrane is in the range of between about 10 kDa -750 kDa. In an embodiment the molecular weight cut off of the membrane is in the range of between about 10 kDa -500 kDa. In an embodiment the molecular weight cut off of the membrane is in the range of between about 10 kDa -300 kDa. In an embodiment the molecular weight cut off of the membrane is in the range of between about 10 kDa -100 kDa.
  • the molecular weight cut off of the membrane is in the range of between about 10 kDa -50 kDa. In an embodiment the molecular weight cut off of the membrane is in the range of between about 10 kDa -30 kDa.
  • the molecular weight cut off of the membrane is in the range of between about 5 kDa -1000 kDa, about 10 kDa -1000 kDa about 20 kDa -1000 kDa, about 30 kDa -1000 kDa, about 40 kDa -1000 kDa, about 50 kDa -1000 kDa, about 75 kDa -1000 kDa, about 100 kDa -1000 kDa, about 150 kDa -1000 kDa, about 200 kDa -1000 kDa, about 300 kDa -1000 kDa, about 400 kDa -1000 kDa, about 500 kDa -1000 kDa or about 750 kDa -1000 kDa.
  • the molecular weight cut off of the membrane is in the range of between about 5 kDa -500 kDa, about 10 kDa -500 kDa, about 20 kDa -500 kDa, about 30 kDa -500 kDa, about 40 kDa -500 kDa, about 50 kDa -500 kDa, about 75 kDa -500 kDa, about 100 kDa -500 kDa, about 150 kDa -500 kDa, about 200 kDa -500 kDa, about 300 kDa -500 kDa or about 400 kDa -500 kDa.
  • the molecular weight cut off of the membrane is in the range of between about about 5 kDa -300 kDa, about 10 kDa -300 kDa, about 20 kDa -300 kDa, about 30 kDa -300 kDa, about 40 kDa -300 kDa, about 50 kDa -300 kDa, about 75 kDa -300 kDa, about 100 kDa -300 kDa, about 150 kDa -300 kDa or about 200 kDa -300 kDa.
  • the molecular weight cut off of the membrane is in the range of between about about 5 kDa -100 kDa, about 10 kDa -100 kDa, about 20 kDa -100 kDa, about 30 kDa -100 kDa, about 40 kDa -100 kDa, about 50 kDa -100 kDa or about 75 kDa -100 kDa.
  • the molecular weight cut off of the membrane is about 5 kDa, about 10 kDa, about 20 kDa, about 30 kDa, about 40 kDa, about 50 kDa, about 60 kDa, about 70 kDa, about 80 kDa, about 90 kDa, about 100 kDa, about 110 kDa, about 120 kDa, about 130 kDa, about 140 kDa, about 150 kDa, about 200 kDa, about 250 kDa, about 300 kDa, about 400 kDa, about 500 kDa, about 750 kDa or about 1000 kDa.
  • the concentration factor of the ultrafiltration step is from about 1 .5 to 10. In an embodiment, the concentration factor is from about 2 to 8. In an embodiment, the concentration factor is from about 2 to 5.
  • the concentration factor is about 1 .5, about 2.0, about 2.5, about 3.0, about 3.5, about 4.0, about 4.5, about 5.0, about 5.5, about 6.0, about 6.5, about 7.0, about 7.5, about 8.0, about 8.5, about 9.0, about 9.5 or about 10.0. In an embodiment, the concentration factor is about 2, about 3, about 4, about 5, or about 6.
  • the solution e.g. the filtrate obtained at section 1 .4 or 1 .5 above
  • the solution is treated by diafiltration.
  • the solution obtained following ultrafiltration (UF) as disclosed in the present section above is further treated by diafiltration (UF/DF treatment).
  • Diafiltration is used to exchange product into a desired buffer solution (or water only).
  • diafiltration is used to change the chemical properties of the retained solution under constant volume. Unwanted particles pass through a membrane while the makeup of the feed stream is changed to a more desirable state through the addition of a replacement solution (a buffer solution, a saline solution, a buffer saline solution or water).
  • the replacement solution is water.
  • the replacement solution is saline in water.
  • the salt is selected from the group consisting of magnesium chloride, potassium chloride, sodium chloride and a combination thereof.
  • the salt is sodium chloride.
  • the replacement solution is sodium chloride at about 1 mM, about 5 mM, about 10 mM, about 15 mM, about 20 mM, about 25 mM, about 30 mM, about 35 mM, about 40 mM, about 45 mM, about 50 mM, about 55 mM, about 60 mM, about 65 mM, about 70 mM, about 80 mM, about 90 mM, about 100 mM, about 110 mM, about 120 mM, about 130 mM, about 140 mM, about 150 mM, about 160 mM, about 170 mM, about 180 mM, about 190 mM, about 200 mM, about 250 mM, about 300 mM, about 350
  • the replacement solution is sodium chloride at about 1 mM, about 5 mM, about 10 mM, about 15 mM, about 20 mM, about 25 mM, about 30 mM, about 35 mM, about 40 mM, about 45 mM, about 50 mM, about 55 mM, about 60 mM, about 65 mM, about 70 mM, about 80 mM, about 90 mM, about 100 mM, about 110 mM, about 120 mM, about 130 mM, about 140 mM, about 150 mM, about 160 mM, about 170 mM, about 180 mM, about 190 mM, about 200 mM, about 250 mM or about 300 mM.
  • the replacement solution is a buffer solution.
  • the replacement solution is a buffer solution wherein the buffer is selected from the group consisting of N-(2-Acetamido)-aminoethanesulfonic acid (ACES), a salt of acetic acid (acetate), N-(2- Acetamido)-iminodiacetic acid (ADA), 2-Aminoethanesulfonic acid (AES, Taurine), ammonia, 2- Amino-2-methyl-1 -propanol (AMP), 2-Amino-2-methyl-1 ,3-propanediol AMPD, ammediol, N- (1 ,1-Dimethyl-2-hydroxyethyl)-3-amino-2-hydroxypropanesulfonic acid (AMPSO), N,N-Bis-(2- hydroxyethyl)-2-aminoethanesulfonic acid (BES), sodium hydrogen carbonate (bicarbonate), N,N’-Bis(2-hydroxyethyl)
  • the diafiltration buffer is selected from the group consisting of a salt of acetic acid (acetate), a salt of citric acid (citrate), a salt of formic acid (formate), a salt of malic acid (Malate), a salt of maleic acid (Maleate), a salt of phosphoric acid (Phosphate) and a salt of succinic acid (Succinate).
  • the diafiltration buffer is a salt of citric acid (citrate).
  • the diafiltration buffer is a salt of succinic acid (Succinate).
  • said salt is a sodium salt.
  • said salt is a potassium salt.
  • the pH of the diafiltration buffer is between about 4.0-11 .0, between about 5.0-10.0, between about 5.5-9.0, between about 6.0-8.0, between about 6.0-7.0, between about 6.5-7.5, between about 6.5-7.0 or between about 6.0-7.5. Any number within any of the above ranges is contemplated as an embodiment of the disclosure.
  • the pH of the diafiltration buffer is about 4.0, about 4.5, about 5.0, about 5.5, about 6.0, about 6.5, about 7.0, about 7.5, about 8.0, about 8.5, about 9.0, about 9.5, about 10.0, about 10.5 or about 11 .0.
  • the pH of the diafiltration buffer is about 6.0, about 6.5, about 7.0, about 7.5, about 8.0, about 8.5 or about 9.0. In an embodiment, the pH of the diafiltration buffer is about 6.5, about 7.0 or about 7.5. In an embodiment, the pH of the diafiltration buffer is about 7.0.
  • the concentration of the diafiltration buffer is between about 0.01 mM- 100mM, between about 0.1 mM-100mM, between about 0.5mM-100mM, between about 1 mM- 100mM, between about 2mM-100mM, between about 3mM-100mM, between about 4mM- 100mM, between about 5mM-100mM, between about 6mM-100mM, between about 7mM- 100mM, between about 8mM-100mM, between about 9mM-100mM, between about 10mM- 100mM, between about 11 mM-100mM, between about 12mM-100mM, between about 13mM- 100mM, between about 14mM-100mM, between about 15mM-100mM, between about 16mM- 100mM, between about 17mM-100mM, between about 18mM-100mM, between about 19mM- 100mM, between about 20mM-100mM, between about 25mM
  • the concentration of the diafiltration buffer is between about 0.01 mM- 50mM, between about 0.1 mM-50mM, between about 0.5mM-50mM, between about 1 mM- 50mM, between about 2mM-50mM, between about 3mM-50mM, between about 4mM-50mM, between about 5mM-50mM, between about 6mM-50mM, between about 7mM-50mM, between about 8mM-50mM, between about 9mM-50mM, between about 10mM-50mM, between about 11 mM-50mM, between about 12mM-50mM, between about 13mM-50mM, between about 14mM-50mM, between about 15mM-50mM, between about 16mM-50mM, between about 17mM-50mM, between about 18mM-50mM, between about 19mM-50mM, between about 20mM-50mM, between about 25mM-50mM, between about 30mM-50mM, between about 35mM-50mM
  • the concentration of the diafiltration buffer is between about 0.01 mM- 25mM, between about 0.1 mM-25mM, between about 0.5mM-25mM, between about 1 mM- 25mM, between about 2mM-25mM, between about 3mM-25mM, between about 4mM-25mM, between about 5mM-25mM, between about 6mM-25mM, between about 7mM-25mM, between about 8mM-25mM, between about 9mM-25mM, between about 10mM-25mM, between about 11 mM-25mM, between about 12mM-25mM, between about 13mM-25mM, between about 14mM-25mM, between about 15mM-25mM, between about 16mM-25mM, between about 17mM-25mM, between about 18mM-25mM, between about 19mM-25mM or between about 20mM-25mM.
  • the concentration of the diafiltration buffer is between about 0.01 mM- 15mM, between about 0.1 mM-15mM, between about 0.5mM-15mM, between about 1 mM- 15mM, between about 2mM-15mM, between about 3mM-15mM, between about 4mM-15mM, between about 5mM-15mM, between about 6mM-15mM, between about 7mM-15mM, between about 8mM-15mM, between about 9mM-15mM, between about 10mM-15mM, between about 11 mM-15mM, between about 12mM-15mM, between about 13mM-15mM or between about 14mM-15mM.
  • the concentration of the diafiltration buffer is between about 0.01 mM- 10mM, between about 0.1 mM-10mM, between about 0.5mM-10mM, between about 1 mM- 10mM, between about 2mM-10mM, between about 3mM-10mM, between about 4mM-10mM, between about 5mM-10mM, between about 6mM-10mM, between about 7mM-10mM, between about 8mM-10mM or between about 9mM-10mM.
  • the concentration of the diafiltration buffer is about 0.01 mM, about 0.05 mM, about 0.1 mM, about 0.2 mM, about 0.3 mM, about 0.4 mM, about 0.5 mM, about 0.6 mM, about 0.7 mM, about 0.8 mM, about 0.9 mM, about 1 mM, about 2 mM, about 3 mM, about 4 mM, about 5 mM, about 6 mM, about 7 mM, about 8 mM, about 9 mM, about 10 mM, about 11 mM, about 12 mM, about 13 mM, about 14 mM, about 15 mM, about 16 mM, about 17 mM, about 18 mM, about 19 mM, about 20 mM, about 25 mM, about 30 mM, about 35 mM, about 40 mM, about 45 mM, about 50 mM, about 55 mM, about 60 .
  • the concentration of the diafiltration buffer is about 0.1 mM, about 0.2 mM, about 1 mM, about 5 mM, about 10 mM, about 15 mM, about 20 mM, about 30 mM, about 40 mM, or about 50 mM.
  • the concentration of the diafiltration buffer is about 10 mM.
  • the replacement solution comprises a chelating agent.
  • the replacement solution comprises an alum chelating agent.
  • the chelating agent is selected from the groups consisting of Ethylene Diamine Tetra Acetate (EDTA), N-(2-Hydroxyethyl)ethylenediamine-N,N',N'-triacetic acid (EDTA-OH), hydroxy ethylene diamine triacetic acid (HEDTA), Ethylene glycol-bis(2-aminoethylether)- N,N,N',N'-tetraacetic acid (EGTA), 1 ,2-cyclohexanediamine-N,N,N',N'-tetraacetic acid (CyDTA), diethylenetriamine-N,N,N',N",N"-pentaacetic acid (DTPA), 1 ,3-diaminopropan-2-ol-N,N,N',N'- tetraacetic acid (DPTA-
  • EDTA Ethy
  • the chelating agent is selected from the groups consisting of Ethylene Diamine Tetra Acetate (EDTA), N-(2-Hydroxyethyl)ethylenediamine-N,N',N'-triacetic acid (EDTA-OH), hydroxy ethylene diamine triacetic acid (HEDTA), Ethylene glycol-bis(2- aminoethylether)-N,N,N',N'-tetraacetic acid (EGTA), 1 ,2-cyclohexanediamine-N,N,N',N'- tetraacetic acid (CyDTA), diethylenetriamine-N,N,N',N",N"-pentaacetic acid (DTPA), 1 ,3- diaminopropan-2-ol-N,N,N',N'-tetraacetic acid (DPTA-OH), ethylenediamine-N,N'-bis(2- hydroxyphenylacetic acid) (EDDHA), a salt of citric
  • the chelating agent is Ethylene Diamine Tetra Acetate (EDTA).
  • the chelating agent is a salt of citric acid (citrate). In some embodiments, the chelating agent is sodium citrate.
  • the chelating agent is employed at a concentration from 1 to 500 mM. In an embodiment, the concentration of the chelating agent in the replacement solution is from 2 to 400 mM. In an embodiment, the concentration of the chelating agent in the replacement solution solution is from 10 to 400 mM. In an embodiment, the concentration of the chelating agent in the replacement solution is from 10 to 200 mM. In an embodiment, the concentration of the chelating agent in the replacement solution is from 10 to 100 mM. In an embodiment, the concentration of the chelating agent in the replacement solution is from 10 to 50 mM. In an embodiment, the concentration of the chelating agent in the replacement solution is from 10 to 30 mM.
  • the concentration of the chelating agent in the replacement solution is about 0.01 mM, about 0.05 mM, about 0.1 mM, about 0.2 mM, about 0.3 mM, about 0.4 mM, about 0.5 mM, about 0.6 mM, about 0.7 mM, about 0.8 mM, about 0.9 mM, about 1 mM, about 2 mM, about 3 mM, about 4 mM, about 5 mM, about 6 mM, about 7 mM, about 8 mM, about 9 mM, about 10 mM, about 11 mM, about 12 mM, about 13 mM, about 14 mM, about 15 mM, about 16 mM, about 17 mM, about 18 mM, about 19 mM, about 20 mM, about 21 mM, about 22 mM, about 23 mM, about 24 mM, about 25 mM, about 26 mM, about 27 mM
  • the concentration of the chelating agent in the replacement solution is about 5 mM, about 10 mM, about 15 mM, about 20 mM, about 25 mM, about 30 mM, about 35 mM, about 40 mM, about 45 mM, about 50 mM, about 55 mM, about 60 mM, about 65 mM, about 70 mM, about 75 mM, about 80 mM, about 85 mM, about 90 mM, about 95 mM or about 100 mM.
  • the concentration of the chelating agent in the replacement solution is about 15 mM, about 20 mM, about 25 mM, about 30 mM, about 35 mM, about 40 mM, about 45 mM or about 50 mM.
  • the diafiltration buffer solution comprises a salt.
  • the salt is selected from the groups consisting of magnesium chloride, potassium chloride, sodium chloride and a combination thereof.
  • the salt is sodium chloride.
  • the diafiltration buffer solution comprises sodium chloride at about 1 , about 5, about 10, about 15, about 20, about 25, about 30, about 35, about 40, about 45, about 50, about 55, about 60, about 65, about 70, about 80, about 90, about 100, about 110, about 120, about 130, about 140, about 150, about 160, about 170, about 180, about 190, about 200, about 250, about 300, about 350, about 400, about 450 or about 500 mM.
  • the diafiltration buffer solution comprises sodium chloride at about 1 , about 5, about 10, about 15, about 20, about 25, about 30, about 35, about 40, about 45, about 50, about 55, about 60, about 65, about 70, about 80, about 90, about 100, about 110, about 120, about 130, about 140, about 150, about 160, about 170, about 180, about 190, about 200, about 250 or about 300 mM.
  • the number of diavolumes is at least 5, 10,
  • the number of diavolumes is about 1 , about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11 , about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, about 20, about 21 , about 22, about 23, about 24, about 25, about 26, about 27, about 28, about 29, about 30, about 31 , about 32, about 33, about 34, about 35, about 36, about 37, about 38, about 39, about 40, about 41 , about 42, about 43, about 44, about 45, about 46, about 47, about 48, about 49, about 50, about 55, about 60, about 65, about 70, about 75, about 80, about 85, about 90, about 95 or about 100. In an embodiment of the present invention the number of diavolumes is about 5, about 6, about 7, about 8, about 9, about 10, about 11 , about 12, about 13, about 14 or about 15.
  • the Ultrafiltration and Dialfiltration steps are performed at a temperature between about 20°C to about 90°C. In an embodiment, the Ultrafiltration and Dialfiltration steps are performed at a temperature between about 35°C to about 80°C, at temperature between about 40°C to about 70°C, at temperature between about 45°C to about 65°C, at temperature between about 50°C to about 60°C, at temperature between about 50°C to about 55°C, at temperature between about 45°C to about 55°C or at temperature between about 45°C to about 55°C.
  • the Ultrafiltration and Dialfiltration steps are performed at a temperature of about 20°C, about 21 °C, about 22°C, about 23°C, about 24°C, about 25°C, about 26°C, about 27°C, about 28°C, about 29°C, about 30°C, about 31 °C, about 32°C, about 33°C, about 34°C, about 35°C, about 36°C, about 37°C, about 38°C, about 39°C, about 40°C, about 41 °C, about 42°C, about 43°C, about 44°C, about 45°C, about about 46°C, about 47°C, about 48°C, about 49°C, about 50°C, about 51 °C, about 52°C, about 53°C, about 54°C, about 55°C, about 56°C, about 57°C, about 58°C, about 59°C, about 60°C, about 61
  • the Dialfiltration step is performed at temperature between about 20°C to about 90°C. In an embodiment, the Dialfiltration step is performed at a temperature between about 35°C to about 80°C, at temperature between about 40°C to about 70°C, at temperature between about 45°C to about 65°C, at temperature between about 50°C to about 60°C, at temperature between about 50°C to about 55°C, at temperature between about 45°C to about 55°C or at temperature between about 45°C to about 55°C.
  • Dialfiltration step is performed at a temperature of about about 20°C, about 21 °C, about 22°C, about 23°C, about 24°C, about 25°C, about 26°C, about 27°C, about 28°C, about 29°C, about 30°C, about 31 °C, about 32°C, about 33°C, about 34°C, about 35°C, about 36°C, about 37°C, about 38°C, about 39°C, about 40°C, about 41 °C, about 42°C, about 43°C, about 44°C, about 45°C, about about 46°C, about 47°C, about 48°C, about 49°C, about 50°C, about 51 °C, about 52°C, about 53°C, about 54°C, about 55°C, about 56°C, about 57°C, about 58°C, about 59°C, about 60°C, about 61 °C, about 62°C, about 63°C, about 64°C, about 65
  • the Ultrafiltration step is performed at temperature between about 20°C to about 90°C. In an embodiment, the Ultrafiltration step is performed at a temperature between about 35°C to about 80°C, at temperature between about 40°C to about 70°C, at temperature between about 45°C to about 65°C, at temperature between about 50°C to about 60°C, at temperature between about 50°C to about 55°C, at temperature between about 45°C to about 55°C or at temperature between about 45°C to about 55°C. Any number within any of the above ranges is contemplated as an embodiment of the disclosure.
  • Ultrafiltration step is performed at a temperature of about 20°C, about 21 °C, about 22°C, about 23°C, about 24°C, about 25°C, about 26°C, about 27°C, about 28°C, about 29°C, about 30°C, about 31 °C, about 32°C, about 33°C, about 34°C, about 35°C, about 36°C, about 37°C, about 38°C, about 39°C, about 40°C, about 41 °C, about 42°C, about 43°C, about 44°C, about 45°C, about about 46°C, about 47°C, about 48°C, about 49°C, about 50°C, about 51 °C, about 52°C, about 53°C, about 54°C, about 55°C, about 56°C, about 57°C, about 58°C, about 59°C, about 60°C, about 61 °C, about 62°C, about 63°C, about 64°C, about 65°C, about 60
  • the solution containing the polysaccharide can optionally be further clarified by an activated carbon filtration step.
  • the solution of section 1.2 further treated by the solid/liquid separation step of section 1 .3 is further clarified by an activated carbon filtration step.
  • the solution further filtered by any of the method of section 1 .4 above and/or by the filtration step of section 1 .5 above is further clarified by an activated carbon filtration step.
  • the solution further clarified by an Ultrafiltration and/or Dialfiltration step of section 1 .6 above is further clarified by an activated carbon filtration step.
  • a step of activated carbon filtration allows for further removing host cell impurities such as proteins and nucleic acids as well as colored impurities (see W02008/118752).
  • activated carbon also named active charcoal
  • activated carbon is added to the solution in an amount sufficient to absorb the majority of the proteins and nucleic acids contaminants, and then removed once the contaminants have been adsorbed onto activated carbon.
  • the activated carbon is added in the form of a powder, as a granular carbon bed, as a pressed carbon block or extruded carbon block (see e.g. Norit active charcoal).
  • the activated carbon is added in an amount of about 0.1 to 20 % (weight volume), 1 to 15 % (weight volume), 1 to 10 % (weight volume), 2 to 10 % (weight volume), 3 to 10 % (weight volume), 4 to 10 % (weight volume), 5 to 10 % (weight volume), 1 to 5 % (weight volume) or 2 to 5 % (weight volume).
  • the mixture is then stirred and left to stand. In an embodiment, the mixture is left to stand for about 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240 minutes or more.
  • the activated carbon is then removed.
  • the activated carbon can be removed for example by centrifugation or filtration.
  • the solution is filtered through activated carbon immobilized in a matrix.
  • the matrix may be any porous filter medium permeable for the solution.
  • the matrix may comprise a support material and/or a binder material.
  • the support material may be a synthetic polymer or a polymer of natural origin. Suitable synthetic polymers may include polystyrene, polyacrylamide and polymethyl methacrylate, while polymers of natural origin may include cellulose, polysaccharide and dextran, agarose.
  • the polymer support material is in the form of a fibre network to provide mechanical rigidity.
  • the binder material may be a resin.
  • the matrix may have the form of a membrane sheet.
  • the activated carbon immobilized in the matrix is in the form of a flow-through carbon cartridge.
  • a cartridge is a self-contained entity containing powdered activated carbon immobilized in the matrix and prepared in the form of a membrane sheet.
  • the membrane sheet may be captured in a plastic permeable support to form a disc.
  • the membrane sheet may be spirally wound.
  • several discs may be stacked upon each other.
  • the discs stacked upon each other have a central core pipe for collecting and removing the carbon-treated sample from the filter.
  • the configuration of stacked discs may be lenticular.
  • the activated carbon in the carbon filter may be derived from different raw materials, e.g. peat, lignite, wood or coconut shell.
  • carbon e.g. wood-based phosphoric acid-activated carbon
  • activated carbon immobilized in a matrix may be placed in a housing to form an independent filter unit.
  • Each filter unit has its own in-let and out-let for the solution to be purified.
  • filter units that are usable in the present invention are the carbon cartridges from Cuno Inc. (Meriden, USA) or Pall Corporation (East Hill, USA).
  • CUNO zetacarbon filters are suitable for use in the invention. These carbon filters comprise a cellulose matrix into which activated carbon powder is entrapped and resin-bonded in place.
  • the activated carbon filter disclosed above has a nominal micron rating of between about 0.01-100 micron, about 0.05-100 micron, about 0.1 -100 micron, about 0.2-100 micron, about 0.3-100 micron, about 0.4-100 micron, about 0.5-100 micron, about 0.6- 100 micron, about 0.7-100 micron, about 0.8-100 micron, about 0.9-100 micron, about 1-100 micron, about 1.25-100 micron, about 1.5-100 micron, about 1.75-100 micron, about 2-100 micron, about 3-100 micron, about 4-100 micron, about 5-100 micron, about 6-100 micron, about 7-100 micron, about 8-100 micron, about 9-100 micron, about 10-100 micron, about 15- 100 micron, about 20-100 micron, about 25-100 micron, about 30-100 micron, about 40-100 micron, about 50-100 micron or about 75-100 micron.
  • the activated carbon filter disclosed above has a nominal micron rating of between about 0.01-50 micron, about 0.05-50 micron, about 0.1-50 micron, about 0.2- 50 micron, about 0.3-50 micron, about 0.4-50 micron, about 0.5-50 micron, about 0.6-50 micron, about 0.7-50 micron, about 0.8-50 micron, about 0.9-50 micron, about 1-50 micron, about 1.25- 50 micron, about 1.5-50 micron, about 1.75-50 micron, about 2-50 micron, about 3-50 micron, about 4-50 micron, about 5-50 micron, about 6-50 micron, about 7-50 micron, about 8-50 micron, about 9-50 micron, about 10-50 micron, about 15-50 micron, about 20-50 micron, about 25-50 micron, about 30-50 micron, about 40-50 micron or about 50-50 micron.
  • the activated carbon filter disclosed above has a nominal micron rating of between about 0.01-25 micron, about 0.05-25 micron, about 0.1-25 micron, about 0.2- 25 micron, about 0.3-25 micron, about 0.4-25 micron, about 0.5-25 micron, about 0.6-25 micron, about 0.7-25 micron, about 0.8-25 micron, about 0.9-25 micron, about 1-25 micron, about 1.25- 25 micron, about 1.5-25 micron, about 1.75-25 micron, about 2-25 micron, about 3-25 micron, about 4-25 micron, about 5-25 micron, about 6-25 micron, about 7-25 micron, about 8-25 micron, about 9-25 micron, about 10-25 micron, about 15-25 micron or about 20-25 micron.
  • the activated carbon filter disclosed above has a nominal micron rating of between about 0.01-10 micron, about 0.05-10 micron, about 0.1-10 micron, about 0.2- 10 micron, about 0.3-10 micron, about 0.4-10 micron, about 0.5-10 micron, about 0.6-10 micron, about 0.7-10 micron, about 0.8-10 micron, about 0.9-10 micron, about 1-10 micron, about 1.25- 10 micron, about 1.5-10 micron, about 1.75-10 micron, about 2-10 micron, about 3-10 micron, about 4-10 micron, about 5-10 micron, about 6-10 micron, about 7-10 micron, about 8-10 micron or about 9-10 micron.
  • the activated carbon filter disclosed above has a nominal micron rating of between about 0.01-8 micron, about 0.05-8 micron, about 0.1-8 micron, about 0.2-8 micron, about 0.3-8 micron, about 0.4-8 micron, about 0.5-8 micron, about 0.6-8 micron, about 0.7-8 micron, about 0.8-8 micron, about 0.9-8 micron, about 1-8 micron, about 1.25-8 micron, about 1 .5-8 micron, about 1 .75-8 micron, about 2-8 micron, about 3-8 micron, about 4-8 micron, about 5-8 micron, about 6-8 micron or about 7-8 micron.
  • the activated carbon filter disclosed above has a nominal micron rating of between about 0.01-5 micron, about 0.05-5 micron, about 0.1-5 micron, about 0.2-5 micron, about 0.3-5 micron, about 0.4-5 micron, about 0.5-5 micron, about 0.6-5 micron, about 0.7-5 micron, about 0.8-5 micron, about 0.9-5 micron, about 1-5 micron, about 1.25-5 micron, about 1 .5-5 micron, about 1 .75-5 micron, about 2-5 micron, about 3-5 micron or about 4-5 micron.
  • the activated carbon filter disclosed above has a nominal micron rating of between about 0.01-2 micron, about 0.05-2 micron, about 0.1-2 micron, about 0.2-2 micron, about 0.3-2 micron, about 0.4-2 micron, about 0.5-2 micron, about 0.6-2 micron, about 0.7-2 micron, about 0.8-2 micron, about 0.9-2 micron, about 1-2 micron, about 1.25-2 micron, about 1 .5-2 micron, about 1 .75-2 micron, about 2-2 micron, about 3-2 micron or about 4-2 micron.
  • the activated carbon filter disclosed above has a nominal micron rating of between about 0.01-1 micron, about 0.05-1 micron, about 0.1-1 micron, about 0.2-1 micron, about 0.3-1 micron, about 0.4-1 micron, about 0.5-1 micron, about 0.6-1 micron, about 0.7-1 micron, about 0.8-1 micron or about 0.9-1 micron.
  • the activated carbon filter disclosed above has a nominal micron ratings of between about 0.05-50 micron, 0.1 -25 micron 0.2-10, micron 0.1-10 micron, 0.2-5 micron or 0.25-1 micron.
  • the activated carbon filtration step is conducted at a feed rate of between 1-500 LMH, 10-500 LMH, 15-500 LMH, 20-500 LMH, 25-500 LMH, 30-500 LMH, 40- 500 LMH, 50-500 LMH, 100-500 LMH, 125-500 LMH, 150-500 LMH, 200-500 LMH, 250-500 LMH, 300-500 LMH or 400-500 LMH.
  • the activated carbon filtration step is conducted at a feed rate of between 1-200 LMH, 10-200 LMH, 15-200 LMH, 20-200 LMH, 25-200 LMH, 30-200 LMH, 40- 200 LMH, 50-200 LMH, 100-200 LMH, 125-200 LMH or 150-200 LMH.
  • the activated carbon filtration step is conducted at a feed rate of between 1-150 LMH, 10-150 LMH, 15-150 LMH, 20-150 LMH, 25-150 LMH, 30-150 LMH, 40- I SO LMH, 50-150 LMH, 100-150 LMH or 125-150 LMH.
  • the activated carbon filtration step is conducted at a feed rate of between 1-100 LMH, 10-100 LMH, 15-100 LMH, 20-100 LMH, 25-100 LMH, 30-100 LMH, 40- 100 LMH, or 50-100 LMH.
  • the activated carbon filtration step is conducted at a feed rate of between 1 -75 LMH, 5-75 LMH, 10-75 LMH, 15-75 LMH, 20-75 LMH, 25-75 LMH, 30-75 LMH, 35-75 LMH, 40-75 LMH, 45-75 LMH, 50-75 LMH, 55-75 LMH, 60-75 LMH, 65-75 LMH, or 70-75 LMH.
  • the activated carbon filtration step is conducted at a feed rate of between 1-50 LMH, 5-50 LMH, 7-50 LMH, 10-50 LMH, 15-50 LMH, 20-50 LMH, 25-50 LMH, 30- 50 LMH, 35-50 LMH, 40-50 LMH or 45-50 LMH.
  • the activated carbon filtration step is conducted at a feed rate of about 1 , about 2, about 5, about 10, about 15, about 20, about 25, about 30, about 35, about 40, about 45, about 50, about 55, about 60, about 65, about 70, about 75, about 80, about 85, about 90, about 95, about 100, about 110, about 120, about 130, about 140, about 150, about 160, about 170, about 180, about 190, about 200, about 225, about 250, about 300, about 350, about 400, about 450, about 500, about 550, about 600, about 700, about 800, about 900, about 950 or about 1000 LMH.
  • the solution is treated by an activated carbon filter wherein the filter has a filter capacity of between 5-1000 L/m 2 , 10-750 L/m 2 , 15-500 L/m 2 , 20-400 L/m 2 , 25-300 L/m 2 , 30-250 L/m 2 , 40-200 L/m 2 or 30-100 L/m 2 .
  • the solution is treated by an activated carbon filter wherein the filter has a filter capacity of about 5, about 10, about 15, about 20, about 25, about 30, about 35, about 40, about 45, about 50, about 55, about 60, about 65, about 70, about 75, about 80, about 85, about 90, about 100, about 125, about 150, about 175, about 200, about 225, about 250, about 275, about 300, about 400, about 500, about 600, about 700, about 800, about 900, or about 1000 L/m 2 .
  • activated carbon filtration step(s) If the content of contaminants is above the fixed threshold after a first activated carbon filtration step, the said step can be repeated.
  • 1 , 2, 3, 4, 5, 6, 7, 8, 9, or 10 activated carbon filtration step(s) are performed.
  • 1 , 2 or 3 activated carbon filtration step(s) are performed.
  • 1 or 2 activated carbon filtration step(s) are performed.
  • the solution is treated by activated carbon filters in series. In an embodiment, the solution is treated by 1 , 2, 3, 4, 5, 6, 7, 8, 9, or 10 activated carbon filters in series. In an embodiment, the solution is treated by 2, 3, 4 or 5 activated carbon filters in series. In an embodiment, the solution is treated by 2 activated carbon filters in series. In an embodiment, the solution is treated by 3 activated carbon filters in series. In an embodiment, the solution is treated by 4 activated carbon filters in series. In an embodiment, the solution is treated by 5 activated carbon filters in series.
  • the activated carbon filtration step is performed in a single pass mode.
  • the activated carbon filtration step is performed in recirculation mode.
  • recirculation mode 2 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 , 32, 33, 34, 35, 36, 37, 38, 39, 40, 41 , 42, 43, 44, 45, 46, 47, 48, 49 or 50 cycles of activated carbon filtration are performed.
  • 2, 3, 4, 5, 6, 7, 8, 9 or 10 cycles of activated carbon filtration are performed.
  • 2 or 3 cycles of activated carbon filtration are performed.
  • 2 cycles of activated carbon filtration are performed.
  • the obtained solution i.e. the filtrate
  • the obtained solution can optionally be further filtered.
  • the solution is subjected to microfiltration.
  • microfiltration is dead-end filtration (perpendicular filtration).
  • the solution is treated by a microfiltration step wherein the filter has a nominal retention range of between about 0.01-2 micron, about 0.05-2 micron, about 0.1-2 micron, about 0.2-2 micron, about 0.3-2 micron, about 0.4-2 micron, about 0.45-2 micron, about 0.5-2 micron, about 0.6-2 micron, about 0.7-2 micron, about 0.8-2 micron, about 0.9-2 micron, about 1-2 micron, about 1 .25-2 micron, about 1 .5-2 micron, or about 1 .75-2 micron.
  • the solution is treated by a microfiltration step wherein the filter has a nominal retention range of between about 0.01-1 micron, about 0.05-1 micron, about 0.1-1 micron, about 0.2-1 micron, about 0.3-1 micron, about 0.4-1 micron, about 0.45-1 micron, about 0.5-1 micron, about 0.6-1 micron, about 0.7-1 micron, about 0.8-1 micron or about 0.9-1 micron.
  • the solution is treated by a microfiltration step wherein the filter has a nominal retention rating of about 0.01 , about 0.05, about 0.1 , about 0.2, about 0.3, about 0.4, about 0.45, about 0.5, about 0.6, about 0.7, about 0.8, about 0.9, about 1 .0, about 1.1 , about 1 .2, about 1 .3, about 1 .4, about 1 .5, about 1 .6, about 1 .7, about 1 .8, about 1 .9 or about 2.0 micron.
  • the solution is treated by a microfiltration step wherein the filter has a nominal retention rating of about 0.2 micron.
  • the solution is treated by a microfiltration step wherein the filter has a filter capacity of 100-6000 L/m 2 , 200-6000 L/m 2 , 300-6000 L/m 2 , 400-6000 L/m 2 , 500-6000 L/m 2 , 750-6000 L/m 2 , 1000-6000 L/m 2 , 1500-6000 L/m 2 , 2000-6000 L/m 2 , 3000-6000 L/m 2 or 4000- 6000 L/m 2 .
  • the solution is treated by a microfiltration step wherein the filter has a filter capacity of 100-4000 L/m 2 , 200-4000 L/m 2 , 300-4000 L/m 2 , 400-4000 L/m 2 , 500-4000 L/m 2 , 750-4000 L/m 2 , 1000-4000 L/m 2 , 1500-4000 L/m 2 , 2000-4000 L/m 2 , 2500-4000 L/m 2 , 3000-4000 L/m 2 , 3000-4000 L/m 2 or 3500-4000 L/m 2 .
  • the solution is treated by a microfiltration step wherein the filter has a filter capacity of 100-3750 L/m 2 , 200-3750 L/m 2 , 300-3750 L/m 2 , 400-3750 L/m 2 , 500-3750 L/m 2 , 750-3750 L/m 2 , 1000-3750 L/m 2 , 1500-3750 L/m 2 , 2000-3750 L/m 2 , 2500-3750 L/m 2 , 3000-3750 L/m 2 , 3000-3750 L/m 2 or 3500-3750 L/m 2 .
  • the solution is treated by a microfiltration step wherein the filter has a filter capacity of 100-1250 L/m 2 , 200-1250 L/m 2 , 300-1250 L/m 2 , 400-1250 L/m 2 , 500-1250 L/m 2 , 750-1250 L/m 2 or 1000-1250 L/m 2 .
  • the solution is treated by a microfiltration step wherein the filter has a filter capacity of about 100, about 200, about 300, about 400, about 550, about 600, about 700, about 800, about 900, about 1000, about 1100, about 1200, about 1300, about 1400, about 1500, about 1600, about 1700, about 1800, about 1900, about 2000, about 2100, about 2200, about 2300, about 2400, about 2500, about 2600, about 2700, about 2800, about 2900, about
  • This unit operation removes any impurities that had hydrophobic characteristics, such as residual lipid polysaccharides (endotoxins) left from the fomer purification steps.
  • the solution containing the polysaccharide can optionally be further purified by a HIC step.
  • the solution of section 1.2 further treated by the solid/liquid separation step of section 1 .3 is further purified by a HIC step.
  • the solution further filtered by any of the method of section 1 .5 above and/or by the filtration step of section 1.4 above is further purified by a HIC step.
  • the solution further clarified by an Ultrafiltration and/or Dialfiltration step of section 1 .6 above is further purified by a HIC step.
  • the solution further clarified by activated carbon filtration step of section 1 .7 is further purified by a HIC step.
  • the solution further clarified by an Ultrafiltration and/or Dialfiltration step of section 1 .6 above is further purified by an ion exchange membrane (IEX) filtration step and can then be further purified by a HIC step.
  • IEX ion exchange membrane
  • the HIC step is conducted using an hydrophobic adsorbent selected from but not limited to the group consisting of a phenyl membrane, butyl-, phenyl-, and octyl- agarose, butyl-, phenyl-, ether-, polypropylenglycol- and hexyl- organic polymer resin.
  • an hydrophobic adsorbent selected from but not limited to the group consisting of a phenyl membrane, butyl-, phenyl-, and octyl- agarose, butyl-, phenyl-, ether-, polypropylenglycol- and hexyl- organic polymer resin.
  • the hydrophobic adsorbent used in the HIC step is a phenyl membrane such as the SARTOBIND Phenyl membrane or CYTIVA’s Phenyl Adsorber membrane.
  • the hydrophobic adsorbent used in the HIC step is a the SARTOBIND Phenyl membrane.
  • the material from the former step is treated with an equilibration buffer to obtain a running buffer comprising the material to be purified and a desired salt concentration.
  • the equilibration buffer comprise a salt and the final salt concentration (i.e in the running buffer) is selected from about 0.1 , about 0.2, about 0.3, about 0.4, about 0.5, about 0.6, about 0.7, about 0.8, about 0.9, about 1 .0, about 1.1 , about 1 .2, about 1 .3, about 1 .4, about 1 .5, about 1 .6, about 1 .7, about 1 .8, about 1 .9, about 2.0, about 2.1 , about 2.2, about 2.3, about 2.4, about 2.5, about 2.6, about 2.7, about 2.8, about 2.9, about 3.0, about 3.1 , about 3.2, about 3.3, about 3.4, about 3.5, about 3.6, about 3.7, about 3.8, about 3.9, about 4.0, about
  • the running buffer has a pH between about 4.0 and about 8.0.
  • the pH of the running buffer is about 4.0, about 4.1 , about 4.2, about 4.3, about 4.4, about 4.5, about 4.6, about 4.7, about 4.8, about 4.9, about 5.0, about 5.1 , about 5.2, about 5.3, about 5.4, about 5.5, about 5.6, about 5.7, about 5.8, about 5.9, about 6.0, about 6.1 , about 6.2, about 6.3, about 6.4, about 6.5, about 6.6, about 6.7, about 6.8, about 6.9, about 7.0, about 7.1 , about 7.2, about 7.3, about 7.4, about 7.5, about 7.6, about 7.7, about 7.8, about 7.9 or about 8.0.
  • the equilibration buffer comprises a salt selected from ammonium sulfate (preferably at a final concentration in the running buffer of 0.5M-3.0M and pH 6.0 ⁇ 2.0), sodium phosphate (preferably at a final concentration in the running buffer of 0.5M-3.0M and pH 7.0 ⁇ l.5), potassium phosphate (preferably at a final concentration in the running buffer of 0.5M-3.0M and pH 7.0 ⁇ l.5), sodium sulfate (preferably at a final concentration in the running buffer of 0.1 M-0.75M and pH 6.0 ⁇ 2.0), sodium citrate (preferably at a final concentration in the running buffer of 0.1 M- 1 5M and pH 6.0 ⁇ 2.0) or sodium chloride (preferably at a final concentration in the running buffer of 0.5M-5.0M and pH 7.0 ⁇ 1.5).
  • ammonium sulfate preferably at a final concentration in the running buffer of 0.5M-3.0M and pH 6.0 ⁇ 2.0
  • sodium phosphate preferably at a final concentration in the running buffer of
  • the equilibration buffer is comprises ammonium sulfate and the final salt concentration in the running buffer is comprised between about 1 0M and about 2.0M, preferably about 1 .0, about 1.1 , about 1 .2, about 1 .3, about 1 .4, about 1 .5, about 1 .6, about 1 .7, about 1 .8, about 1 .9, about 2.0 M).
  • the hydrophobic adsorbent is equilibrated using the running buffer and the material to be purified in the running buffer is then ran through the column or membrane.
  • the hydrophobic adsorbent is a phenyl membrane and the flow rate is comprised between about 0.1 and about 20 membrane volumes per min, about 0.1 and about 10 membrane volumes per min, about 0.2 and about 10 membrane volumes per min, about 0.2 and about 5 membrane volumes per min, about 0.1 and about 1 membrane volume per min.
  • the hydrophobic adsorbent is a phenyl membrane and the flow rate is comprised between about 0.1 and about 1 .0 membrane volume per min, preferably about 0.1 , about 0.2, about 0.3, about 0.4, about 0.5, about 0.6, about 0.7, about 0.8, about 0.9 or about 1 .0 membrane volume per min.
  • the HIC membrane is then rinsed with the running buffer and can also be further washed with water.
  • the flow through effluent along with the buffer rinse was collected as HIC filtrate, and the water wash was also collected for analysis.
  • the obtained solution i.e. the filtrate
  • the obtained solution can optionally be further clarified by Ultrafiltration and/or Dialfiltration.
  • the solution e.g. obtained at section 1 .9 or 1 .8 above
  • the solution is treated by ultrafiltration.
  • the solution is treated by ultrafiltration and the molecular weight cut off of the membrane is in the range of between about 5 kDa -1000 kDa. In an embodiment the molecular weight cut off of the membrane is in the range of between about 10 kDa -750 kDa. In an embodiment the molecular weight cut off of the membrane is in the range of between about 10 kDa -500 kDa. In an embodiment the molecular weight cut off of the membrane is in the range of between about 10 kDa -300 kDa. In an embodiment the molecular weight cut off of the membrane is in the range of between about 10 kDa -100 kDa.
  • the molecular weight cut off of the membrane is in the range of between about 10 kDa -50 kDa. In an embodiment the molecular weight cut off of the membrane is in the range of between about 10 kDa -30 kDa.
  • the molecular weight cut off of the membrane is in the range of between about 5 kDa -1000 kDa, about 10 kDa -1000 kDa about 20 kDa -1000 kDa, about 30 kDa -1000 kDa, about 40 kDa -1000 kDa, about 50 kDa -1000 kDa, about 75 kDa -1000 kDa, about 100 kDa -1000 kDa, about 150 kDa -1000 kDa, about 200 kDa -1000 kDa, about 300 kDa -1000 kDa, about 400 kDa -1000 kDa, about 500 kDa -1000 kDa or about 750 kDa -1000 kDa.
  • the molecular weight cut off of the membrane is in the range of between about 5 kDa -500 kDa, about 10 kDa -500 kDa, about 20 kDa -500 kDa, about 30 kDa -500 kDa, about 40 kDa -500 kDa, about 50 kDa -500 kDa, about 75 kDa -500 kDa, about 100 kDa -500 kDa, about 150 kDa -500 kDa, about 200 kDa -500 kDa, about 300 kDa -500 kDa or about 400 kDa -500 kDa.
  • the molecular weight cut off of the membrane is in the range of between about about 5 kDa -300 kDa, about 10 kDa -300 kDa, about 20 kDa -300 kDa, about 30 kDa -300 kDa, about 40 kDa -300 kDa, about 50 kDa -300 kDa, about 75 kDa -300 kDa, about 100 kDa -300 kDa, about 150 kDa -300 kDa or about 200 kDa -300 kDa.
  • the molecular weight cut off of the membrane is in the range of between about 5 kDa -100 kDa, about 10 kDa -100 kDa, about 20 kDa -100 kDa, about 30 kDa -100 kDa, about 40 kDa -100 kDa, about 50 kDa -100 kDa or about 75 kDa -100 kDa.
  • the molecular weight cut off of the membrane is about 5 kDa, about 10 kDa, about 20 kDa, about 30 kDa, about 40 kDa, about 50 kDa, about 60 kDa, about 70 kDa, about 80 kDa, about 90 kDa, about 100 kDa, about 110 kDa, about 120 kDa, about 130 kDa, about 140 kDa, about 150 kDa, about 200 kDa, about 250 kDa, about 300 kDa, about 400 kDa, about 500 kDa, about 750 kDa or about 1000 kDa.
  • the concentration factor of the ultrafiltration step is from about 1 .5 to about 10.0.
  • the concentration factor is from about 2.0 to about 8.0.
  • the concentration factor is from about 2.0 to about 5.0.
  • the concentration factor is about 1 .5, about 2.0, about 2.5, about 3.0, about 3.5, about 4.0, about 4.5, about 5.0, about 5.5, about 6.0, about 6.5, about 7.0, about 7.5, about 8.0, about 8.5, about 9.0, about 9.5 or about 10.0. In an embodiment, the concentration factor is about 2.0, about 3.0, about 4.0, about 5.0, or about 6.0.
  • the solution e.g. the filtrate obtained at section 1 .9 or 1 .8 above
  • the solution is treated by diafiltration.
  • the solution obtained following ultrafiltration (UF) as disclosed in the present section above is further treated by diafiltration (UF/DF treatment).
  • Diafiltration is used to exchange product into a desired buffer solution (or water only).
  • diafiltration is used to change the chemical properties of the retained solution under constant volume. Unwanted particles pass through a membrane while the makeup of the feed stream is changed to a more desirable state through the addition of a replacement solution (a buffer solution, a saline solution, a buffer saline solution or water).
  • the replacement solution is water.
  • the replacement solution is saline in water.
  • the salt is selected from the groups consisting of magnesium chloride, potassium chloride, sodium chloride and a combination thereof.
  • the salt is sodium chloride.
  • the replacement solution is sodium chloride at about 1 , about 5, about 10, about 15, about 20, about 25, about 30, about 35, about 40, about 45, about 50, about 55, about 60, about 65, about 70, about 80, about 90, about 100, about 110, about 120, about 130, about 140, about 150, about 160, about 170, about 180, about 190, about 200, about 250, about 300, about 350, about 400, about 450 or about 500 mM.
  • the replacement solution is sodium chloride at about 1 , about 5, about 10, about 15, about 20, about 25, about 30, about 35, about 40, about 45, about 50, about 55, about 60, about 65, about 70, about 80, about 90, about 100, about 110, about 120, about 130, about 140, about 150, about 160, about 170, about 180, about 190, about 200, about 250 or about 300 mM.
  • the replacement solution is sodium chloride at about 25, about 30, about 35, about 40, about 45, about 50, about 55, about 60, about 65, about 70, about 80, about 90 or about 100 mM.
  • the replacement solution is a buffer solution.
  • the replacement solution is a buffer solution wherein the buffer is selected from the group consisting of N-(2-Acetamido)-aminoethanesulfonic acid (ACES), a salt of acetic acid (acetate), N-(2- Acetamido)-iminodiacetic acid (ADA), 2-Aminoethanesulfonic acid (AES, Taurine), ammonia, 2- Amino-2-methyl-1 -propanol (AMP), 2-Amino-2-methyl-1 ,3-propanediol AMPD, ammediol, N- (1 ,1-Dimethyl-2-hydroxyethyl)-3-amino-2-hydroxypropanesulfonic acid (AMPSO), N,N-Bis-(2- hydroxyethyl)-2-aminoethanesulfonic acid (BES), sodium hydrogen carbonate (bicarbonate), N,N’-Bis(2-hydroxyethyl)
  • the diafiltration buffer is selected from the group consisting of a salt of acetic acid (acetate), a salt of citric acid (citrate), a salt of formic acid (formate), a salt of malic acid (malate), a salt of maleic acid (maleate), a salt of phosphoric acid (phosphate) and a salt of succinic acid (succinate).
  • the diafiltration buffer is a salt of citric acid (citrate).
  • the diafiltration buffer is a salt of succinic acid (succinate).
  • the diafiltration buffer is a salt of phosphoric acid (phosphate).
  • said salt is a sodium salt.
  • said salt is a potassium salt.
  • the pH of the diafiltration buffer is between about 4.0-11 .0, between about 5.0-10.0, between about 5.5-9.0, between about 6.0-8.0, between about 6.0-7.0, between about 6.5-7.5, between about 6.5-7.0 or between about 6.0-7.5. Any number within any of the above ranges is contemplated as an embodiment of the disclosure.
  • the pH of the diafiltration buffer is about 4.0, about 4.5, about 5.0, about 5.5, about 6.0, about 6.5, about 7.0, about 7.5, about 8.0, about 8.5, about 9.0, about 9.5, about 10.0, about 10.5 or about 11 .0.
  • the pH of the diafiltration buffer is about 6.0, about 6.5, about 7.0, about 7.5, about 8.0, about 8.5 or about 9.0.
  • the pH of the diafiltration buffer is about about 6.5, about 7.0 or about 7.5.
  • the pH of the diafiltration buffer is about 6.0.
  • the pH of the diafiltration buffer is about 6.5.
  • the pH of the diafiltration buffer is about 7.0.
  • the concentration of the diafiltration buffer is between about 0.01 mM- 100mM, between about 0.1 mM-100mM, between about 0.5mM-100mM, between about 1 mM- 100mM, between about 2mM-100mM, between about 3mM-100mM, between about 4mM- 100mM, between about 5mM-100mM, between about 6mM-100mM, between about 7mM- 100mM, between about 8mM-100mM, between about 9mM-100mM, between about 10mM- 100mM, between about 11 mM-100mM, between about 12mM-100mM, between about 13mM- 100mM, between about 14mM-100mM, between about 15mM-100mM, between about 16mM- 100mM, between about 17mM-100mM, between about 18mM-100mM, between about 19mM- 100m
  • the concentration of the diafiltration buffer is between about 0.01 mM- 50mM, between about 0.1 mM-50mM, between about 0.5mM-50mM, between about 1 mM- 50mM, between about 2mM-50mM, between about 3mM-50mM, between about 4mM-50mM, between about 5mM-50mM, between about 6mM-50mM, between about 7mM-50mM, between about 8mM-50mM, between about 9mM-50mM, between about 10mM-50mM, between about 11 mM-50mM, between about 12mM-50mM, between about 13mM-50mM, between about 14mM-50mM, between about 15mM-50mM, between about 16mM-50mM, between about 17mM-50mM, between about 18mM-50mM, between about 19mM-50mM, between about 20mM-50mM, between about 25mM-50mM, between about 30mM-50mM, between about 35mM-50mM
  • the concentration of the diafiltration buffer is between about 0.01 mM- 25mM, between about 0.1 mM-25mM, between about 0.5mM-25mM, between about 1 mM- 25mM, between about 2mM-25mM, between about 3mM-25mM, between about 4mM-25mM, between about 5mM-25mM, between about 6mM-25mM, between about 7mM-25mM, between about 8mM-25mM, between about 9mM-25mM, between about 10mM-25mM, between about 11 mM-25mM, between about 12mM-25mM, between about 13mM-25mM, between about 14mM-25mM, between about 15mM-25mM, between about 16mM-25mM, between about 17mM-25mM, between about 18mM-25mM, between about 19mM-25mM or between about 20mM-25mM.
  • the concentration of the diafiltration buffer is between about 0.01 mM- 15mM, between about 0.1 mM-15mM, between about 0.5mM-15mM, between about 1 mM- 15mM, between about 2mM-15mM, between about 3mM-15mM, between about 4mM-15mM, between about 5mM-15mM, between about 6mM-15mM, between about 7mM-15mM, between about 8mM-15mM, between about 9mM-15mM, between about 10mM-15mM, between about 11 mM-15mM, between about 12mM-15mM, between about 13mM-15mM or between about 14mM-15mM.
  • the concentration of the diafiltration buffer is between about 0.01 mM- 10mM, between about 0.1 mM-10mM, between about 0.5mM-10mM, between about 1 mM- 10mM, between about 2mM-10mM, between about 3mM-10mM, between about 4mM-10mM, between about 5mM-10mM, between about 6mM-10mM, between about 7mM-10mM, between about 8mM-10mM or between about 9mM-10mM.
  • the concentration of the diafiltration buffer is about 0.01 mM, about 0.05 mM, about 0.1 mM, about 0.2 mM, about 0.3 mM, about 0.4 mM, about 0.5 mM, about 0.6 mM, about 0.7 mM, about 0.8 mM, about 0.9 mM, about 1 mM, about 2 mM, about 3 mM, about 4 mM, about 5 mM, about 6 mM, about 7 mM, about 8 mM, about 9 mM, about 10 mM, about 11 mM, about 12 mM, about 13 mM, about 14 mM, about 15 mM, about 16 mM, about 17 mM, about 18 mM, about 19 mM, about 20 mM, about 25 mM, about 30 mM, about 35 mM, about 40 mM, about 45 mM, about 50 mM, about 55 mM, about 60 .
  • the concentration of the diafiltration buffer is about 0.1 mM, about 0.2 mM, about 1 mM, about 5 mM, about 10 mM, about 15 mM, about 20 mM, about 25mM, about 30 mM, about 40 mM, or about 50 mM. In an embodiment, the concentration of the diafiltration buffer is about 30 mM. In an embodiment, the concentration of the diafiltration buffer is about 25 mM. In an embodiment, the concentration of the diafiltration buffer is about 20 mM. In an embodiment, the concentration of the diafiltration buffer is about 15 mM. In an embodiment, the concentration of the diafiltration buffer is about 10 mM.
  • the diafiltration buffer solution comprises a salt.
  • the salt is selected from the groups consisting of magnesium chloride, potassium chloride, sodium chloride and a combination thereof.
  • the salt is sodium chloride.
  • the diafiltration buffer solution comprises sodium chloride at about 1 , about 5, about 10, about 15, about 20, about 25, about 30, about 35, about 40, about 45, about 50, about 55, about 60, about 65, about 70, about 80, about 90, about 100, about 110, about 120, about 130, about 140, about 150, about 160, about 170, about 180, about 190, about 200, about 250 or about 300 mM.
  • the number of diavolumes is at least 5, 10,
  • the number of diavolumes is about 1 , about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11 , about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, about 20, about 21 , about 22, about 23, about 24, about 25, about 26, about 27, about 28, about 29, about 30, about 31 , about 32, about 33, about 34, about 35, about 36, about 37, about 38, about 39, about 40, about 41 , about 42, about 43, about 44, about 45, about 46, about 47, about 48, about 49, about 50, about 55, about 60, about 65, about 70, about 75, about 80, about 85, about 90, about 95 or about 100. In an embodiment of the present invention the number of diavolumes is about 5, about 6, about 7, about 8, about 9, about 10, about 11 , about 12, about 13, about 14 or about 15.
  • the Ultrafiltration and Dialfiltration steps are performed at temperature between about 20°C to about 90°C. In an embodiment, the Ultrafiltration and Dialfiltration steps are performed at a temperature between about 35°C to about 80°C, at temperature between about 40°C to about 70°C, at temperature between about 45°C to about 65°C, at temperature between about 50°C to about 60°C, at temperature between about 50°C to about 55°C, at temperature between about 45°C to about 55°C or at temperature between about 45°C to about 55°C. Any number within any of the above ranges is contemplated as an embodiment of the disclosure.
  • the Ultrafiltration and Dialfiltration steps are performed at a temperature of about 20°C, about 21 °C, about 22°C, about 23°C, about 24°C, about 25°C, about 26°C, about 27°C, about 28°C, about 29°C, about 30°C, about 31 °C, about 32°C, about 33°C, about 34°C, about 35°C, about 36°C, about 37°C, about 38°C, about 39°C, about 40°C, about 41 °C, about 42°C, about 43°C, about 44°C, about 45°C, about about 46°C, about 47°C, about 48°C, about 49°C, about 50°C, about 51 °C, about 52°C, about 53°C, about 54°C, about 55°C, about 56°C, about 57°C, about 58°C, about 59°C, about 60°C, about 61 °C, about 62°C, about 63°C, about 64°C
  • the Dialfiltration step is performed at temperature between about 20°C to about 90°C. In an embodiment, the Dialfiltration step is performed at a temperature between about 35°C to about 80°C, at temperature between about 40°C to about 70°C, at temperature between about 45°C to about 65°C, at temperature between about 50°C to about 60°C, at temperature between about 50°C to about 55°C, at temperature between about 45°C to about 55°C or at temperature between about 45°C to about 55°C. Any number within any of the above ranges is contemplated as an embodiment of the disclosure.
  • Dialfiltration step is performed at a temperature of about about 20°C, about 21 °C, about 22°C, about 23°C, about 24°C, about 25°C, about 26°C, about 27°C, about
  • the Dialfiltration step is performed at a temperature of about 50°C.
  • the Ultrafiltration step is performed at temperature between about 20°C to about 90°C. In an embodiment, the Ultrafiltration step is performed at a temperature between about 35°C to about 80°C, at temperature between about 40°C to about 70°C, at temperature between about 45°C to about 65°C, at temperature between about 50°C to about 60°C, at temperature between about 50°C to about 55°C, at temperature between about 45°C to about 55°C or at temperature between about 45°C to about 55°C. Any number within any of the above ranges is contemplated as an embodiment of the disclosure.
  • Ultrafiltration step is performed at a temperature of about about 20°C, about 21 °C, about 22°C, about 23°C, about 24°C, about 25°C, about 26°C, about 27°C, about 28°C, about 29°C, about 30°C, about 31 °C, about 32°C, about 33°C, about 34°C, about 35°C, about 36°C, about 37°C, about 38°C, about 39°C, about 40°C, about 41 °C, about 42°C, about 43°C, about 44°C, about 45°C, about about 46°C, about 47°C, about 48°C, about 49°C, about
  • the Ultrafiltration step is performed at a temperature of about 50°C.
  • a polysaccharide can become slightly reduced in size during the purification procedures.
  • the purified solution of polysaccharide of the present invention (e.g. obtained by Ultrafiltration and/or Dialfiltration of section 1 .10) is not sized.
  • the polysaccharide can be homogenized by sizing techniques. Mechanical or chemical sizing maybe employed. Chemical hydrolysis maybe conducted using for example acetic acid. Mechanical sizing maybe conducted using High Pressure Homogenization Shearing.
  • the purified solution of polysaccharide obtained by Ultrafiltration and/or Dialfiltration of section 1.10 is sized to a target molecular weight.
  • molecular weight of polysaccharide refers to molecular weight calculated for example by size exclusion chromatography (SEC) combined with multiangle laser light scattering detector (MALLS).
  • the purified polysaccharide is sized to a molecular weight of between about 5 kDa and about 4,000 kDa. In other such embodiments, the purified polysaccharide is sized to a molecular weight of between about 10 kDa and about 4,000 kDa. In other such embodiments, the purified polysaccharide is sized to a molecular weight of between about 50 kDa and about 4,000 kDa.
  • the polysaccharide the purified polysaccharide is sized to a molecular weight of between about 50 kDa and about 3,500 kDa; between about 50 kDa and about 3,000 kDa; between about 50 kDa and about 2,500 kDa; between about 50 kDa and about 2,000 kDa; between about 50 kDa and about 1 ,750 kDa; about between about 50 kDa and about 1 ,500 kDa; between about 50 kDa and about 1 ,250 kDa; between about 50 kDa and about 1 ,000 kDa; between about 50 kDa and about 750 kDa; between about 50 kDa and about 500 kDa; between about 100 kDa and about 4,000 kDa; between about 100 kDa and about 3,500 kDa; about 100 kDa and about 3,000 kDa; about 100 kDa and about and about
  • the polysaccharide the purified polysaccharide is sized to a molecular weight of between about 250 kDa and about 3,500 kDa; between about 250 kDa and about 3,000 kDa; between about 250 kDa and about 2,500 kDa; between about 250 kDa and about 2,000 kDa; between about 250 kDa and about 1 ,750 kDa; about between about 250 kDa and about 1 ,500 kDa; between about 250 kDa and about 1 ,250 kDa; between about 250 kDa and about 1 ,000 kDa; between about 250 kDa and about 750 kDa; between about 250 kDa and about 500 kDa; between about 300 kDa and about 4,000 kDa; between about 300 kDa and about 3,500 kDa; about 300 kDa and about 3,000 kDa; about 300 kDa and about 300 kDa and
  • the purified polysaccharide is sized to a molecular weight of about 5 kDa, about 10 kDa, about 15 kDa, about 20 kDa, about 25 kDa, about 30 kDa, about 35 kDa, about 40 kDa, about 45 kDa, about 50 kDa, about 75 kDa, about 90 kDa, about 100 kDa, about 150 kDa, about 200 kDa, about 250 kDa, about 300 kDa, about 350 kDa, about 400 kDa, about 450 kDa, about 500 kDa, about 550 kDa, about 600 kDa, about 650 kDa, about 700 kDa, about 750 kDa, about 800 kDa, about 850 kDa, about 900 kDa, about 950 kDa, about 1000 kDa, about 1250 kDa
  • the purified polysaccharides are capsular polysaccharide from serotypes 1 , 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11 A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23F or 33F of S. pneumoniae, wherein the capsular polysaccharide has a molecular weight falling within one of the ranges or having about the size as described here above.
  • the purified solution of polysaccharide of the invention is sterilely filtered.
  • the Ultrafiltration and/or Dialfiltration step of section 1.10 can optionally be followed by a sterile filtration step.
  • the homogenizing / sizing step of section 1.11 if conducted can optionally be followed by a sterile filtration step.
  • any of the step of sections 1.2 to 1.9 can optionally be followed by a sterile filtration step.
  • sterile filtration is dead-end filtration (perpendicular filtration). In an embodiment, sterile filtration is tangential filtration.
  • the solution is treated by a sterile filtration step wherein the filter has a nominal retention range of between about 0.01-0.2 micron, about 0.05-0.2 micron, about 0.1- 0.2 micron or about 0.15-0.2 micron.
  • the solution is treated by a sterile filtration step wherein the filter has a nominal retention range of about 0.05, about 0.1 , about 0.15 or about 0.2micron.
  • the solution is treated by a sterile filtration step wherein the filter has a nominal retention range of about 0.2micron. In an embodiment, the solution is treated by a sterile filtration step wherein the filter has a filter capacity of about 25-1500 L/m 2 , 50-1500 L/m 2 , 75-1500 L/m 2 , 100-1500 L/m 2 , 150-1500 L/m 2 , 200-1500 L/m 2 , 250-1500 L/m 2 , 300-1500 L/m 2 , 350-1500 L/m 2 , 400-1500 L/m 2 , 500-1500 L/m 2 , 750-1500 L/m 2 , 1000-1500 L/m 2 or 1250-1500 L/m 2 .
  • the solution is treated by a sterile filtration step wherein the filter has a filter capacity of about 25-1000 L/m 2 , 50-1000 L/m 2 , 75-1000 L/m 2 , 100-1000 L/m 2 , 150-1000 L/m 2 , 200-1000 L/m 2 , 250-1000 L/m 2 , 300-1000 L/m 2 , 350-1000 L/m 2 , 400-1000 L/m 2 , 500-1000 L/m 2 or 750-1000 L/m 2 .
  • the solution is treated by a sterile filtration step wherein the filter has a filter capacity of 25-500 L/m 2 , 50-500 L/m 2 , 75-500 L/m 2 , 100-500 L/m 2 , 150-500 L/m 2 , 200- 500 L/m 2 , 250-500 L/m 2 , 300-500 L/m 2 , 350-500 L/m 2 or 400-500 L/m 2 .
  • the solution is treated by a sterile filtration step wherein the filter has a filter capacity of 25-300 L/m 2 , 50-300 L/m 2 , 75-300 L/m 2 , 100-300 L/m 2 , 150-300 L/m 2 , 200-300 L/m 2 or 250-300 L/m 2 .
  • the solution is treated by a sterile filtration step wherein the filter has a filter capacity of 25-250 L/m 2 , 50-250 L/m 2 , 75-250 L/m 2 , 100-250 L/m 2 or 150-250 L/m 2 , 200- 250 L/m 2 .
  • the solution is treated by a sterile filtration step wherein the filter has a filter capacity of 25-100 L/m 2 , 50-100 L/m 2 or 75-100 L/m 2 .
  • the solution is treated by a microfiltration step wherein the filter has a filter capacity of about 25, about 50, about 75, about 100, about 150, about 200, about 250, about 300, about 350, about 400, about 500, about 600, about 700, about 800, about 900, about 1000, about 1100, about 1200, about 1300, about 1400 or about 1500 L/m 2 .
  • the polysaccharide can be finally prepared as a liquid solution.
  • the polysaccharide can be furher processed (e.g. lyophilized as a dried powder, see W02006/110381). Therefore in an embodiment, the polysaccharide is a dried powder.
  • the polysaccharide is a freeze-dried cake.
  • the polysaccharide purified by the method of the present invention may be used as an antigen.
  • Plain polysaccharides are used as antigens in vaccines (see the 23-valent unconjugated pneumococcal polysaccharide vaccine PNEUMOVAX).
  • the polysaccharide purified by the method of the present invention may also be conjugated to carrier protein(s) to obtain a glycoconjugate.
  • carrier protein(s) may also be conjugated to obtain a glycoconjugate.
  • the polysaccharide purified by the method of the present invention may be conjugated to carrier protein(s) to obtain a glyco conjugate.
  • 'glycoconjugate' indicates a saccharide covalently linked to a carrier protein.
  • a saccharide is linked directly to a carrier protein.
  • a saccharide is linked to a carrier protein through a spacer/linker.
  • covalent conjugation of saccharides to carriers enhances the immunogenicity of saccharides as it converts them from T-independent antigens to T-dependent antigens, thus allowing priming for immunological memory. Conjugation is particularly useful for pediatric vaccines.
  • Purified polysaccharides by the method of the invention may be activated (e.g., chemically activated) to make them capable of reacting (e.g. with a linker or directly with the carrier protein) and then incorporated into glycoconjugates, as further described herein.
  • the purified polysaccharide maybe sized to a target molecular weight before conjugation e.g. by the methods disclosed at section 1.11 above. Therefore in an embodiment, the purified polysaccharide is sized before conjugation. In an embodiment, the purified polysaccharide as disclosed herein may be sized before conjugation to obtain an oligosaccharide. Oligosaccharides have a low number of repeat units (typically 5-15 repeat units) and are typically derived by sizing (e.g. hydrolysis) of the polysaccharide.
  • the saccharide to be used for conjugation is a polysaccharide.
  • High molecular weight polysaccharides are able to induce certain antibody immune responses due to the epitopes present on the antigenic surface.
  • the isolation and purification of high molecular weight polysaccharides is preferably contemplated for use in the conjugates of the present invention.
  • the polysaccharide is sized and remains a polysaccharide. In an embodiment, the polysaccharide is not sized.
  • the purified polysaccharide before conjugation has a molecular weight of between 5 kDa and 4,000 kDa. In other such embodiments, the purified polysaccharide has a molecular weight of between 10 kDa and 4,000 kDa. In other such embodiments, the purified polysaccharide has a molecular weight of between 50 kDa and 4,000 kDa.
  • the polysaccharide has a molecular weight of between 50 kDa and 3,500 kDa; between 50 kDa and 3,000 kDa; between 50 kDa and 2,500 kDa; between 50 kDa and 2,000 kDa; between 50 kDa and 1 ,750 kDa; between 50 kDa and 1 ,500 kDa; between 50 kDa and 1 ,250 kDa; between 50 kDa and 1 ,000 kDa; between 50 kDa and 750 kDa; between 50 kDa and 500 kDa; between 100 kDa and 4,000 kDa; between 100 kDa and 3,500 kDa; 100 kDa and 3,000 kDa; 100 kDa and 2,500 kDa; 100 kDa and 2,250 kDa; between 100 kDa and 2,000 kDa; between 100 kDa and kDa and
  • the polysaccharide has a molecular weight of between 250 kDa and
  • the purified polysaccharide has a molecular weight of about 5 kDa, 10 kDa, 15 kDa, 20 kDa, 25 kDa, 30 kDa, 35 kDa, 40 kDa, 45 kDa, 50 kDa, 75 kDa, 90 kDa, 100 kDa, 150 kDa, 200 kDa, 250 kDa, 300 kDa, 350 kDa, 400 kDa, 450 kDa, 500 kDa, 550 kDa, 600 kDa, 650 kDa, 700 kDa, 750 kDa, 800 kDa, 850 kDa, 900 kDa, 950 kDa, 1000 kDa, 1250 kDa, 1500 kDa, 1750 kDa, 2000 kDa, 2250 kDa, 2500 kDa,
  • the purified polysaccharide is a capsular saccharide (polysaccharide or oligosaccharide).
  • the purified polysaccharide is a capsular polysaccharide from Escherichia coli.
  • the purified polysaccharide is a capsular polysaccharide from an Escherichia coli part of the Enterovirulent Escherichia coli group (EEC Group) such as Escherichia coli - enterotoxigenic (ETEC), Escherichia coli - enteropathogenic (EPEC), Escherichia coli - 0157:H7 enterohemorrhagic (EHEC), or Escherichia coli - enteroinvasive (EIEC).
  • ETEC Escherichia coli - enterotoxigenic
  • EPEC Escherichia coli - enteropathogenic
  • EHEC Escherichia coli - 0157:H7 enterohemorrhagic
  • EIEC Escherichia coli - enteroinvasive
  • the purified polysaccharide is a capsular polysaccharide from an Uropathogenic Escherichia coli (UPEC).
  • the purified polysaccharide is a capsular polysaccharide from an Escherichia coli serotype selected from the group consisting of serotypes 0157:H7, 026:1-111 ,
  • the purified polysaccharide is a capsular polysaccharide from an Escherichia coli serotype selected from the group consisting of serotypes 06:K2:H1 and 018:K1 :H7. In an embodiment, the purified polysaccharide is a capsular polysaccharide from an Escherichia coli serotype selected from the group consisting of serotypes 045:K1 , 017:K52:H18, 019:H34 and 07:K1. In an embodiment, the purified polysaccharide is a capsular polysaccharide from an Escherichia coli serotype O104:H4.
  • the purified polysaccharide is a capsular polysaccharide from Escherichia coli serotype 01 :K12:H7. In an embodiment, the purified polysaccharide is a capsular polysaccharide from an Escherichia coli serotype 0127:1-16. In an embodiment, the purified polysaccharide is a capsular polysaccharide from an Escherichia coli serotype 0139:1-128. In an embodiment, the purified polysaccharide is a capsular polysaccharide from an Escherichia coli serotype 0128:1-12.
  • the purified polysaccharide is a capsular polysaccharide from Neisseria meningitidis.
  • the purified polysaccharide is a capsular polysaccharide from N. meningitidis serogroup A (MenA), N. meningitidis serogroup W135 (MenW135), N. meningitidis serogroup Y (MenY), N. meningitidis serogroup X (MenX) or N. meningitidis serogroup C (MenC).
  • the purfified polysaccharide is a capsular polysaccharide from Klebsiella pneumoniae.
  • the source of bacterial capsular polysaccharides is K. pneumoniae serogroup 01 (01), K. pneumoniae serogroup 02 (02), K. pneumoniae serogroup O2ao (O2ao), K. pneumoniae serogroup 03 (03), K. pneumoniae serogroup 04 (04), K. pneumoniae serogroup 05 (05), K. pneumoniae serogroup 07 (07), K. pneumoniae serogroup 08 (08) orK. pneumoniae serogroup 09 (09).
  • the source of bacterial capsular polysaccharides is K. pneumoniae serogroup 01 (01).
  • the source of bacterial capsular polysaccharides is K. pneumoniae serogroup 02 (02). In an embodiment the source of bacterial capsular polysaccharides is K. pneumoniae serogroup O2ao (02ac). In an embodiment the source of bacterial capsular polysaccharides is K. pneumoniae serogroup 03 (03). In an embodiment the source of bacterial capsular polysaccharides is K. pneumoniae serogroup 04 (04). In an embodiment the source of bacterial capsular polysaccharides is K. pneumoniae serogroup 05 (05). In an embodiment the source of bacterial capsular polysaccharides is K. pneumoniae serogroup 07 (07). In an embodiment the source of bacterial capsular polysaccharides is K. pneumoniae serogroup 08 (08). In an embodiment the source of bacterial capsular polysaccharides is K. pneumoniae serogroup 09 (09).
  • Any suitable conjugation reaction can be used, with any suitable linker where necessary. See for example W02007116028 pages 17-22.
  • the purified oligosaccharides or polysaccharides described herein are chemically activated to make the saccharides capable of reacting with the carrier protein.
  • the glycoconjugate is prepared using reductive amination.
  • Reductive amination involves two steps, (1) oxidation (activation) of the purified saccharide, (2) reduction of the activated saccharide and a carrier protein (e.g., CRM 197 , DT, TT or PD) to form a glycoconjugate (see e.g. WO2015110941 , WO2015110940).
  • oxidation activation
  • a carrier protein e.g., CRM 197 , DT, TT or PD
  • sizing of the polysaccharide to a target molecular weight (MW) range can be performed.
  • Mechanical or chemical hydrolysis may be employed. Chemical hydrolysis may be conducted using acetic acid.
  • the size of the purified polysaccharide is reduced by mechanical homogenization.
  • the purified polysacharide or oligosaccharide is conjugated to a carrier protein by a process comprising the step of:
  • step (c) compounding the activated polysaccharide or oligosaccharide of step (a) or (b) with a carrier protein;
  • the saccharide is said to be activated and is referred to as “activated polysaccharide or oligosaccharide”.
  • the oxidation step (a) may involve reaction with periodate.
  • periodate includes both periodate and periodic acid; the term also includes both metaperiodate - and orthoperiodate and the various salts of periodate (e.g., sodium periodate and potassium periodate).
  • the oxidizing agent is sodium periodate.
  • the periodate used for the oxidation is metaperiodate.
  • the periodate used for the oxidation is sodium metaperiodate.
  • the oxidation step (a) may involve reaction with a stable nitroxyl or nitroxide radical compound, such as piperidine-N-oxy or pyrrolidine-N-oxy compounds, in the presence of an oxidant to selectively oxidize primary hydroxyls of the said polysaccharide or oligosaccharide to produce an activated saccharide containing aldehyde groups (see W02014097099).
  • a stable nitroxyl or nitroxide radical compound is any one as disclosed at page 3 line 14 to page 4 line 7 of WO2014097099 and the oxidant is any one as disclosed at page 4 line 8 to 15 of WO2014097099.
  • said stable nitroxyl or nitroxide radical compound is 2,2,6,6-tetramethyl-1-piperidinyloxy (TEMPO) and the oxidant is N-chlorosuccinimide (NCS).
  • the quenching agent is as disclosed in WO2015110941 (see page 30 line 3 to 26).
  • the reduction reaction (d) is carried out in aqueous solvent.
  • the reduction reaction (d) is carried out in aprotic solvent.
  • the reduction reaction (d) is carried out in DMSO (dimethylsulfoxide) or in DMF (dimethylformamide)) solvent.
  • the reducing agent is sodium cyanoborohydride, sodium triacetoxyborohydride, sodium or zinc borohydride in the presence of Bronsted or Lewis acids, amine boranes such as pyridine borane, 2-Picoline Borane, 2,6-diborane-methanol, dimethylamine-borane, t-BuMe'PrN-BH 3 , benzylamine-BH 3 or 5-ethyl-2-methylpyridine borane (PEMB).
  • the reducing agent is sodium cyanoborohydride.
  • this capping agent is sodium borohydride (NaBH 4 ).
  • the glycoconjugate can be purified (enriched with respect to the amount of saccharide-protein conjugate) by a variety of techniques known to the skilled person. These techniques include dialysis, concentration/diafiltration operations, tangential flow filtration precipitation/elution, column chromatography (DEAE or hydrophobic interaction chromatography), and depth filtration.
  • the glycoconjugate is prepared using cyanylation chemistry.
  • the purified polysaccharide or oligosaccharide is activated with cyanogen bromide.
  • the activation corresponds to cyanylation of the hydroxyl groups of the polysaccharide or oligosaccharide.
  • the activated polysaccharide or oligosaccharide is then coupled directly or via a spacer (linker) group to an amino group on the carrier protein.
  • the purified polysaccharide or oligosaccharide is activated with 1- cyano-4-dimethylamino pyridinium tetrafluoroborate (CDAP) to form a cyanate ester.
  • CDAP 1- cyano-4-dimethylamino pyridinium tetrafluoroborate
  • the activated polysaccharide or oligosaccharide is then coupled directly or via a spacer (linker) group to an amino group on the carrier protein.
  • the spacer could be cystamine or cysteamine to give a thiolated polysaccharide or oligosaccharide which could be coupled to the carrier via a thioether linkage obtained after reaction with a maleimide-activated carrier protein (for example using N-[y- maleimidobutyrloxyjsuccinimide ester (GMBS)) or a haloacetylated carrier protein (for example using iodoacetimide, N-succinimidyl bromoacetate (SBA; SIB), N-succinimidyl(4- iodoacetyl)aminobenzoate (SIAB), sulfosuccinimidyl(4-iodoacetyl)aminobenzoate (sulfo-SIAB), N-succinimidyl iodoacetate (SIA) or succinimidyl 3-[bromoacetamido]proprionate (SBA;
  • the cyanate ester (optionally made by CDAP chemistry) is coupled with hexane diamine or adipic acid dihydrazide (ADH) and the amino-derivatised saccharide is conjugated to the carrier protein (e.g., CRM 197 ) using carbodiimide (e.g., EDAC or EDC) chemistry via a carboxyl group on the protein carrier.
  • the carrier protein e.g., CRM 197
  • carbodiimide e.g., EDAC or EDC
  • the glyco conjugate is prepared by using bis electrophilic reagents such as carbonyldiimidazole (CDI) or carbonylditriazole (CDT).
  • the conjugation reaction is preferably made in aprotic solvents such as DMF or DMSO via a direct route or using bigeneric linkers (see e.g. WO2011041003).
  • the glycoconjugate is prepared by a method of making glycoconjugates as disclosed in WO2014027302.
  • the resulting glycoconjugate comprises a saccharide covalently conjugated to a carrier protein through a bivalent, heterobifunctional spacer (2-((2-oxoethyl)thio)ethyl)carbamate (eTEC).
  • eTEC bivalent, heterobifunctional spacer
  • the glycoconjugate is prepared by a method of making glycoconjugates as disclosed in WO2015121783.
  • carbodiimides e.g. EDO (1-Ethyl-3-(3- dimethylaminopropyl) carbodiimide hydrochloride, EDO plus Sulfo NHS, CMC (1-Cyclohexyl-3- (2-morpholinoethyl)carbodiimide, DCC (N,N’-Dicyclohexyl carbodiimide), or DIC (diisopropyl carbodiimide).
  • EDO 1-Ethyl-3-(3- dimethylaminopropyl) carbodiimide hydrochloride
  • EDO plus Sulfo NHS CMC (1-Cyclohexyl-3- (2-morpholinoethyl)carbodiimide
  • DCC N,N’-Dicyclohexyl carbodiimide
  • DIC diisopropyl carbodiimide
  • the polysaccharide or oligosaccaride is conjugated to the carrier protein via a linker, for instance a bifunctional linker.
  • the linker is optionally heterobifunctional or homobifunctional, having for example a reactive amino group and a reactive carboxylic acid group, 2 reactive amino groups or two reactive carboxylic acid groups.
  • the linker has for example between 4 and 20, 4 and 12, 5 and 10 carbon atoms.
  • a possible linker is adipic acid dihydrazide (ADH).
  • linkers include B-propionamido (WO 00/10599), nitrophenyl- ethylamine, haloalkyl halide), glycosidic linkages (US4673574, US4808700), hexane diamine and 6-aminocaproic acid (US4459286).
  • a component of the glycoconjugate is a carrier protein to which the purified polysaccharide or oligosaccharide is conjugated.
  • the terms "protein carrier” or “carrier protein” or “carrier” may be used interchangeably herein. Carrier proteins should be amenable to standard conjugation procedures.
  • the carrier protein of the glycoconjugate is selected in the group consisiting of: DT (Diphtheria toxin), TT (tetanus toxid) or fragment C of TT, CRM197 (a nontoxic but antigenically identical variant of diphtheria toxin), other DT mutants (such as CRM176, CRM228, CRM45 (Uchida et al. (1973) J. Biol. Chem. 218:3838-3844), CRMg, CRM102, CRM103 or CRM107; and other mutations described by Nicholls and Youle in Genetically Engineered Toxins, Ed: Frankel, Maecel Dekker Inc.
  • PhtD, PhtE sequences of PhtA, PhtB, PhtD or PhtE are disclosed in WO 00/37105 and WO 00/39299) and fusions of Pht proteins, for example PhtDE fusions, PhtBE fusions, Pht A-E (WO 01/98334, WO 03/054007, WO 2009/000826), OMPC (meningococcal outer membrane protein), which is usually extracted from Neisseria meningitidis serogroup B (EP0372501), PorB (from N.
  • PD Hemophilus influenzae protein D
  • PD Hemophilus influenzae protein D
  • immunologically functional equivalents thereof synthetic peptides (EP0378881 , EP0427347), heat shock proteins (WO 93/17712, WO 94/03208), pertussis proteins (WO 98/58668,
  • pneumococcal surface protein PspA (WO 02/091998), iron uptake proteins (WO 01/72337), toxin A or B of Clostridium difficile (WO 00/61761), transferrin binding proteins, pneumococcal adhesion protein (PsaA), recombinant Pseudomonas aeruginosa exotoxin A (in particular non-toxic mutants thereof (such as exotoxin A bearing a substution at glutamic acid 553 (Douglas et al. (1987) J. Bacteriol. 169(11):4967-4971)).
  • carrier proteins such as ovalbumin, keyhole limpet hemocyanin (KLH), bovine serum albumin (BSA) or purified protein derivative of tuberculin (PPD) also can be used as carrier proteins.
  • suitable carrier proteins include inactivated bacterial toxins such as cholera toxoid (e.g., as described in WO 2004/083251), Escherichia coli LT, E. coli ST, and exotoxin A from P. aeruginosa.
  • the carrier protein of the glycoconjugate is independently selected from the group consisting of TT, DT, DT mutants (such as CRM 197 ), H. influenzae protein D, PhtX, PhtD, PhtDE fusions (particularly those described in WO 01/98334 and WO 03/054007), detoxified pneumolysin, PorB, N19 protein, PspA, OMPC, toxin A or B of C. difficile and PsaA.
  • the carrier protein of the glycoconjugate is DT (Diphtheria toxoid). In another embodiment, the carrier protein of the glycoconjugate is TT (tetanus toxoid).
  • the carrier protein of the glycoconjugate is PD (H. influenzae protein D; see, e.g., EP0594610 B).
  • the purified polysaccharide or oligosaccharide is conjugated to CRM 197 protein.
  • the CRM 197 protein is a nontoxic form of diphtheria toxin but is immunologically indistinguishable from the diphtheria toxin.
  • CRM 197 is produced by Corynebacterium diphtheriae infected by the nontoxigenic phage ⁇ 197 tox- created by nitrosoguanidine mutagenesis of the toxigenic corynephage beta (Uchida et al. (1971) Nature New Biology 233:8-11).
  • the CRM 197 protein has the same molecular weight as the diphtheria toxin but differs therefrom by a single base change (guanine to adenine) in the structural gene. This single base change causes an amino acid substitution (glutamic acid for glycine) in the mature protein and eliminates the toxic properties of diphtheria toxin.
  • the CRM 197 protein is a safe and effective T-cell dependent carrier for saccharides. Further details about CRM 197 and production thereof can be found, e.g., in U.S. Patent No. 5,614,382.
  • the purified polysaccharide or oligosaccharide is conjugated to CRM 197 protein orthe A chain of CRM 197 (see CN103495161). In an embodiment, the purified polysaccharide or oligosaccharide is conjugated the A chain of CRM 197 obtained via expression by genetically recombinant E. coli (see CN103495161).
  • the ratio of carrier protein to polysaccharide or oligosaccharide in the glycoconjugate is between 1 :5 and 5:1 ; e.g. between 1 :0.5 and 4:1 , between 1 :1 and 3.5:1 , between 1 .2:1 and 3:1 , between 1 .5:1 and 2.5:1 ; e.g. between 1 :2 and 2.5:1 or between 1 :1 and 2:1 (w/w).
  • the ratio of carrier protein to polysaccharide or oligosaccharide in the glycoconjugate is about 1 :1 , 1.1 : 1 , 1 .2:1 , 1 .3:1 , 1 .4:1 , 1 .5:1 or 1 .6:1 .
  • the glycoconjugate can be purified (enriched with respect to the amount of saccharide-protein conjugate) by a variety of techniques known to the skilled person. These techniques include dialysis, concentration/diafiltration operations, tangential flow filtration precipitation/elution, column chromatography (DEAE or hydrophobic interaction chromatography), and depth filtration.
  • compositions may include a small amount of free carrier.
  • the unconjugated form is preferably no more than 5% of the total amount of the carrier protein in the composition as a whole, and more preferably present at less than 2% by weight.
  • the invention relates to an immunogenic composition comprising any of the purified polysaccharides and/or glycoconjugates disclosed herein.
  • the invention relates to an immunogenic composition comprising any of the glycoconjugates disclosed herein.
  • the invention relates to an immunogenic composition comprising from 1 to 25 different glycoconjugates disclosed at section 2.1 .
  • the invention relates to an immunogenic composition
  • an immunogenic composition comprising from 1 to 25 glycoconjugates from different serotypes of S. pneumoniae (1 to 25 pneumococcal conjugates).
  • the invention relates to an immunogenic composition comprising glycoconjugates from 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23,
  • the immunogenic compositions comprises glycoconjugates from 16 or 20 different serotypes of S. pneumoniae.
  • the immunogenic composition is a 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19 or 20-valent pneumococcal conjugate compositions.
  • the immunogenic composition is a 14, 15, 16, 17, 18 or 19-valent pneumococcal conjugate compositions.
  • the immunogenic composition is a 16-valent pneumococcal conjugate composition.
  • the immunogenic composition is a 19-valent pneumococcal conjugate compositions.
  • the immunogenic composition is a 20-valent pneumococcal conjugate composition.
  • said immunogenic composition comprises glycoconjugates from S. pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F and 23F.
  • said immunogenic composition comprises in addition glycoconjugates from S. pneumoniae serotypes 1 , 5 and 7F.
  • any of the immunogenic compositions above comprises in addition glycoconjugates from S. pneumoniae serotypes 6A and 19A.
  • any of the immunogenic compositions above comprise in addition a glycoconjugate from S. pneumoniae serotype 3.
  • any of the immunogenic compositions above comprise in addition a glycoconjugates from S. pneumoniae serotype 22F and 33F.
  • any of the immunogenic compositions above comprise in addition a glycoconjugates from S. pneumoniae serotypes 8, 10A, 11 A, 12F and 15B.
  • any of the immunogenic compositions above comprise in addition a glycoconjugates from S. pneumoniae serotype 2.
  • any of the immunogenic compositions above comprise in addition a glycoconjugates from S. pneumoniae serotypes 9N.
  • any of the immunogenic compositions above comprise in addition a glycoconjugates from S. pneumoniae serotypes 17F.
  • any of the immunogenic compositions above comprise in addition a glycoconjugates from S. pneumoniae serotypes 20.
  • the immunogenic composition of the invention comprises glycoconjugates from S. pneumoniae serotypes 8, 10A, 11 A, 12F, 15B, 22F and 33F.
  • any of the immunogenic compositions above comprise in addition a glycoconjugates from S. pneumoniae serotype 2.
  • any of the immunogenic compositions above comprise in addition a glycoconjugates from S. pneumoniae serotypes 9N.
  • any of the immunogenic compositions above comprise in addition a glycoconjugates from S. pneumoniae serotypes 17F.
  • any of the immunogenic compositions above comprise in addition a glycoconjugates from S. pneumoniae serotypes 20.
  • the saccharides are each individually conjugated to different molecules of the protein carrier (each molecule of protein carrier only having one type of saccharide conjugated to it).
  • the capsular saccharides are said to be individually conjugated to the carrier protein.
  • all the glycoconjugates of the above immunogenic compositions are individually conjugated to the carrier protein.
  • the glycoconjugate from S. pneumoniae serotype 22F is conjugated to CRM 197 .
  • the glycoconjugate from S. pneumoniae serotype 33F is conjugated to CRM197.
  • the glycoconjugate from S. pneumoniae serotype 15B is conjugated to CRM797.
  • the glycoconjugate from S. pneumoniae serotype 12F is conjugated to CRM197.
  • the glycoconjugate from S. pneumoniae serotype 10A is conjugated to CRM197.
  • the glycoconjugate from S. pneumoniae serotype 11 A is conjugated to CRM197.
  • the glycoconjugate from S. pneumoniae serotype 8 is conjugated to CRM197.
  • the glycoconjugates from S. pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F and 23F are conjugated to CRM197.
  • the glycoconjugates from S. pneumoniae serotypes 1 , 5 and 7F are conjugated to CRM197.
  • the glycoconjugates from S. pneumoniae serotypes 6A and 19A are conjugated to CRM197.
  • the glycoconjugate from S. pneumoniae serotype 3 is conjugated to CRM197.
  • glycoconjugates of any of the above immunogenic compositions are all individually conjugated to CRM197.
  • the glycoconjugates from S. pneumoniae serotypes 1 , 4, 5, 6B, 7F, 9V, 14 and/or 23F of any of the above immunogenic compositions are individually conjugated to PD.
  • the glycoconjugate from S. pneumoniae serotype 18C of any of the above immunogenic compositions is conjugated to TT.
  • the glycoconjugate from S. pneumoniae serotype 19F of any of the above immunogenic compositions is conjugated to DT.
  • the glycoconjugates from S. pneumoniae serotypes 1 , 4, 5, 6B, 7F, 9V, 14 and/or 23F of any of the above immunogenic compositions are individually conjugated to PD, the glycoconjugate from S. pneumoniae serotype 18C is conjugated to TT and the glycoconjugate from S. pneumoniae serotype 19F is conjugated to DT.
  • the above immunogenic compositions comprise from 8 to 20 different serotypes of S. pneumoniae.
  • the invention relates to an immunogenic composition comprising from 1 to 5 glycoconjugates from different N. meningitidis serogroups (1 to 5 meningococcal conjugates). In one embodiment the invention relates to an immunogenic composition comprising glycoconjugates from 1 , 2, 3, 4, or 5 different N. meningitidis serogroups. In one embodiment the immunogenic compositions comprise 4 or 5 different N. meningitidis. In an embodiment the immunogenic composition is a 1 , 2, 3, 4 or 5-valent meningococcal conjugate compositions. In an embodiment the immunogenic composition is a 2-valent meningococcal conjugate composition. In an embodiment the immunogenic composition is a 4-valent meningococcal conjugate composition. In an embodiment the immunogenic composition is a 5- valent meningococcal conjugate composition.
  • the immunogenic composition comprises a conjugated N. meningitidis serogroup Y capsular saccharide (MenY), and/or a conjugated N. meningitidis serogroup C capsular saccharide (MenC).
  • the immunogenic composition comprises a conjugated N. meningitidis serogroup A capsular saccharide (MenA), a conjugated N. meningitidis serogroup W135 capsular saccharide (MenW135), a conjugated N. meningitidis serogroup Y capsular saccharide (MenY), and/or a conjugated N. meningitidis serogroup C capsular saccharide (MenC).
  • MenA conjugated N. meningitidis serogroup A capsular saccharide
  • MenW1335 capsular saccharide MenW1335 capsular saccharide
  • MenY conjugated N. meningitidis serogroup Y capsular saccharide
  • MenC conjugated N. meningitidis serogroup C capsular saccharide
  • the immunogenic compositions comprise a conjugated N. meningitidis serogroup W135 capsular saccharide (MenW135), a conjugated N. meningitidis serogroup Y capsular saccharide (MenY), and/or a conjugated N. meningitidis serogroup C capsular saccharide (MenC).
  • the immunogenic composition comprises a conjugated N. meningitidis serogroup A capsular saccharide (MenA), a conjugated N. meningitidis serogroup W135 capsular saccharide (MenW135), a conjugated N. meningitidis serogroup Y capsular saccharide (MenY), a conjugated N. meningitidis serogroup C capsular saccharide (MenC) and/or a conjugated N. meningitidis serogroup X capsular saccharide (MenX).
  • MenA conjugated N. meningitidis serogroup A capsular saccharide
  • MenW1335 capsular saccharide MenW1335 capsular saccharide
  • MenY conjugated N. meningitidis serogroup Y capsular saccharide
  • MenC conjugated N. meningitidis serogroup C capsular saccharide
  • MenX conjugated N. meningitidis
  • the immunogenic compositions disclosed herein may further comprise at least one, two or three adjuvants. In some embodiments, the immunogenic compositions disclosed herein may further comprise one adjuvant.
  • adjuvant refers to a compound or mixture that enhances the immune response to an antigen. Antigens may act primarily as a delivery system, primarily as an immune modulator or have strong features of both. Suitable adjuvants include those suitable for use in mammals, including humans.
  • alum e.g., aluminum phosphate, aluminum sulfate or aluminum hydroxide
  • calcium phosphate e.g., calcium phosphate
  • liposomes e.g., calcium phosphate, liposomes
  • oil-in-water emulsions such as MF59 (4.3% w/v squalene, 0.5% w/v polysorbate 80 (Tween 80), 0.5% w/v sorbitan trioleate (Span 85)
  • water- in-oil emulsions such as Montanide
  • PLG poly(D,L-lactide-co-glycolide)
  • the immunogenic compositions disclosed herein comprise aluminum salts (alum) as adjuvant (e.g., aluminum phosphate, aluminum sulfate or aluminum hydroxide).
  • the immunogenic compositions disclosed herein comprise aluminum phosphate or aluminum hydroxide as adjuvant.
  • adjuvants to enhance effectiveness of the immunogenic compositions as disclosed herein include, but are not limited to: (1) oil-in-water emulsion formulations (with or without other specific immunostimulating agents such as muramyl peptides (see below) or bacterial cell wall components), such as for example (a) SAF, containing 10% Squalane, 0.4% Tween 80, 5% pluronic-blocked polymer L121 , and thr-MDP either microfluidized into a submicron emulsion or vortexed to generate a larger particle size emulsion, and (b) RIBITM adjuvant system (RAS), (Ribi Immunochem, Hamilton, MT) containing 2% Squalene, 0.2% Tween 80, and one or more bacterial cell wall components such as monophosphorylipid A (MPL), trehalose dimycolate (TDM), and cell wall skeleton (CWS), preferably MPL + CWS (DETOXTM); (2) saponin adjuvity
  • WO 99/52549 a polyoxyethylene sorbitan ester surfactant in combination with an octoxynol (e.g., WO 01/21207) or a polyoxyethylene alkyl ether or ester surfactant in combination with at least one additional non-ionic surfactant such as an octoxynol (e.g., WO 01/21152); (9) a saponin and an immunostimulatory oligonucleotide (e.g., a CpG oligonucleotide) (e.g., WO 00/62800); (10) an immunostimulant and a particle of metal salt (see, e.g., WO 00/23105); (11) a saponin and an oil-in-water emulsion (e.g., WO 99/11241); (12) a saponin (e.g., QS21) + 3dMPL + IM2 (optionally + a sterol)
  • Muramyl peptides include N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-25 acetyl-normuramyl-L-alanyl-D- isoglutamine (nor-MDP), N-acetylmuramyl-L-alanyl-D-isoglutarninyl-L-alanine-2-(1 '-2'- dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamine MTP-PE), etc.
  • thr-MDP N-acetyl-muramyl-L-threonyl-D-isoglutamine
  • nor-MDP N-25 acetyl-normuramyl-L-alanyl-D- isoglutamine
  • the immunogenic compositions as disclosed herein comprise a CpG Oligonucleotide as adjuvant.
  • the immunogenic compositions may be formulated in liquid form (i.e., solutions or suspensions) or in a lyophilized form. Liquid formulations may advantageously be administered directly from their packaged form and are thus ideal for injection without the need for reconstitution in aqueous medium as otherwise required for lyophilized compositions of the invention.
  • Formulation of the immunogenic composition of the present disclosure can be accomplished using art-recognized methods.
  • the individual polysaccharides and/or conjugates can be formulated with a physiologically acceptable vehicle to prepare the composition.
  • physiologically acceptable vehicles include, but are not limited to, water, buffered saline, polyols (e.g., glycerol, propylene glycol, liquid polyethylene glycol) and dextrose solutions.
  • the present disclosure provides an immunogenic composition
  • an immunogenic composition comprising any of combination of polysaccahride or glycoconjugates disclosed herein and a pharmaceutically acceptable excipient, carrier, or diluent.
  • the immunogenic composition of the disclosure is in liquid form, preferably in aqueous liquid form.
  • Immunogenic compositions of the disclosure may comprise one or more of a buffer, a salt, a divalent cation, a non-ionic detergent, a cryoprotectant such as a sugar, and an antioxidant such as a free radical scavenger or chelating agent, or any multiple combinations thereof.
  • the immunogenic compositions of the disclosure comprise a buffer.
  • said buffer has a pKa of about 3.5 to about 7.5.
  • the buffer is phosphate, succinate, histidine or citrate.
  • the buffer is succinate at a final concentration of 1 mM to 10 mM. In one particular embodiment, the final concentration of the succinate buffer is about 5 mM.
  • the immunogenic compositions of the disclosure comprise a salt.
  • the salt is selected from the groups consisting of magnesium chloride, potassium chloride, sodium chloride and a combination thereof.
  • the salt is sodium chloride.
  • the immunogenic compositions of the invention comprise sodium chloride at 150 mM.
  • the immunogenic compositions of the disclosure comprise a surfactant.
  • the surfactant is selected from the group consisting of polysorbate 20 (TWEENTM20), polysorbate 40 (TWEENTM40), polysorbate 60 (TWEEN TM60), polysorbate 65 (TWEENTM65), polysorbate 80 (TWEENTM80), polysorbate 85 (TWEENTM85), TRITONTM N-101 , TRITONTM X-100, oxtoxynol 40, nonoxynol-9, triethanolamine, triethanolamine polypeptide oleate, polyoxyethylene-660 hydroxystearate (PEG-15, Solutol H 15), polyoxyethylene-35-ricinoleate (CREMOPHOR® EL), soy lecithin and a poloxamer.
  • the surfactant is polysorbate 80.
  • the final concentration of polysorbate 80 in the formulation is at least 0.0001% to 10% polysorbate 80 weight to weight (w/w). In some said embodiments, the final concentration of polysorbate 80 in the formulation is at least 0.001% to 1% polysorbate 80 weight to weight (w/w). In some said embodiments, the final concentration of polysorbate 80 in the formulation is at least 0.01% to 1 % polysorbate 80 weight to weight (w/w).
  • the final concentration of polysorbate 80 in the formulation is 0.01 %, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09% or 0.1% polysorbate 80 (w/w). In another embodiment, the final concentration of the polysorbate 80 in the formulation is 1% polysorbate 80 (w/w).
  • the surfactant is polysorbate 20.
  • the final concentration of polysorbate 20 in the formulation is at least 0.0001% to 10% polysorbate 20 weight to weight (w/w). In some said embodiments, the final concentration of polysorbate 20 in the formulation is at least 0.001 % to 1 % polysorbate 20 weight to weight (w/w). In some said embodiments, the final concentration of polysorbate 20 in the formulation is at least 0.01 % to 1 % polysorbate 20 weight to weight (w/w).
  • the final concentration of polysorbate 20 in the formulation is 0.01 %, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09% or 0.1% polysorbate 20 (w/w). In another embodiment, the final concentration of the polysorbate 20 in the formulation is 1% polysorbate 20 (w/w).
  • the surfactant is polysorbate 40.
  • the final concentration of polysorbate 40 in the formulation is at least 0.0001% to 10% polysorbate 40 weight to weight (w/w). In some said embodiments, the final concentration of polysorbate 40 in the formulation is at least 0.001 % to 1 % polysorbate 40 weight to weight (w/w). In some said embodiments, the final concentration of polysorbate 40 in the formulation is at least 0.01 % to 1% polysorbate 40 weight to weight (w/w).
  • the final concentration of polysorbate 40 in the formulation is 0.01 %, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09% or 0.1% polysorbate 40 (w/w). In another embodiment, the final concentration of the polysorbate 40 in the formulation is 1% polysorbate 40 (w/w).
  • the surfactant is polysorbate 60.
  • the final concentration of polysorbate 60 in the formulation is at least 0.0001% to 10% polysorbate 60 weight to weight (w/w). In some said embodiments, the final concentration of polysorbate 60 in the formulation is at least 0.001 % to 1 % polysorbate 60 weight to weight (w/w). In some said embodiments, the final concentration of polysorbate 60 in the formulation is at least 0.01 % to 1% polysorbate 60 weight to weight (w/w).
  • the final concentration of polysorbate 60 in the formulation is 0.01 %, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09% or 0.1 % polysorbate 60 (w/w). In another embodiment, the final concentration of the polysorbate 60 in the formulation is 1% polysorbate 60 (w/w).
  • the surfactant is polysorbate 65.
  • the final concentration of polysorbate 65 in the formulation is at least 0.0001% to 10% polysorbate 65 weight to weight (w/w). In some said embodiments, the final concentration of polysorbate 65 in the formulation is at least 0.001 % to 1 % polysorbate 65 weight to weight (w/w). In some said embodiments, the final concentration of polysorbate 65 in the formulation is at least 0.01 % to 1% polysorbate 65 weight to weight (w/w).
  • the final concentration of polysorbate 65 in the formulation is 0.01 %, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09% or 0.1% polysorbate 65 (w/w). In another embodiment, the final concentration of the polysorbate 65 in the formulation is 1% polysorbate 65 (w/w).
  • the surfactant is polysorbate 85.
  • the final concentration of polysorbate 85 in the formulation is at least 0.0001% to 10% polysorbate 85 weight to weight (w/w). In some said embodiments, the final concentration of polysorbate 85 in the formulation is at least 0.001 % to 1 % polysorbate 85 weight to weight (w/w). In some said embodiments, the final concentration of polysorbate 85 in the formulation is at least 0.01 % to 1% polysorbate 85 weight to weight (w/w).
  • the final concentration of polysorbate 85 in the formulation is 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09% or 0.1% polysorbate 85 (w/w). In another embodiment, the final concentration of the polysorbate 85 in the formulation is 1% polysorbate 85 (w/w).
  • the immunogenic composition of the disclosure has a pH of 5.5 to 7.5, more preferably a pH of 5.6 to 7.0, even more preferably a pH of 5.8 to 6.0.
  • the present disclosure provides a container filled with any of the immunogenic compositions disclosed herein.
  • the container is selected from the group consisting of a vial, a syringe, a flask, a fermentor, a bioreactor, a bag, a jar, an ampoule, a cartridge and a disposable pen.
  • the container is siliconized.
  • the container of the present disclosure is made of glass, metals (e.g., steel, stainless steel, aluminum, etc.) and/or polymers (e.g., thermoplastics, elastomers, thermoplastic-elastomers). In an embodiment, the container of the present disclosure is made of glass.
  • the present disclosure provides a syringe filled with any of the immunogenic compositions disclosed herein.
  • the syringe is siliconized and/or is made of glass.
  • a typical dose of the immunogenic composition of the invention for injection has a volume of 0.1 ml_ to 2 ml_, more preferably 0.2 ml_ to 1 ml_, even more preferably a volume of about 0.5 ml_.
  • polysaccharide purified by the method of the present invention and the conjugates disclosed herein may be used as antigens.
  • they may be part of a vaccine.
  • the polysaccharides purified by the method of the present invention or the glycoconjugates obtained using said polysaccharides are for use in generating an immune response in a subject.
  • the subject is a mammal, such as a human, cat, sheep, pig, horse, bovine or dog.
  • the subject is a human.
  • the polysaccharides purified by the method of the present invention, the glycoconjugates obtained using said polysaccharides or the immunogenic compositions disclosed herein are for use in a vaccine.
  • the polysaccharides purified by the method of the present invention, the glycoconjugates obtained using said polysaccharides or the immunogenic compositions disclosed herein are for use as a medicament.
  • immunogenic compositions described herein may be used in various therapeutic or prophylactic methods for preventing, treating or ameliorating a bacterial infection, disease or condition in a subject.
  • immunogenic compositions described herein may be used to prevent, treat or ameliorate a S. pneumoniae, S. aureus, E. faecalis, Haemophilus influenzae type b, E. coli, Neisseria meningitidis, S. agalactiae or Klebsiella pneumoniae infection, disease or condition in a subject.
  • the disclosure provides a method of preventing, treating or ameliorating an infection, disease or condition associated with S. pneumoniae, S. aureus, E. faecalis, Haemophilus influenzae type b, E. coli, Neisseria meningitidis, S. agalactiae or Klebsiella pneumoniae in a subject, comprising administering to the subject an immunologically effective amount of an immunogenic composition of the disclosure (in particular an immunogenic composition comprising the corresponding polysaccharide or glycoconjugate thereof).
  • an immunogenic composition of the disclosure in particular an immunogenic composition comprising the corresponding polysaccharide or glycoconjugate thereof.
  • the disclosure provides a method of inducing an immune response to S. pneumoniae, S. aureus, E. faecalis, Haemophilus influenzae type b, E. coli, Neisseria meningitidis, S. agalactiae or Klebsiella pneumoniae in a subject comprising administering to the subject an immunologically effective amount of an immunogenic composition of the disclosure (in particular an immunogenic composition comprising the corresponding polysaccharide or glycoconjugate thereof).
  • the immunogenic compositions disclosed herein are for use as a vaccine.
  • the immunogenic compositions described herein may be used to prevent S. pneumoniae, S. aureus, E. faecalis, Haemophilus influenzae type b, E. coli,
  • the invention provides a method of preventing an infection by S. pneumoniae, S. aureus, E. faecalis, Haemophilus influenzae type b, E. coli, Neisseria meningitidis, S. agalactiae or Klebsiella pneumoniae in a subject comprising administering to the subject an immunologically effective amount of an immunogenic composition of the disclosure.
  • the subject is a mammal, such as a human, cat, sheep, pig, horse, bovine or dog. In one aspect, the subject is a human.
  • the immunogenic compositions of the present disclosure can be used to protect or treat a human susceptible to a S. pneumoniae, S. aureus, E. faecalis, Haemophilus influenzae type b, E. coli, Neisseria meningitidis, S. agalactiae or Klebsiella pneumoniae infection, by means of administering the immunogenic compositions via a systemic or mucosal route.
  • the immunogenic compositions disclosed herein are administered by intramuscular, intraperitoneal, intradermal or subcutaneous routes.
  • the immunogenic compositions disclosed herein are administered by intramuscular, intraperitoneal, intradermal or subcutaneous injection.
  • the immunogenic compositions disclosed herein are administered by intramuscular or subcutaneous injection.
  • a second, third or fourth dose may be given. Following an initial vaccination, subjects can receive one or several booster immunizations adequately spaced.
  • the schedule of vaccination of the immunogenic composition according to the disclosure is a single dose.
  • the schedule of vaccination of the immunogenic composition according to the disclosure is a multiple dose schedule.
  • the saccharide is produced in a recombinant Gram-negative bacterium. In one embodiment, the saccharide is produced in a recombinant E. coli cell. In one embodiment, the saccharide is produced in a recombinant Salmonella cell. Exemplary bacteria include E. coli 025K5H1, E. coli BD559, E. coli GAR2831 , E. coli GAR865, E. coli GAR868, E. coli GAR869, E. coli GAR872, E. coli GAR878, E. coli GAR896, E. coli GAR1902, E. coli 025a ETC NR-5, E.
  • the bacterium is not E. coli GAR2401 . This genetic approach towards saccharide production allows for efficient production of O-polysaccharides and O-antigen molecules as vaccine components.
  • wzz protein refers to a chain length determinant polypeptide, such as, for example, wzzB, wzz, WZZSF, WZZST, fepE, wzz fepE , wzzl and wzz2.
  • GenBank accession numbers for the exemplary wzz gene sequences are AF011910 for E4991/76,
  • GenBank accession numbers for the G7 and Bi316-41 wzz genes sequences are U39305 and U39306, respectively. Further GenBank accession numbers for exemplary wzz gene sequences are NP_459581 for Salmonella enterica subsp. enterica serovar Typhimurium str. LT2 FepE; AIG66859 for E.
  • the wzz family protein is any one of wzzB, wzz, WZZSF, WZZST, fepE, wzz fePE , wzz1 and wzz2, most preferably wzzB, more preferably fepE.
  • Exemplary wzzB sequences include:
  • a modified saccharide (modified as compared to the corresponding wild-type saccharide) may be produced by expressing (not necessarily overexpressing) a wzz family protein (e.g., fepE) from a Gram-negative bacterium in a Gramnegative bacterium and/or by switching off (i.e., repressing, deleting, removing) a second wzz gene (e.g., wzzB) to generate high molecular weight saccharides, such as lipopolysaccharides, containing intermediate or long O-antigen chains.
  • the modified saccharides may be produced by expressing (not necessarily overexpressing) wzz2 and switching off wzzl.
  • the modified saccharides may be produced by expressing (not necessarily overexpressing) wzzfepE and switching off wzzB.
  • the modified saccharides may be produced by expressing (not necessarily overexpressing) wzzB but switching off wzzfepE.
  • the modified saccharides may be produced by expressing fepE.
  • the wzz family protein is derived from a strain that is heterologous to the host cell.
  • the invention relates to saccharides produced by expressing a wzz family protein, preferably fepE, in a Gram-negative bacterium to generate high molecular weight saccharides containing intermediate or long O-antigen chains, which have an increase of at least 1 , 2, 3, 4, or 5 repeating units, as compared to the corresponding wild-type O- polysaccharide.
  • a wzz family protein preferably fepE
  • the invention relates to saccharides produced by a Gramnegative bacterium in culture that expresses (not necessarily overexpresses) a wzz family protein (e.g., wzzB) from a Gram-negative bacterium to generate high molecular weight saccharides containing intermediate or long O-antigen chains, which have an increase of at least 1 , 2, 3, 4, or 5 repeating units, as compared to the corresponding wild-type O-antigen.
  • a wzz family protein e.g., wzzB
  • the saccharide includes any one Formula selected from Table 1 , wherein the number of repeat units n in the saccharide is greater than the number of repeat units in the corresponding wild-type O-polysaccharide by 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 , 32, 33, 34, 35, 36, 37, 38,
  • the saccharide includes an increase of at least 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 , 32, 33, 34, 35, 36, 37, 38, 39, 40, 41 , 42, 43, 44, 45, 46, 47, 48, 49, or 50 repeat units, as compared to the corresponding wild-type O-polysaccharide.
  • Methods of determining the length of saccharides are known in the art. Such methods include nuclear magnetic resonance, mass spectroscopy, and size exclusion chromatography.
  • the invention relates to a saccharide produced in a recombinant E. coli host cell, wherein the gene for an endogenous wzz O-antigen length regulator (e.g., wzzB) is deleted and is replaced by a (second) wzz gene from a Gram-negative bacterium heterologous to the recombinant E. coli host cell (e.g., Salmonella fepE) to generate high molecular weight saccharides, such as lipopolysaccharides, containing intermediate or long O-antigen chains.
  • the recombinant E. coli host cell includes a wzz gene from Salmonella, preferably from Salmonella enterica.
  • the host cell includes the heterologous gene for a wzz family protein as a stably maintained plasmid vector. In another embodiment, the host cell includes the heterologous gene for a wzz family protein as an integrated gene in the chromosomal DNA of the host cell. Methods of stably expressing a plasmid vector in an E. coli host cell and methods of integrating a heterologous gene into the chromosome of an E. coli host cell are known in the art. In one embodiment, the host cell includes the heterologous genes for an O-antigen as a stably maintained plasmid vector.
  • the host cell includes the heterologous genes for an O-antigen as an integrated gene in the chromosomal DNA of the host cell.
  • Methods of stably expressing a plasmid vector in an E. coli host cell and a Salmonella host cell are known in the art.
  • Methods of integrating a heterologous gene into the chromosome of an E. coli host cell and a Salmonella host cell are known in the art.
  • the recombinant host cell is cultured in a medium that comprises a carbon source.
  • a carbon source for culturing E. coli are known in the art.
  • Exemplary carbon sources include sugar alcohols, polyols, aldol sugars or keto sugars including but not limited to arabinose, cellobiose, fructose, glucose, glycerol, inositol, lactose, maltose, mannitol, mannose, rhamnose, raffinose, sorbitol, sorbose, sucrose, trehalose, pyruvate, succinate and methylamine.
  • the medium includes glucose.
  • the medium includes a polyol or aldol sugar, for example, mannitol, inositol, sorbose, glycerol, sorbitol, lactose and arabinose as the carbon source. All of the carbon sources may be added to the medium before the start of culturing, or it may be added step by step or continuously during culturing.
  • a polyol or aldol sugar for example, mannitol, inositol, sorbose, glycerol, sorbitol, lactose and arabinose. All of the carbon sources may be added to the medium before the start of culturing, or it may be added step by step or continuously during culturing.
  • An exemplary culture medium for the recombinant host cell includes an element selected from any one of KH 2 P0 4 , K 2 HP0 4 , (NH 4 ) 2 S0 4 , sodium citrate, Na 2 S0 4 , aspartic acid, glucose, MgS0 4 , FeS0 4 -7H 2 0, Na 2 Mo0 4 -2H 2 0, H 3 B0 3 , CoCI 2 -6H 2 0, CuCI 2 -2H 2 0, MnCI 2 -4H 2 0, ZnCI 2 and CaCI 2 -2H 2 0.
  • the medium includes KH 2 P0 4 , K 2 HP0 4 , (NH 4 ) 2 S0 4 , sodium citrate, Na 2 S0 4 , aspartic acid, glucose, MgS0 4 , FeS0 4 -7H 2 0, Na 2 Mo0 4 -2H 2 0, H 3 B0 3 , CoCI 2 - 6H 2 0, CUCI 2 -2H 2 0, MnCI 2 -4H 2 0, ZnCI 2 and CaCI 2 -2H 2 0.
  • the medium used herein may be solid or liquid, synthetic (i.e. man-made) or natural, and may include sufficient nutrients for the cultivation of the recombinant host cell.
  • the medium is a liquid medium.
  • the medium may further include suitable inorganic salts. In some embodiments, the medium may further include trace nutrients. In some embodiments, the medium may further include growth factors. In some embodiments, the medium may further include an additional carbon source. In some embodiments, the medium may further include suitable inorganic salts, trace nutrients, growth factors, and a supplementary carbon source. Inorganic salts, trace nutrients, growth factors, and supplementary carbon sources suitable for culturing E. coli are known in the art.
  • the medium may include additional components as appropriate, such as peptone, N-Z Amine, enzymatic soy hydrosylate, additional yeast extract, malt extract, supplemental carbon sources and various vitamins. In some embodiments, the medium does not include such additional components, such as peptone, N-Z Amine, enzymatic soy hydrosylate, additional yeast extract, malt extract, supplemental carbon sources and various vitamins.
  • Suitable supplemental carbon sources include, but are not limited to other carbohydrates, such as glucose, fructose, mannitol, starch or starch hydrolysate, cellulose hydrolysate and molasses; organic acids, such as acetic acid, propionic acid, lactic acid, formic acid, malic acid, citric acid, and fumaric acid; and alcohols, such as glycerol, inositol, mannitol and sorbitol.
  • carbohydrates such as glucose, fructose, mannitol, starch or starch hydrolysate, cellulose hydrolysate and molasses
  • organic acids such as acetic acid, propionic acid, lactic acid, formic acid, malic acid, citric acid, and fumaric acid
  • alcohols such as glycerol, inositol, mannitol and sorbitol.
  • the medium further includes a nitrogen source.
  • Nitrogen sources suitable for culturing E. coli are known in the art.
  • Illustrative examples of suitable nitrogen sources include, but are not limited to ammonia, including ammonia gas and aqueous ammonia; ammonium salts of inorganic or organic acids, such as ammonium chloride, ammonium nitrate, ammonium phosphate, ammonium sulfate and ammonium acetate; urea; nitrate or nitrite salts, and other nitrogen-containing materials, including amino acids as either pure or crude preparations, meat extract, peptone, fish meal, fish hydrolysate, corn steep liquor, casein hydrolysate, soybean cake hydrolysate, yeast extract, dried yeast, ethanol-yeast distillate, soybean flour, cottonseed meal, and the like.
  • the medium includes an inorganic salt.
  • suitable inorganic salts include, but are not limited to salts of potassium, calcium, sodium, magnesium, manganese, iron, cobalt, zinc, copper, molybdenum, tungsten and other trace elements, and phosphoric acid.
  • the medium includes appropriate growth factors.
  • appropriate trace nutrients, growth factors, and the like include, but are not limited to coenzyme A, pantothenic acid, pyridoxine-HCI, biotin, thiamine, riboflavin, flavine mononucleotide, flavine adenine dinucleotide, DL-6,8-thioctic acid, folic acid, Vitamin B i2 , other vitamins, amino acids such as cysteine and hydroxyproline, bases such as adenine, uracil, guanine, thymine and cytosine, sodium thiosulfate, p- or r-aminobenzoic acid, niacinamide, nitriloacetate, and the like, either as pure or partially purified chemical compounds or as present in natural materials.
  • the amounts may be determined empirically by one skilled in the art according to methods and techniques known in the art.
  • the modified saccharide (as compared to the corresponding wild-type saccharide) described herein is synthetically produced, for example, in vitro. Synthetic production or synthesis of the saccharides may facilitate the avoidance of cost- and timeintensive production processes.
  • the saccharide is synthetically synthesized, such as, for example, by using sequential glycosylation strategy or a combination of sequential glycosylations and [3+2] block synthetic strategy from suitably protected monosaccharide intermediates. For example, thioglycosides and glycosyl trichloroacetimidate derivatives may be used as glycosyl donors in the glycosylations.
  • a saccharide that is synthetically synthesized in vitro has the identical structure to a saccharide produced by recombinant means, such as by manipulation of a wzz family protein described above.
  • the saccharide produced includes a structure derived from any E. coli serotype including, for example, any one of the following E. coli serotypes: 01 (e.g., 01A, 01 B, and 01C), 02, 03, 04 (e.g., 04:K52 and 04:K6), 05 (e.g., 05ab and O5ao (strain 180/C3)), 06 (e.g., 06:K2; K13; K15 and 06:K54), 07, 08, 09, 010, 011 , 012, 013, 014, 015, 016, 017, 018 (e.g., 018A, O18ao, 018A1 ,
  • 018B, and 018B1) 019, 020, 021 , 022 , 023 (e.g., 023A), 024 , 025 (e.g., 025a and 025 b), 026, 027, 028, 029 , 030 , 032, 033, 034, 035 , 036 , 037, 038, 039, 040, 041 , 042 , 043, 044, 045 (e.g., 045 and 045rel), 046 , 048 , 049, 050, 051 , 052,
  • the individual polysaccharides are typically purified (enriched with respect to the amount of polysaccharide-protein conjugate) through methods known in the art, such as, for example, dialysis, concentration operations, diafiltration operations, tangential flow filtration, precipitation, elution, centrifugation, precipitation, ultra-filtration, depth filtration, and/or column chromatography (ion exchange chromatography, multimodal ion exchange chromatography, DEAE, and hydrophobic interaction chromatography).
  • the polysaccharides are purified through a method that includes tangential flow filtration.
  • Purified polysaccharides may be activated (e.g., chemically activated) to make them capable of reacting (e.g., either directly to the carrier protein or via a linker such as an eTEC spacer) and then incorporated into glycoconjugates of the invention, as further described herein.
  • activated e.g., chemically activated
  • linker such as an eTEC spacer
  • the saccharide of the invention is derived from an E. coli serotype, wherein the serotype is 025a. In another preferred embodiment, the serotype is 025b. In another preferred embodiment, the serotype is 01 A. In another preferred embodiment, the serotype is 02. In another preferred embodiment, the serotype is 06. In another preferred embodiment, the serotype is 017. In another preferred embodiment, the serotype is 015. In another preferred embodiment, the serotype is 018A. In another preferred embodiment, the serotype is 075. In another preferred embodiment, the serotype is 04. In another preferred embodiment, the serotype is 016. In another preferred embodiment, the serotype is 013. In another preferred embodiment, the serotype is 07. In another preferred embodiment, the serotype is 08. In another preferred embodiment, the serotype is 09.
  • any of the serotypes listed above refers to a serotype that encompasses a repeating unit structure (O-unit, as described below) known in the art and is unique to the corresponding serotype.
  • O25a also known in the art as serotype “025” refers to a serotype that encompasses Formula 025 shown in Table 1 .
  • 025b refers to a serotype that encompasses Formula 025b shown in Table 1 .
  • the serotypes are referred generically herein unless specified otherwise such that, for example, the term Formula “018” refers generically to encompass Formula 018A, Formula 018ac, Formula 18A1 , Formula 018B, and Formula 018B1 .
  • O1 refers generically to encompass the species of Formula that include the generic term "O1" in the Formula name according to Table 1 , such as any one of Formula 01A, Formula 01A1 , Formula 01B, and Formula 01C, each of which is shown in Table 1. Accordingly, an “01 serotype” refers generically to a serotype that encompasses any one of Formula 01A, Formula 01A1 , Formula 01B, and Formula 01C.
  • an “06 serotype” refers generically to a serotype that encompasses any one of Formula 06:K2; K13; K15; and 06:K54.
  • the term “02” refers to Formula 02 shown in Table 1.
  • the term “02 O- antigen” refers to a saccharide that encompasses Formula 02 shown in Table 1 .
  • O-antigen refers to a saccharide that encompasses the formula labeled with the corresponding serotype name.
  • 025B O-antigen refers to a saccharide that encompasses Formula 025B shown in Table 1 .
  • the term “01 O-antigen” generically refers to a saccharide that encompasses a Formula including the term “01 ,” such as the Formula 01 A, Formula 01 A1 , Formula 01 B, and Formula 01C, each of which are shown in Table 1.
  • 06 O-antigen generically refers to a saccharide that encompasses a Formula including the term “06,” such as Formula 06:K2; Formula 06:K13; Formula 06:K15 and Formula 06:K54, each of which are shown in Table 1.
  • O-polysaccharide refers to any structure that includes an O- antigen, provided that the structure does not include a whole cell or Lipid A.
  • the O-polysaccharide includes a lipopolysaccharide wherein the Lipid A is not bound.
  • the step of removing Lipid A is known in the art and includes, as an example, heat treatment with addition of an acid.
  • An exemplary process includes treatment with 1 % acetic acid at 100°C for 90 minutes. This process is combined with a process of isolating Lipid A as removed.
  • An exemplary process for isolating Lipid A includes ultracentrifugation.
  • the O-polysaccharide refers to a structure that consists of the O- antigen, in which case, the O-polysaccharide is synonymous with the term O-antigen.
  • the O-polysaccharide refers to a structure that includes repeating units of the O-antigen, without the core saccharide. Accordingly, in one embodiment, the O- polysaccharide does not include an E. coli R1 core moiety. In another embodiment, the O- polysaccharide does not include an E. coli R2 core moiety. In another embodiment, the O- polysaccharide does not include an E. coli R3 core moiety. In another embodiment, the O- polysaccharide does not include an E.
  • the O- polysaccharide does not include an E. coli K12 core moiety.
  • the O-polysaccharide refers to a structure that includes an O-antigen and a core saccharide.
  • the O-polysaccharide refers to a structure that includes an O-antigen, a core saccharide, and a KDO moiety.
  • LPS Methods of purifying an O-polysaccharide, which includes the core oligosaccharide, from LPS are known in the art. For example, after purification of LPS, purified LPS may be hydrolyzed by heating in 1 % (v/v) acetic acid for 90 minutes at 100 degrees Celsius, followed by ultracentrifugation at 142,000 x g for 5 hours at 4 degrees Celsius. The supernatant containing the O-polysaccharide is freeze-dried and stored at 4 degrees Celsius. In certain embodiments, deletion of capsule synthesis genes to enable simple purification of O-polysaccharide is described.
  • the O-polysaccharide can be isolated by methods including, but not limited to mild acid hydrolysis to remove lipid A from LPS.
  • Other embodiments may include use of hydrazine as an agent for O-polysaccharide preparation.
  • Preparation of LPS can be accomplished by known methods in the art.
  • the O-polysaccharides purified from wild-type, modified, or attenuated Gram-negative bacterial strains that express (not necessarily overexpress) a Wzz protein are provided for use in conjugate vaccines.
  • a Wzz protein e.g., wzzB
  • the O-polysaccharide chain is purified from the Gram-negative bacterial strain expressing (not necessarily overexpressing) wzz protein for use as a vaccine antigen either as a conjugate or complexed vaccine.
  • the O-polysaccharide has a molecular weight that is increased by about 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 11-fold, 12-fold, 13-fold, 14-fold, 15-fold, 16-fold, 17-fold, 18-fold, 19-fold, 20-fold, 21-fold, 22-fold, 23-fold, 24- fold, 25-fold, 26-fold, 27-fold, 28-fold, 29-fold, 30-fold, 31 -fold, 32-fold, 33-fold, 34-fold, 35-fold, 36-fold, 37-fold, 38-fold, 39-fold, 40-fold, 41 -fold, 42-fold, 43-fold, 44-fold, 45-fold, 46-fold, 47- fold, 48-fold, 49-fold, 50-fold, 51 -fold, 52-fold, 53-fold, 54-fold, 55-fold, 56-fold, 57-fold, 58-fold, 59-
  • the O-polysaccharide has a molecular weight that is increased by at least 1-fold and at most 5-fold, as compared to the corresponding wild-type O-polysaccharide. In another embodiment, the O-polysaccharide has a molecular weight that is increased by at least 2-fold and at most 4-fold, as compared to the corresponding wild-type O-polysaccharide.
  • An increase in molecular weight of the O- polysaccharide, as compared to the corresponding wild-type O-polysaccharide is preferably associated with an increase in number of O-antigen repeat units. In one embodiment, the increase in molecular weight of the O-polysaccharide is due to the wzz family protein.
  • the O-polysaccharide has a molecular weight that is increased by about 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 , 32, 33, 34, 35, 36, 37, 38, 39, 40, 41 , 42, 43, 44, 45, 46, 47, 48, 49, 50, 51 , 52, 53, 54, 55, 56, 57, 58, 59, 60, 61 , 62, 63, 64, 65, 66, 67, 68, 69, 70, 71 , 72, 73, 74, 75, 76, 77, 78, 79,
  • the O- polysaccharide of the invention has a molecular weight that is increased by at least 1 and at most 200 kDa, as compared to the corresponding wild-type O-polysaccharide. In one embodiment, the molecular weight is increased by at least 5 and at most 200kDa. In one embodiment, the molecular weight is increased by at least 10 and at most 200kDa.
  • the molecular weight is increased by at least 12 and at most 200kDa. In one embodiment, the molecular weight is increased by at least 15 and at most 200kDa. In one embodiment, the molecular weight is increased by at least 18 and at most 200kDa. In one embodiment, the molecular weight is increased by at least 20 and at most 200kDa. In one embodiment, the molecular weight is increased by at least 21 and at most 200kDa. In one embodiment, the molecular weight is increased by at least 22 and at most 200kDa. In one embodiment, the molecular weight is increased by at least 30 and at most 200kDa. In one embodiment, the molecular weight is increased by at least 1 and at most lOOkDa.
  • the molecular weight is increased by at least 5 and at most lOOkDa. In one embodiment, the molecular weight is increased by at least 10 and at most lOOkDa. In one embodiment, the molecular weight is increased by at least 12 and at most lOOkDa. In one embodiment, the molecular weight is increased by at least 15 and at most lOOkDa. In one embodiment, the molecular weight is increased by at least 20 and at most lOOkDa. In one embodiment, the molecular weight is increased by at least 1 and at most 75kDa. In one embodiment, the molecular weight is increased by at least 5 and at most 75kDa.
  • the molecular weight is increased by at least 10 and at most 75kDa. In one embodiment, the molecular weight is increased by at least 12 and at most 75kDa. In one embodiment, the molecular weight is increased by at least 15 and at most 75kDa. In one embodiment, the molecular weight is increased by at least 18 and at most 75kDa. In one embodiment, the molecular weight is increased by at least 20 and at most 75kDa. In one embodiment, the molecular weight is increased by at least 30 and at most 75kDa. In one embodiment, the molecular weight is increased by at least 10 and at most 90kDa. In one embodiment, the molecular weight is increased by at least 12 and at most 85kDa.
  • the molecular weight is increased by at least 10 and at most 75kDa. In one embodiment, the molecular weight is increased by at least 10 and at most 70kDa. In one embodiment, the molecular weight is increased by at least 10 and at most 60kDa. In one embodiment, the molecular weight is increased by at least 10 and at most 50kDa. In one embodiment, the molecular weight is increased by at least 10 and at most 49kDa. In one embodiment, the molecular weight is increased by at least 10 and at most 48kDa. In one embodiment, the molecular weight is increased by at least 10 and at most 47kDa. In one embodiment, the molecular weight is increased by at least 10 and at most 46kDa.
  • the molecular weight is increased by at least 20 and at most 45kDa. In one embodiment, the molecular weight is increased by at least 20 and at most 44kDa. In one embodiment, the molecular weight is increased by at least 20 and at most 43kDa. In one embodiment, the molecular weight is increased by at least 20 and at most 42kDa. In one embodiment, the molecular weight is increased by at least 20 and at most 41 kDa.
  • Such an increase in molecular weight of the O- polysaccharide, as compared to the corresponding wild-type O-polysaccharide, is preferably associated with an increase in number of O-antigen repeat units. In one embodiment, the increase in molecular weight of the O-polysaccharide is due to the wzz family protein.
  • the O-polysaccharide includes any one Formula selected from Table 1 , wherein the number of repeat units n in the O-polysaccharide is greater than the number of repeat units in the corresponding wild-type O-polysaccharide by 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 , 32, 33, 34, 35, 36, 37,
  • the saccharide includes an increase of at least 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 , 32, 33, 34, 35, 36, 37, 38, 39, 40, 41 , 42, 43, 44, 45, 46, 47, 48, 49, or 50 repeat units, as compared to the corresponding wild-type O-polysaccharide.
  • the O-antigen is part of the lipopolysaccharide (LPS) in the outer membrane of Gramnegative bacteria.
  • LPS lipopolysaccharide
  • the O-antigen is on the cell surface and is a variable cell constituent.
  • the variability of the O-antigen provides a basis forserotyping of Gram-negative bacteria.
  • the current E. coli serotyping scheme includes O-polysaccharides 1 to 181.
  • the O-antigen includes oligosaccharide repeating units (O-units), the wild type structure of which usually contains two to eight residues from a broad range of sugars.
  • O-units of exemplary E. coli O-antigens are shown in Table 1.
  • the O-units of exemplary K. pneumoniae O-antigens are shown in Table 1a.
  • saccharide of the invention may be one oligosaccharide unit. In one embodiment, saccharide of the invention is one repeating oligosaccharide unit of the relevant serotype. In such embodiments, the saccharide may include a structure selected from any one of Formula 08, Formula 09a, Formula 09, Formula O20ab, Formula O20ac, Formula 052, Formula 097, and Formula 0101 .
  • saccharide of the invention may be oligosaccharides. Oligosaccharides have a low number of repeat units (typically 5-15 repeat units) and are typically derived synthetically or by hydrolysis of polysaccharides.
  • the saccharide may include a structure selected from any one of Formula 08, Formula 09a,
  • all of the saccharides of the present invention and in the immunogenic compositions of the present invention are polysaccharides.
  • High molecular weight polysaccharides may induce certain antibody immune responses due to the epitopes present on the antigenic surface.
  • the isolation and purification of high molecular weight polysaccharides are preferably contemplated for use in the conjugates, compositions and methods of the present invention.
  • the number of repeat O units in each individual O-antigen polymer depends on the wzz chain length regulator, an inner membrane protein. Different wzz proteins confer different ranges of modal lengths (4 to >100 repeat units).
  • modal length refers to the number of repeating O-units. Gram-negative bacteria often have two different Wzz proteins that confer two distinct OAg modal chain lengths, one longer and one shorter.
  • wzz family proteins e.g., wzzB
  • Gram-negative bacteria may allow for the manipulation of O-antigen length, to shift or to bias bacterial production of O- antigens of certain length ranges, and to enhance production of high-yield large molecular weight lipopolysaccharides.
  • a “short” modal length as used herein refers to a low number of repeat O-units, e.g., 1-20.
  • a “long” modal length as used herein refers to a number of repeat O-units greater than 20 and up to a maximum of 40.
  • a “very long” modal length as used herein refers to greater than 40 repeat O-units.
  • the saccharide produced has an increase of at least 10 repeating units, 15 repeating units, 20 repeating units, 25 repeating units, 30 repeating units, 35 repeating units, 40 repeating units, 45 repeating units, 50 repeating units, 55 repeating units, 60 repeating units, 65 repeating units, 70 repeating units, 75 repeating units, 80 repeating units, 85 repeating units, 90 repeating units, 95 repeating units, or 100 repeating units, as compared to the corresponding wild-type O-polysaccharide.
  • the saccharide of the invention has an increase of 1 , 2, 3, 4, 5, 6,
  • the saccharide includes an increase of at least 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 , 32, 33, 34, 35, 36, 37, 38, 39, 40, 41 , 42, 43, 44, 45, 46, 47, 48, 49, or 50 repeat units, as compared to the corresponding wild-type O- polysaccharide. Methods of determining the number of repeat units in the saccharide are also known in the art.
  • the number of repeat units may be calculated by dividing the molecular weight of the polysaccharide (without the molecular weight of the core saccharide or KDO residue) by the molecular weight of the repeat unit (i.e., molecular weight of the structure in the corresponding Formula, shown for example in Table 1 , which may be theoretically calculated as the sum of the molecular weight of each monosaccharide within the Formula).
  • the molecular weight of each monosaccharide within the Formula is known in the art.
  • the molecular weight of a repeat unit of Formula 025b for example, is about 862 Da.
  • the molecular weight of a repeat unit of Formula 01 a for example, is about 845 Da.
  • the molecular weight of a repeat unit of Formula 02 is about 829 Da.
  • the molecular weight of a repeat unit of Formula 06 is about 893 Da.
  • n refers to the number of repeating units (represented in brackets in Table 1) in a polysaccharide molecule.
  • repeating structures may be interspersed with regions of imperfect repeats, such as, for example, missing branches.
  • polysaccharides isolated and purified from natural sources such as bacteria may be heterogenous in size and in branching. In such a case, n may represent an average or median value for n for the molecules in a population.
  • the O-polysaccharide has an increase of at least one repeat unit of an O-antigen, as compared to the corresponding wild-type O-polysaccharide.
  • the repeat units of O-antigens are shown in Table 1 and Table 1a.
  • the O-polysaccharide includes 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 , 32, 33, 34, 35, 36, 37, 38, 39, 40, 41 , 42, 43, 44, 45, 46, 47, 48, 49, 50, 51 ,
  • the saccharide has a total of at least 3 to at most 80 repeat units.
  • the O-polysaccharide has an increase of 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 , 32, 33, 34,
  • the saccharide includes an O-antigen wherein n in any of the O-antigen formulas (such as, for example, the Formulas shown in Table 1) is an integer of at least 1 , 2, 3, 4, 5, 10, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 , 32, 33, 34, 35, 36, 37, 38, 39, 40, and at most 200, 100, 99, 98, 97, 96, 95, 94, 93, 92,
  • n is at least 31 to at most 90. In a preferred embodiment, n is 40 to 90, more preferably 60 to 85.
  • the saccharide includes an O-antigen wherein n in any one of the O-antigen Formulas is at least 1 and at most 200. In one embodiment, n in any one of the O- antigen Formulas is at least 5 and at most 200. In one embodiment, n in any one of the O- antigen Formulas is at least 10 and at most 200. In one embodiment, n in any one of the O- antigen Formulas is at least 25 and at most 200. In one embodiment, n in any one of the O- antigen Formulas is at least 50 and at most 200. In one embodiment, n in any one of the O- antigen Formulas is at least 75 and at most 200.
  • n in any one of the O- antigen Formulas is at least 100 and at most 200. In one embodiment, n in any one of the O- antigen Formulas is at least 125 and at most 200. In one embodiment, n in any one of the O- antigen Formulas is at least 150 and at most 200. In one embodiment, n in any one of the O- antigen Formulas is at least 175 and at most 200. In one embodiment, n in any one of the O- antigen Formulas is at least 1 and at most 100. In one embodiment, n in any one of the O- antigen Formulas is at least 5 and at most 100. In one embodiment, n in any one of the O- antigen Formulas is at least 10 and at most 100.
  • n in any one of the O- antigen Formulas is at least 25 and at most 100. In one embodiment, n in any one of the O- antigen Formulas is at least 50 and at most 100. In one embodiment, n in any one of the O- antigen Formulas is at least 75 and at most 100. In one embodiment, n in any one of the O- antigen Formulas is at least 1 and at most 75. In one embodiment, n in any one of the O- antigen Formulas is at least 5 and at most 75. In one embodiment, n in any one of the O-antigen Formulas is at least 10 and at most 75. In one embodiment, n in any one of the O-antigen
  • Formulas is at least 20 and at most 75.
  • n in any one of the O-antigen is at least 20 and at most 75.
  • Formulas is at least 25 and at most 75.
  • n in any one of the O-antigen is at least 25 and at most 75.
  • Formulas is at least 30 and at most 75.
  • n in any one of the O-antigen is at least 30 and at most 75.
  • Formulas is at least 40 and at most 75.
  • n in any one of the O-antigen is at least 40 and at most 75.
  • Formulas is at least 50 and at most 75.
  • n in any one of the O-antigen is at least 50 and at most 75.
  • Formulas is at least 30 and at most 90. In one embodiment, n in any one of the O-antigen Formulas is at least 35 and at most 85. In one embodiment, n in any one of the O-antigen
  • Formulas is at least 35 and at most 75.
  • n in any one of the O-antigen is at least 35 and at most 75.
  • Formulas is at least 35 and at most 70.
  • n in any one of the O-antigen is at least 35 and at most 70.
  • Formulas is at least 35 and at most 60.
  • n in any one of the O-antigen is at least 35 and at most 60.
  • Formulas is at least 35 and at most 50.
  • n in any one of the O-antigen is at least 35 and at most 50.
  • Formulas is at least 35 and at most 49.
  • n in any one of the O-antigen is at least 35 and at most 49.
  • Formulas is at least 35 and at most 48.
  • n in any one of the O-antigen is at least 35 and at most 48.
  • n in any one of the O-antigen Formulas is at least 35 and at most 47. In one embodiment, n in any one of the O-antigen Formulas is at least 35 and at most 46. In one embodiment, n in any one of the O-antigen Formulas is at least 36 and at most 45. In one embodiment, n in any one of the O-antigen Formulas is at least 37 and at most 44. In one embodiment, n in any one of the O-antigen Formulas is at least 38 and at most 43. In one embodiment, n in any one of the O-antigen Formulas is at least 39 and at most 42. In one embodiment, n in any one of the O-antigen Formulas is at least 39 and at most 41 .
  • n in the saccharide is 31 , 32, 33, 34, 35, 36, 37, 38,
  • n is at least 35 to at most 60.
  • n is any one of 35, 36, 37, 38, 39, 40, 41 , 42, 43, 44, 45, 46, 47, 48, 49, 50, 51 , 52, 53, 54, 55, 56, 57, 58, 59, and 60, preferably 50.
  • n is at least 55 to at most 75.
  • n is 55, 56, 57,
  • the saccharide structure may be determined by methods and tools known art, such as, for example, NMR, including 1 D, 1 H, and/or 13C, 2D TOCSY, DQF-COSY, NOESY, and/or HMQC.
  • the purified polysaccharide before conjugation has a molecular weight of between 5 kDa and 400 kDa.
  • the saccharide has a molecular weight of between 10 kDa and 400 kDa; between 5 kDa and 400 kDa; between 5 kDa and 300 kDa; between 5 kDa and 200 kDa; between 5 kDa and 150 kDa; between 10 kDa and 100 kDa; between 10 kDa and 75 kDa; between 10 kDa and 60 kDa; between 10 kDa and 40 kDa; between 10 kDa and 100 kDa; 10 kDa and 200 kDa; between 15 kDa and 150 kDa; between 12 kDa and 120 kDa; between 12 kDa and 75 kDa; between 12 kDa and 50 kDa; between 12 and 60 k
  • the polysaccharide has a molecular weight of between 7 kDa to 15 kDa; 8 kDa to 16 kDa; 9 kDa to 25 kDa; 10 kDa to 100; 10 kDa to 60 kDa; 10 kDa to 70 kDa; 10 kDa to 160 kDa; 15 kDa to 600 kDa; 20 kDa to 1000 kDa; 20 kDa to 600 kDa; 20 kDa to 400 kDa; 30 kDa to 1 ,000 KDa; 30 kDa to 60 kDa; 30 kDa to 50 kDa or 5 kDa to 60 kDa. Any whole number integer within any of the above ranges is contemplated as an embodiment of the disclosure.
  • molecular weight of polysaccharide or of carrier protein- polysaccharide conjugate refers to molecular weight calculated by size exclusion chromatography (SEC) combined with multiangle laser light scattering detector (MALLS).
  • polysaccharide can become slightly reduced in size during normal purification procedures. Additionally, as described herein, polysaccharide can be subjected to sizing techniques before conjugation. Mechanical or chemical sizing maybe employed. Chemical hydrolysis may be conducted using acetic acid. Mechanical sizing may be conducted using High Pressure Homogenization Shearing. The molecular weight ranges mentioned above refer to purified polysaccharides before conjugation (e.g., before activation). Table 1 : E. coli serogroups/serotypes and O-unit moieties
  • the core oligosaccharide is positioned between Lipid A and the O-antigen outer region in wild-type E. coli LPS. More specifically, the core oligosaccharide is the part of the polysaccharide that includes the bond between the O-antigen and the lipid A in wild type E. coli. This bond includes a ketosidic bond between the hemiketal function of the innermost 3-deoxy-d- manno-oct-2-ulosonic acid (KDO)) residue and a hydroxyl-group of a GlcNAc-residue of the lipid A.
  • the core oligosaccharide region shows a high degree of similarity among wild-type E. coli strains. It usually includes a limited number of sugars.
  • the core oligosaccharide includes an inner core region and an outer core region.
  • the inner core is composed primarily of L-glycero-D-manno-heptose (heptose) and KDO residues.
  • the inner core is highly conserved.
  • a KDO residue includes the following Formula KDO:
  • the outer region of the core oligosaccharide displays more variation than the inner core region, and differences in this region distinguish the five chemotypes in E. coir. R1 , R2, R3, R4, and K-12. Hepll is the last residue of the inner core oligosaccharide. While all of the outer core oligosaccharides share a structural theme, with a (hexose) 3 carbohydrate backbone and two side chain residues, the order of hexoses in the backbone and the nature, position, and linkage of the side chain residues can all vary.
  • the structures for the R1 and R4 outer core oligosaccharides are highly similar, differing in only a single b-linked residue.
  • the core oligosaccharides of wild-type E. coli are categorized in the art based on the structures of the distal oligosaccharide, into five different chemotypes: E. coli R1, E. coli R2, E. coli R3, E. coli R4, and E. coli K12.
  • the compositions described herein include glycoconjugates in which the O-polysaccharide includes a core oligosaccharide bound to the O-antigen.
  • the composition induces an immune response against at least any one of the core E. coli chemotypes E. coli R1, E. coli R2, E. coli R3, E. coli R4, and E. coli K12.
  • the composition induces an immune response against at least two core E. coli chemotypes.
  • the composition induces an immune response against at least three core E. coli chemotypes.
  • the composition induces an immune response against at least four core E. coli chemotypes.
  • the composition induces an immune response against all five core E. coli chemotypes.
  • compositions described herein include glycoconjugates in which the O-polysaccharide does not include a core oligosaccharide bound to the O-antigen.
  • such a composition induces an immune response against at least any one of the core E. coli chemotypes E. coli R1, E. coli R2, E. coli R3, E. coli R4, and E. coli K12, despite the glycoconjugate having an O-polysaccharide that does not include a core oligosaccharide.
  • E. coli serotypes may be characterized according to one of the five chemotypes. Table 2 lists exemplary serotypes characterized according to chemotype. The serotypes in bold represent the serotypes that are most commonly associated with the indicated core chemotype. Accordingly, in a preferred embodiment, the composition induces an immune response against at least any one of the core E. coli chemotypes E. coli R1 , E. coli R2, E. coli R3, E. coli R4, and E. coli K12, which includes an immune response against any one of the respective corresponding E. coli serotypes.
  • the composition includes a saccharide that includes a structure derived from a serotype having an R1 chemotype, e.g., selected from a saccharide having Formula 025a, Formula 06, Formula 02, Formula 01 , Formula 075, Formula 04, Formula 016, Formula 08, Formula 018, Formula 09, Formula 013, Formula 020, Formula 021 , Formula 091 , and Formula 0163, wherein n is 1 to 100.
  • the saccharide in said composition further includes an E. coli R1 core moiety.
  • the composition includes a saccharide that includes a structure derived from a serotype having an R1 chemotype, e.g., selected from a saccharide having Formula 025a, Formula 06, Formula 02, Formula 01 , Formula 075, Formula 04, Formula 016, Formula 018, Formula 013, Formula 020, Formula 021 , Formula 091 , and Formula 0163, wherein n is 1 to 100, preferably 31 to 100, more preferably 35 to 90, most preferably 35 to 65.
  • the saccharide in said composition further includes an E. coli R1 core moiety in the saccharide.
  • the composition includes a saccharide that includes a structure derived from a serotype having an R2 chemotype, e.g., selected from a saccharide having Formula 021 , Formula 044, Formula 011 , Formula 089, Formula 0162, and Formula 09, wherein n is 1 to 100, preferably 31 to 100, more preferably 35 to 90, most preferably 35 to 65.
  • the saccharide in said composition further includes an E. coli R2 core moiety.
  • the composition includes a saccharide that includes a structure derived from a serotype having an R3 chemotype, e.g., selected from a saccharide having Formula 025b, Formula 015, Formula 0153, Formula 021 , Formula 017, Formula 011 , Formula 0159, Formula 022, Formula 086, and Formula 093, wherein n is 1 to 100, preferably 31 to 100, more preferably 35 to 90, most preferably 35 to 65.
  • the saccharide in said composition further includes an E. coli R3 core moiety.
  • the composition includes a saccharide that includes a structure derived from a serotype having an R4 chemotype, e.g., selected from a saccharide having Formula 02, Formula 01 , Formula 086, Formula 07, Formula 0102, Formula 0160, and Formula 0166, wherein n is 1 to 100, preferably 31 to 100, more preferably 35 to 90, most preferably 35 to 65.
  • the saccharide in said composition further includes an E. coli R4 core moiety.
  • the composition includes a saccharide that includes a structure derived from a serotype having an K-12 chemotype (e.g., selected from a saccharide having Formula 025b and a saccharide having Formula 016), wherein n is 1 to 1000, preferably 31 to 100, more preferably 35 to 90, most preferably 35 to 65.
  • the saccharide in said composition further includes an E. coli K-12 core moiety.
  • the saccharide includes the core saccharide. Accordingly, in one embodiment, the O-polysaccharide further includes an E. coli R1 core moiety. In another embodiment, the O-polysaccharide further includes an E. coli R2 core moiety. In another embodiment, the O-polysaccharide further includes an E. coli R3 core moiety. In another embodiment, the O-polysaccharide further includes an E. coli R4 core moiety. In another embodiment, the O-polysaccharide further includes an E. coli K12 core moiety.
  • the saccharide does not include the core saccharide. Accordingly, in one embodiment, the O-polysaccharide does not include an E. coli R1 core moiety. In another embodiment, the O-polysaccharide does not include an E. coli R2 core moiety. In another embodiment, the O-polysaccharide does not include an E. coli R3 core moiety. In another embodiment, the O-polysaccharide does not include an E. coli R4 core moiety. In another embodiment, the O-polysaccharide does not include an E. coli K12 core moiety.
  • any of the compositions disclosed herein may further include at least one saccharide that is, or derived from, at least one K. pneumoniae serotype selected from 01 (and d-Gal-lll variants), 02 (and d-Gal-l 11 variants), O2ao, 03, 04, 05, 07, 08, and 012.
  • any of the compositions disclosed herein may further include a polypeptide derived from K. pneumoniae selected from a polypeptide derived from K. pneumoniae Type I fimbrial protein or an immunogenic fragment thereof; and a polypeptide derived from K.
  • K. pneumoniae 01 and 02 antigens contain homopolymer galac-tose units (orgalactans).
  • K. pneumoniae 01 and 02 antigens each contain D- galactan I units (sometimes referred to as the 02a repeat unit), but 01 antigens differ in that 01 antigens have a D-galactan II cap structure.
  • D-galactan III (d-Gal-l II) is a variant of D-galactan I.
  • the saccharide derived from K. pneumoniae 01 includes a repeat unit of [ ⁇ 3)- ⁇ -D-Galf : -(1 ⁇ 3)-a-D-Galp-(1 ⁇ ].
  • the saccharide derived from K. pneumoniae 01 includes a repeat unit of [ ⁇ 3)-a-D- Galp-(1 ⁇ 3)- ⁇ -D-Galp-(1 ⁇ ], In some embodiments, the saccharide derived from K. pneumoniae 01 includes a repeat unit of [ ⁇ 3)- ⁇ -D-Gal/ : -(1 ⁇ 3)-a-D-Galp-(1 ⁇ ], and a repeat unit of [ ⁇ 3)-a-D- Galp-(1 ⁇ 3)- ⁇ -D-Galp-(1 ⁇ ]. In some embodiments, the saccharide derived from K.
  • pneumoniae 01 includes a repeat unit of ⁇ 3)- ⁇ -D-Gal/ : - (1 ⁇ 3)-[a-D-Galp-(1 ⁇ 4)]-a-D-Galp-(1 ⁇ ] (referred to as the D-Gal-l 11 repeat unit).
  • the saccharide derived from K. pneumoniae 02 includes a repeat unit of [ ⁇ 3)-a-D-Galp-(1 ⁇ 3)- ⁇ -D-Galf : -(1 ⁇ ] (which may be an element of K. pneumoniae serotype 02a antigen). In some embodiments, the saccharide derived from K. pneumoniae 02 includes a repeat unit of [ ⁇ 3)- ⁇ -D-GlcpNAc-(1 ⁇ 5)- ⁇ -D-Galf-(1 ⁇ ] (which may be an element of K. pneumoniae serotype 02c antigen). In some embodiments, the saccharide derived from K.
  • pneumoniae 02 includes a modification of the 02a repeat unit by side chain addition of (1 ⁇ 4)-linked Galp residues (which may be an element of the K. pneumoniae 02afg antigen).
  • the saccharide derived from K. pneumoniae 02 includes a modification of the 02a repeat unit by side chain addition of (1 ⁇ 2)-linked Galp residues (which may be an element of the K. pneumoniae 02aeh antigen).
  • O-antigen polysaccharide structure of K. pneumoniae serotypes 03 and 05 are disclosed in the art to be identical to those of E. coli serotypes 09a (Formula 09a) and 08 (Formula 08), respectively.
  • the saccharide derived from K. pneumoniae 04 includes a repeat unit of [ ⁇ 4)-a-D-Galp-(1 ⁇ 2)- ⁇ -D-Ribf : -(1 ⁇ )].
  • the saccharide derived from K. pneumoniae 07 includes a repeat unit of [ ⁇ 2-a-L-Rhap- (1 ⁇ 2)- ⁇ -D-Ribf- (1 ⁇ 3)-a-L-Rhap-(1 ⁇ 3)-a-L-Rhap-(1 ⁇ ],
  • the saccharide derived from K. pneumoniae 08 serotype includes the same repeat-unit structure as K. pneumoniae 02a, but is nonstoichiometrically O-acetylated.
  • the saccharide derived from K. pneumoniae 012 serotype includes a repeat unit of [a-Rhap-(1 ⁇ 3)- ⁇ -GlcpNAc] disaccharide repeat unit.
  • Table 1a K. pneumoniae serogroups/serotypes and O-unit moieties
  • the term "about” means within a statistically meaningful range of a value, such as a stated concentration range, time frame, molecular weight, temperature or pH. Such a range can be within an order of magnitude, typically within 20%, more typically within 10%, and even more typically within 5% or within 1% of a given value or range. Sometimes, such a range can be within the experimental errortypical of standard methods used forthe measurement and/or determination of a given value or range. The allowable variation encompassed by the term "about” will depend upon the particular system under study, and can be readily appreciated by one of ordinary skill in the art. Whenever a range is recited within this application, every number within the range is also contemplated as an embodiment of the disclosure.
  • an “immunogenic amount”, an “immunologically effective amount”, a “therapeutically effective amount”, a “prophylactically effective amount”, or “dose”, each of which is used interchangeably herein, generally refers to the amount of antigen or immunogenic composition sufficient to elicit an immune response, either a cellular (T cell) or humoral (B cell or antibody) response, or both, as measured by standard assays known to one skilled in the art.
  • Clinical strains and derivatives are listed in Table 3. Additional reference strains included: 025K5H1 , a clinical 025a serotype strain; and S. entehca serovar Typhimurium strain LT2.
  • O- Polysaccharide O- Polysaccharide
  • EXAMPLE 2 OLIGONUCLEOTIDE PRIMERS FOR WZZB, FEPE AND O-ANTIGEN GENE CLUSTER CLONING
  • EXAMPLE 3 PLASMIDS
  • Plasmid vectors and subclones are listed in Table 5. PCR fragments harboring various E. coli and Salmonella wzzB and fepE genes were amplified from purified genomic DNA and subcloned into the high copy number plasmid provided in the Invitrogen PCR®Blunt cloning kit. This plasmid is based on the pUC replicon. Primers P3 and P4 were used to amplify E.
  • coli wzzB genes with their native promoter, and are designed to bind to regions in proximal and distal genes encoding UDP-glucose-6-dehydrogenase and phosphoribosyladenine nucleotide hydrolase respectively (annotated in Genbank MG1655 NC_000913.3).
  • a PCR fragment containing Salmonella fepE gene and promoter were amplified using primers previously described.
  • Analogous E. coli fepE primers were designed based on available Genbank genome sequences or whole genome data generated internally (in case of GAR2401 and 025K5H1). Low copy number plasmid pBAD33 was used to express O-antigen biosynthetic genes under control of the arabinose promoter.
  • the plasmid was first modified to facilitate cloning (via Gibson method ) of long PCR fragments amplified using universal primers homologous to the 5’ promoter and 3’ 6-phosphogluconate dehydrogenase ( gnd) gene Table 5.
  • the fermentation broth was treated with acetic acid to a final concentration of 1 - 2% (final pH of 4.1).
  • the extraction of OAg and delipidation were achieved by heating the acid treated broth to 100°C for 2 hours.
  • the batch was cooled to ambient temperature and 14% NH 4 OH was added to a final pH of 6.1.
  • the neutralized broth was centrifuged and the centrate was collected. To the centrate was added CaCI 2 in sodium phosphate and the resulting slurry was incubated for 30 mins at room temperature.
  • the solids were removed by centrifugation and the centrate was concentrated 12-fold using a 10kDa membrane, followed by two diafiltrations against water.
  • the retentate which contained OAg was then purified using a carbon filter.
  • the carbon filtrate was diluted 1 :1 (v/v) with 4.0M ammonium sulfate.
  • the final ammonium sulfate concentration was 2M.
  • the ammonium sulfate treated carbon filtrate was further purified using a membrane with 2M ammonium sulfate as the running buffer.
  • the OAg was collected in the flow through.
  • the HIC filtrate was concentrated and then buffer exchanged against water (20 diavolumes) using a 5kDa membrane.
  • the MWCO was further reduced to enhance yield.
  • the solids were removed by centrifugation and the centrate was concentrated 12-fold using a 10kDa membrane, followed by two diafiltrations against water or 20 - 25mM Tris buffer that contained 20 - 25mM NaCI pH 7.2 - 7..
  • the retentate which contained OAg was then purified using a carbon filter.
  • the carbon filtrate was further purified by ion exchange (IEX) membrane chromatography.
  • the IEX filtrate was then diluted 1 :1 (v/v) with 4.0M ammonium sulfate. The final ammonium sulfate concentration was 2M.
  • the ammonium sulfate treated IEX filtrate was further purified using a HIC membrane with 2M ammonium sulfate as the running buffer.
  • the OAg was collected in the flow through.
  • the HIC filtrate was concentrated and then buffer exchanged against water (20 diavolumes) using a 5kDa membrane.
  • the purification process described here is applicable to both short chain and long chain O-Ag polysaccharides. Most examples given here are for long chain O-Ag, except for Example 10 and 11 , which are short chain O-Ag for E.coli serotype 08 and 09, respectively.
  • EXAMPLE 5 METHODS FOR PURIFYING E. COLI O-ANTIGEN POLYSACCHARIDES
  • the process begins with acid hydrolysis after the completion of fermentation to release the O-Ag from the lipopolysaccharides (LPS). This was achieved by treating the crude suspension of serotype 025b cell culture with the acetic acid to the final concentration of 1 .0 % (v/v) that brought the pH to about 4.0. The acidic broth was then heated to the temperature of 100°C and incubated for 2.0 hours. After the product was released, the batch was cooled to the ambient temperature of 20 - 30°C.
  • LPS lipopolysaccharides
  • DOE design of experiment
  • the main purpose of this step is to precipitate cell debris, host cell proteins and nucleic acids from the broth that contains the released product. It also enhances the efficiency of the downstream clarification unit operation.
  • the acidified broth after the release of product from Step 1 was treated with the 10% Alum solution to the final concentration of 2% (w/v), and the pH was further adjusted to 3.2 using sulfuric acid.
  • the flocculated slurry was incubated at ambient temperature for 1.0 hour, followed by centrifugation at 12,000 - 14,000 g for 30 minutes.
  • the supernatant was then filtered by a 0.2- ⁇ m filter or another suitable depth filter to remove any small particles that might skipped into the solution.
  • the depth filtrate was proceeding to the initial purification of UFDF-1 .
  • the acidified broth was neutralized to pH of 6.0 - 7.0.
  • the neutralized filtrate was centrifuged at 12,000 g for 30 minutes.
  • the neutralized supernatant was filtered via 0.2- ⁇ m filter.
  • the neutrzlized filtrate can be stored at 4°C for at least one week without any adverse impact on the quality of the product.
  • the neutralized filtrate will go through the flocculation process described in the above paragraph.
  • the subsequent purification steps illustrated in this example use this flocculation method, unless indicated otherwise.
  • the depth filtrate from Step 2 above is further purified through ultrafiltration and diafiltration (UFDF) using 10-kDa Sartocon Hydrosart membrane.
  • the amount of depth filtrate processed is typically 20 - 30 liters per m 2 of membrane area.
  • the purposes of this operation are: (i) volume reduction by concentrating the solution 10 - 20 folds and (ii) buffer exchange by replacing the fermentation media with desired buffer through diafiltration.
  • the buffer used in this step was 20mM citrate / 0.1 M NaCI pH 6.0 followed by the second buffer of 20mM Tris / 20mM NaCI pH 7.2.
  • the numbers of diavolumes were 10 for both diafiltration steps.
  • the retentate from the UFDF was collected and analyzed.
  • the 3M R32SP carbon filter is used at loading of approximately 150 g of O-Ag from retentate of UFDF-1 perm 2 of carbon filter area.
  • the carbon filter was first rinsed with water followed by the diafiltration buffer at approximately 20 liters of buffer per m 2 of filter area.
  • the retentate from UFDF-1 was then filtered at a flow rate of 50 LMH (liters per m 2 per hour) in a single pass mode.
  • the filter was then rinsed with the buffer, and the filtrate including rinse that contained the product was collected as carbon filtrate.
  • IEX membrane Chromatography This step was originally developed for serotypes 02 and 06 O-antigens to remove the non-specific negatively charged impurities (see Example 6 and 15). Therefore, by exploring the electrostatic interaction property of these molecules using the ion exchange (IEX) membrane chromatography, impurities from non-serotype specific extrar or intracellular polysaccharides may be removed.
  • IEX ion exchange
  • the IEX membrane used here is Millipure’s NatriFlo membrane cassette.
  • the Sartobind Q membrane from Sartorius Stedim can also be used. All examples illustrated here used the NatriFlo membrane (or refer to thereafter as HD-Q) for the IEX membrane chromatography, unless indicated otherwise.
  • the membrane was first equilibrated with the 20mM Tris / 20mM NaCI pH 7.2, typically 20 - 30 membrane volume (MV).
  • the carbon filtrate from previous step was pumped through the membrane at flow rate of 30 - 40 mL/min with about 200 - 250 mg of O-Ag in carbon filtrate per mL of MV.
  • the flow through effluent or filtrate that contained the product was collected.
  • the membrane was rinsed with equilibration buffer and then washed with the high salt buffer of 20mM Tris / 1.0M NaCI pH 7.2.
  • This unit operation removes any impurities that had hydrophobic characteristics, such as residual lipid A left from the acid hydrolysis step.
  • the Sartobind Phenyl 150-mL membrane was used for the HIC step.
  • the carbon filtrate from Step 4 was treated with 4.0M ammonium sulfate (AS) soution to the final concentration of 2.0M.
  • the phenyl membrane was first equilibrated with the running buffer of 2.0M ammonium sulfate (AS).
  • the AS treated carbon filtrate was pushed through the HIC membrane at flow rate of 40-mL/min.
  • the HIC membrane was then rinse with the running buffer, followed by the water wash.
  • the flow through effluent along with the buffer rinse was collected as HIC filtrate, and the water wash was also collected for analysis.
  • this HIC filtration step can also be performed for IEX filtrate from Step 4.
  • This unit operation concentrates the product to the desired concentration and replaces the ammonium sulfate with the desirable buffer or water for conjugation. This step is performed using a 5-kDa molecular weight cutoff filter.
  • the HIC filtrate was concentrated ⁇ 10-folds, and then followed by diafiltration using water with ⁇ 20 numbers of diavolumes (DV).
  • the cross-flow rate and TMP for the UFDF-2 run were typically set at 300 LMH and 0.5 - 1 .0 bars, respectively.
  • the conductivity and the UV280 signals of the permeate as a function of DV during the diafiltration were analyzed. After 10 DVs, the conductivity reached steady state, indicating the completion of buffer exchange.
  • the process begins with acid hydrolysis after the completion of the fermentation process to release the O-Ag from the lipopolysaccharides (LPS).
  • LPS lipopolysaccharides
  • the main purpose of this step is to precipitate cell debris, host cell proteins and nucleic acids from the broth that contains the product. It also enhances the efficiency of the downstream clarification process.
  • the flocculation was performed for the neutralized filtrate after the acid hydrolysis described in the Example 5 under Section of “Flocculation”.
  • the 10% Alum solution was added to the neutralized filtrate to the final concentration of 2% (w/v), and the pH was further adjusted to 3.2 using sulfuric acid.
  • the flocculated slurry is incubated at ambient temperature for 1.0 hour, followed by centrifugation at 12,000 - 14,000 g for 30 minutes.
  • the supernatant is filtered by a 0.2- ⁇ m filter or other suitable depth filter to remove any small particles that may skipped into the solution.
  • the depth filtrate was proceeded to the next step of UFDF-1 .
  • the depth filtrate from Step 2 above is further purified through ultrafiltration and diafiltration (UFDF) using 10-kDa Sartocon Hydrosart membrane cassette.
  • the amount of material processed is typically 20 - 30 liters per m 2 of membrane area.
  • the purposes of this operation are: (i) volume reduction by concentrating the solution 10 - 20 folds and (ii) buffer exchange by replacing the fermentation media with desired buffer through diafiltration.
  • the buffer used in this step is 20mM citrate / 0.1 M NaCI pH 6.0 followed by the second buffer of 20mM Tris / 20mM NaCI pH 7.2.
  • the numbers of diavolumes are 20 and 10 for each diafiltration step, respectively.
  • the 3M R32SP carbon filter is used at loading of approximately 150 g of O-Ag per m 2 of carbon filter area.
  • the carbon filter was first rinsed with water followed by the diafiltration buffer at approximately 20 liters of buffer per m 2 of membrane area.
  • the retentate from UFDF-1 was then filtered at a flow rate of 50 LMH (liters per m 2 per hour) in a single pass mode.
  • the filter was then rinsed with the buffer, and the filtrate/rinse that contained the product was collected the SEC-HPLC chromatograms for the UFDF retentate and the carbon filtrateindicate that the Rl and UV280 related impurities were removed and carbon filtrate literately became colorless. However, the front shoulder impurity peak is still present in the carbon filtrate.
  • IEX membrane Chromatography This step was developed to remove the non-specific negatively charged impurity (see Section IEX membrane Chromatography in Example 5).
  • the HD-Q membrane was first equilibrated with the 20mM Tris/20mM NaCI pH 7.2, typically 20 - 30 membrane volume (MV).
  • the carbon filtrate was then loaded onto the membrane at about 100 - 250 mg of O-Ag per mL of MV.
  • the flow through effluent or filtrate that contained the product was collected.
  • the membrane was rinsed with equilibration buffer and then washed with the high salt buffer, 20mM Tris / 1 .0M NaCI pH 7.2.
  • This unit operation removes any impurities that had hydrophobic characteristics, such as residual lipid A left from the acid hydrolysis step.
  • the Sartobind Phenyl 150-mL membrane was used forthe HIC step.
  • the IEX filtrate from previous step was treated with 4.0M ammonium sulfate (AS) soution to the final concentration of 2.0M.
  • the phenyl membrane was first equilibrated with the running buffer of 2.0M ammonium sulfate.
  • the AS treated IEX filtrate was filtered through the HIC membrane at flow rate of 40-60 mL/min.
  • the HIC membrane was then rinse with the running buffer, followed by the water wash.
  • the flow through effluent along with the buffer rinse was collected as HIC filtrate, and the water wash was also collected for analysis.
  • the SEC-HPLC chromatograms forthe HIC filtrate and HIC filtrate indicate that small front shoulder impurity peakthat is present in the carbon filtrate was removed by the HIC filtration step.
  • This unit operation concentrates the product to the desired concentration and replaces the ammonium sulfate from the previous HIC purification step with the desirable buffer or water for conjugation.
  • This step is performed using a 5-kDa molecular weight cutoff membrane of Sartocon Hydrosart from Sartorius.
  • the HIC filtrate was concentrated ⁇ 10-folds, and then followed by diafiltration using water with ⁇ 20 numbers of diavolumes (DV).
  • the cross-flow rate and TMP for the UFDF-2 run were typically set at 300 LMH and 0.5 - 1 .0 bars, respectively.
  • the process begins with acid hydrolysis after fermentation process to release the O-Ag from the lipopolysaccharides (LPS). Based on this DOE results conducted for the serotype 025b O-Ag (see Example 5), the conditions used for acid hydrolysis for all serotypes of O-antigens are pH 3.8 ⁇ 0.1 , temperature 95 ⁇ 5°C and incubation time of 2.0 hours. This step was performed in the fermentation tank.
  • the main purpose of this step is to precipitate cell debris, host cell proteins and nucleic acids from the broth that contains the product. It also enhances the efficiency of the downstream clarification process.
  • the flocculation was performed here for the neutralized filtrate after the acid hydrolysis described in the Example 5 under Section of “Flocculation”.
  • the 10% Alum solution was added to the neutralized filtrate to the final concentration of 2% (w/v), and the pH was further adjusted to 3.2 using sulfuric acid.
  • the flocculated slurry is incubated at ambient temperature for 1.0 hour, followed by centrifugation at 12,000 - 14,000 g for 30 minutes.
  • the supernatant is filtered by a 0.2- ⁇ m filter or other suitable depth filter to remove any small particles that may skipped into the solution.
  • the depth filtrate was proceeded to the next step of UFDF-1 .
  • Purification begins with the depth filtrate (from step 2 above) by ultrafiltration and diafiltration (UFDF) using 10-kDa Sartocon Hydrosart membrane cassette.
  • the amount of material processed is typically 20 - 30 liters per m 2 of membrane area.
  • the purposes of this operation are: (i) volume reduction by concentrating the solution 10 - 20 folds and (ii) buffer exchange by replacing the fermentation media with desired buffer through diafiltration.
  • the buffer used in this step is 20mM citrate / 0.1 M NaCI pH 6.0 followed by the second buffer of 20mM Tris / 20mM NaCI pH 7.2.
  • the numbers of diavolumes are 10 and 15 for each diafiltration step, respectively.
  • the SEC-HPLC chromatograms of neutralized filtrate, depth filtrate after flocculation and retentate after the UFDF-1 were analyzed.
  • the effectiveness of flocculation and UFDF-1 for removing the host cell proteins and small MW impurities was demonstrated by both Rl and UV280 chromatograms.
  • the 3M R32SP carbon filter is used at loading of approximately 100 - 150 g of O-Ag per m 2 of carbon filter area.
  • the carbon was first rinsed with water followed by the diafiltration buffer at approximately 20 liters of buffer per m 2 of membrane area.
  • the retentate from UFDF-1 was then filtered at a flow rate of 50 LMH (liters per m 2 per hour) in single pass mode.
  • the carbon filter was then rinsed with buffer. The filtrate and the buffer rinse that contained the product was collected.
  • This step was developed to remove the non-specific negatively charged impurity (see Section IEX membrane Chromatography in Example 5).
  • the IEX membrane was first equilibrated with the 20mM Tris / 20mM NaCI pH 7.2, typically 20 - 30 membrane volume (MV).
  • the carbon filtrate was then loaded onto the membrane at about 200 - 250 mg of O-Ag per mL of MV.
  • the flow through effluent or filtrate that contained the product was collected.
  • the membrane was rinsed with equilibration buffer and then washed with the high salt buffer, 20mM Tris / 1 0M NaCI pH 7.2.
  • This unit operation removes any impurities that had hydrophobic characteristics, such as residual lipid A left from the acid hydrolysis step.
  • the Sartobind Phenyl 150-mL membrane was used for the HIC step.
  • the IEX filtrate was treated with 4.0M ammonium sulfate (AS) soution to the final concentration of 2.0M.
  • the phenyl membrane was first equilibrated with the running buffer of 2.0M ammonium sulfate.
  • the AS treated IEX filtrate was pushed through the HIC membrane at flow rate of 40 - 60 mL/min.
  • the HIC membrane was then rinse with the running buffer, followed by the water wash.
  • the flow through effluent along with the buffer rinse was collected as HIC filtrate, and the water wash was also collected for analysis.
  • This unit operation concentrates the product to the desired concentration and replaces the ammonium sulfate with the desirable buffer or water for conjugation. This step is performed using a 5-kDa molecular weight cutoff filter.
  • the HIC filtrate was concentrated ⁇ 10-folds, and then followed by diafiltration using water with ⁇ 20 numbers of diavolumes (DV).
  • the cross-flow rate and TMP for the UFDF-2 run were typically set at 300 LMH and 0.5 - 1.0 bars, respectively.
  • the retentate from the UFDF-1 was collected along with the rinse.
  • the final pool was filtered through a 0.2- ⁇ m filter.
  • the SEC-HPLC profile for the final purified 075 O-Ag was analyzed. Table-3-1 below summerizes the quality attributes of the final purified 075 O-Ag.
  • the process begins with acid hydrolysis after fermentation to release the O-Ag from the lipopolysaccharides (LPS). Based on the DOE results conducted for the serotype 025b O-Ag (see Example 5), the conditions used for acid hydrolysis for all serotypes of O-antigens are pH 3.8 ⁇ 0.1 , temperature 95 ⁇ 5°C and incubation time of 2.0 hours. This step was performed in the fermentation tank.
  • the main purpose of this step is to precipitate cell debris, host cell proteins and nucleic acids from the broth that contains the product. It also enhances the efficiency of the downstream clarification process.
  • the flocculation was performed here for the neutralized filtrate after the acid hydrolysis described in the Example 5 under Section of “Flocculation”.
  • the 10% Alum solution was added to the neutralized filtrate to the final concentration of 2% (w/v), and the pH was further adjusted to 3.2 using sulfuric acid.
  • the flocculated slurry is incubated at ambient temperature for 1.0 hour, followed by centrifugation at 12,000 - 14,000 g for 30 minutes.
  • the supernatant is filtered by a 0.2- ⁇ m filter or other suitable depth filter to remove any small particles that may skipped into the solution.
  • the depth filtrate was proceeded to the next step of UFDF-1 .
  • Purification begins with the depth filtrate (from step 2 above) by ultrafiltration and diafiltration using 10-kDa Sartocon Hydrosart membrane cassette.
  • the amount of material processed is typically 20 - 30 liters per m 2 of membrane area.
  • the purposes of this operation are: (i) volume reduction by concentrating the solution 10 - 20 folds and (ii) buffer exchange by replacing the fermentation media with desired buffer through diafiltration.
  • the buffer used in this step is 20mM citrate /0.1 M NaCI pH 6.0 followed by the second buffer of 20mM Tris / 20mM NaCI pH 7.2.
  • the numbers of diavolumes are 10 and 15 for each diafiltration step, respectively.
  • the SEC-HPLC chromatograms of depth filtrate and retentate after the UFDF-1 were analyzed. The effectiveness of flocculation and UFDF-1 for removing the host cell proteins and small MW impurities was demonstrated by both Rl and UV280 chromatograms.
  • the 3M carbon filter is used at loading of approximately 100 - 150 g of O-Ag per m 2 of carbon filter area.
  • the carbon was first rinsed with water followed by the diafiltration buffer at approximately 20 liters of buffer per m 2 of membrane area.
  • the retentate from UFDF-1 was then filtered at a flow rate of 50 LMH (liters per m 2 per hour) in a single pass mode.
  • the carbon filter was rinsed with the buffer.
  • the filtrate and rinse that contained the product were combined as carbon filtrate.
  • This unit operation removes any impurities that had hydrophobic characteristics, such as residual lipid A left from the acid hydrolysis step and assure that endotoxin level will be kept at minimum level.
  • the Sartobind Phenyl 150-mL membrane was used for the HIC step.
  • the carbon filtrate was treated with 4.0M ammonium sulfate (AS) soution to the final concentration of 2.0M.
  • the phenyl membrane was first equilibrated with the running buffer of 2.0M ammonium sulfate.
  • the AS treated carbon filtrate was filtered through the HIC membrane at flow rate of 40 - 60 mL/min.
  • the HIC membrane was then rinse with the running buffer, followed by the water wash.
  • This unit operation concentrates the product to the desired concentration and replaces the ammonium sulfate with the desirable buffer or water for conjugation. This step is performed using a Sartocon Hydrosart 5-kDa membrane from Sartorius.
  • the HIC filtrate was concentrated ⁇ 10-folds, and then followed by diafiltration using water with ⁇ 20 numbers of diavolumes (DV).
  • the cross-flow rate and TMP for the UFDF-2 run were typically set at 300 LMH and 0.5 - 1.0 bars, respectively.
  • the retentate from the UFDF-1 was collected along with the rinse.
  • the final pool was filtered through a 0.2- ⁇ m filter.
  • the SEC-HPLC profile for the final purified 01 O-Ag was analyzed. Table 4-1 below summerizes the quality attributes of the final purified 01 O-Ag.
  • the process begins with acid hydrolysis after fermentation process to release the O-Ag from the lipopolysaccharides (LPS). Based on this DOE results conducted for the serotype 025b O-Ag (see Example 5), the conditions used for acid hydrolysis for all serotypes of O-antigens are pH 3.8 ⁇ 0.1 , temperature 95 ⁇ 5°C and incubation time of 2.0 hours. This step was performed in the fermentation tank.
  • the main purpose of this step is to precipitate cell debris, host cell proteins and nucleic acids from the broth that contains the product. It also enhances the efficiency of the downstream clarification process.
  • the flocculation was performed here with the neutralized filtrate after the acid hydrolysis described in the Example 5 under Section of “Flocculation”.
  • the 10% Alum solution was added to the neutralized filtrate to the final concentration of 2% (w/v), and the pH was further adjusted to 3.2 using sulfuric acid.
  • the flocculated slurry is incubated at ambient temperature for 1.0 hour, followed by centrifugation at 12,000 - 14,000 g for 30 minutes.
  • the supernatant is filtered by a 0.2- ⁇ m filter or other suitable depth filter to remove any small particles that may skipped into the solution.
  • the depth filtrate was proceeded to the next step of UFDF-1 .
  • the comparison of SEC-HPLC chromatograms for the neutralized filtrate and depth filtrate after flocculation were analyzed.
  • Purification begins with the depth filtrate (from step 2 above) by ultrafiltration and diafiltration (UFDF) using 10-kDa Sartocon Hydrosart membrane cassette.
  • the amount of material processed is typically 20 - 30 liters per m 2 of membrane area.
  • the purposes of this operation are: (i) volume reduction by concentrating the solution 10 - 20 folds and (ii) buffer exchange by replacing the fermentation media with desired buffer through diafiltration.
  • the buffer used in this step is 20mM citrate / 0.1 M NaCI pH 6.0 followed by the second buffer of 20mM Tris / 20mM NaCI pH 7.2.
  • the numbers of diavolumes are 10 for each diafiltration step, respectively.
  • Carbon filtration This unit operation reduces the level of host cell impurities such as proteins and nucleic acids as well as colored impurities (see W02008118752).
  • the 3M carbon filter is used at loading of approximately 100 - 150 g of O-Ag per m 2 of carbon filter area.
  • the carbon was first rinsed with water followed by the diafiltration buffer at approximately 20 liters of buffer per m 2 of membrane area.
  • the retentate from UFDF-1 was then filtered at a flow rate of 50 LMH (liters per m 2 per hour) in single pass mode.
  • the carbon filter was then rinsed with buffer.
  • the filtrate and the buffer rinse that contained the product was collected.
  • This step was developed to remove the non-specific negatively charged impurity (see Section IEX membrane Chromatography in Example 5).
  • the IEX membrane used here is Millipure’s NatriFlo cassette.
  • the Sartobind Q membrane from Sartorius Stedim can also be used.
  • the membrane was first equilibrated with the 25mM Tris / 25mM NaCI pH 7.5, typically 20 - 30 membrane volume (MV).
  • the carbon filtrate was then loaded onto the membrane at about 200 - 250 mg of O-Ag per mL of MV.
  • the flow through effluent or filtrate that contained the product was collected.
  • the membrane was rinsed with equilibration buffer and then washed with the high salt buffer, 25mM Tris / 1 0M NaCI pH 7.5.
  • the conductivity and UV profiles of the IEX membrane chromatographic run were analyzed.
  • the UV signal showed a peak during the high salt wash, indicating there was an unknown negatively charged impurity that was present in the carbon filtrate.
  • the SEC- HPLC chromatograms for the carbon filtrate, IEX filtrate and the high salt wash effluent indicate that the high salt elution sample showed a small double peak with the similar retention time of the product.
  • This unit operation removes any impurities that had hydrophobic characteristics, such as residual lipid A left from the acid hydrolysis step.
  • the Sartobind Phenyl 150-mL membrane was used for the HIC step.
  • the IEX filtrate was treated with 4.0M ammonium sulfate (AS) soution to the final concentration of 2.0M.
  • the phenyl membrane was first equilibrated with the running buffer of 2.0M ammonium sulfate.
  • the AS treated IEX filtrate was pushed through the HIC membrane at flow rate of 40 - 60 mL/min.
  • the HIC membrane was then rinse with the running buffer, followed by the water wash.
  • the flow through effluent along with the buffer rinse was collected as HIC filtrate, and the water wash was also collected for analysis.
  • the chromatographic profiles of UV and conductivity for the HIC membrane filtration were analyzed. There was a small visible peak shown in the water wash step, indicating a trace amount of the unspecified substance bound onto
  • This unit operation concentrates the product to the desired concentration and replaces the ammonium sulfate with the desirable buffer or water for conjugation. This step is performed using a 5-kDa molecular weight cutoff filter.
  • the HIC filtrate was concentrated ⁇ 10-folds, and then followed by diafiltration using water with ⁇ 20 numbers of diavolumes (DV).
  • the cross-flow rate and TMP for the UFDF-2 run were typically set at 300 LMH and 0.5 - 1.0 bars, respectively.
  • the retentate from the UFDF-2 was collected along with the rinse.
  • the final pool was filtered through a 0.2- ⁇ m filter.
  • the conductivity and the UV280 signals of the permeate as a function of DV during the diafiltration indicate that after 10 DV, the conductivity reached steady state, indicating the completion of buffer exchange.
  • the SEC-HPLC profiles for the final purified 015 O-Ag were analyzed. Table 5-1 below summerizes the quality attributes of the final purified 015 O-Ag.
  • the serotype 08 is a short chain O-antigen, and the molecular weight is expected to be in the range of 10 - 15 kDa.
  • the purification process outlined also applies to all the short chain E. coli O-Ag.
  • the process begins with acid hydrolysis after fermentation process to release the O-Ag from the lipopolysaccharides (LPS).
  • LPS lipopolysaccharides
  • the conditions used for acid hydrolysis for all serotypes of O-antigens are pH 3.8 ⁇ 0.1 , temperature 95 ⁇ 5°C and incubation time of 2.0 hours. This step was performed in the fermentation tank.
  • the main purpose of this step is to precipitate cell debris, host cell proteins and nucleic acids from the broth that contains the product. It also enhances the efficiency of the downstream clarification process.
  • the flocculation was performed here with the neutralized filtrate after the acid hydrolysis described in the Example 5 under Section of “Flocculation”.
  • the 10% Alum solution was added to the neutralized filtrate to the final concentration of 2% (w/v), and the pH was further adjusted to 3.2 using sulfuric acid.
  • the flocculated slurry is incubated at ambient temperature for 1.0 hour, followed by centrifugation at 12,000 - 14,000 g for 30 minutes.
  • the supernatant is filtered by a 0.2- ⁇ m filter or other suitable depth filter to remove any small particles that may skipped into the solution.
  • the depth filtrate was proceeded to the next step of UFDF-1 .
  • Purification begins with the depth filtrate (from step 2 above) by ultrafiltration and diafiltration (UFDF) using 10-kDa Sartocon Hydrosart membrane cassette.
  • the amount of material processed is typically 20 - 30 liters per m 2 of membrane area.
  • the purposes of this operation are: (i) volume reduction by concentrating the solution 10 - 20 folds and (ii) buffer exchange by replacing the fermentation media with desired buffer through diafiltration.
  • the buffer used in this step is 20mM citrate / 0.1 M NaCI pH 6.0 followed by the second buffer of 20mM Tris / 20mM NaCI pH 7.2.
  • the numbers of diavolumes are 10 for each diafiltration step, respectively.
  • the SEC-HPLC chromatograms of retentate after the UFDF-1 were analyzed.
  • the 3M carbon filter is used at loading of approximately 100 - 150 g of O-Ag per m 2 of carbon filter area.
  • the carbon was first rinsed with water followed by the diafiltration buffer at approximately 20 liters of buffer per m 2 of membrane area.
  • the retentate from UFDF-1 was then filtered at a flow rate of 50 LMH (liters per m 2 per hour) in single pass mode.
  • the carbon filter was then rinsed with buffer. The filtrate and the buffer rinse that contained the product was collected.
  • This step was developed to remove the non-specific negatively charged impurity (see Section IEX membrane Chromatography in Example 5).
  • the IEX membrane used here is Millipure’s NatriFlo (HD-Q) cassette.
  • the Sartobind Q membrane from Sartorius Stedim can also be used.
  • the membrane was first equilibrated with the 20mM Tris / 20mM NaCI pH 7.2, typically 20 - 30 membrane volume (MV).
  • the carbon filtrate was then loaded onto the membrane at about 200 - 250 g of O-Ag per mL of MV.
  • the flow through effluent or filtrate that contained the product was collected.
  • the membrane was rinsed with equilibration buffer and then washed with the high salt buffer, 20mM Tris / 1 0M NaCI pH 7.2.
  • This unit operation removes any impurities that had hydrophobic characteristics, such as residual lipid A left from the acid hydrolysis step.
  • the Sartobind Phenyl 150-mL membrane was used for the HIC step.
  • the IEX filtrate was treated with 4.0M ammonium sulfate (AS) soution to the final concentration of 2.0M.
  • the phenyl membrane was first equilibrated with the running buffer of 2.0M ammonium sulfate.
  • the AS treated IEX filtrate was pushed through the HIC membrane at flow rate of 40 - 60 mL/min.
  • the HIC membrane was then rinse with the running buffer, followed by the water wash.
  • the flow through effluent along with the buffer rinse was collected as HIC filtrate, and the water wash was also collected for analysis.
  • the chromatographic profiles of UV and conductivity for the HIC membrane filtration were analyzed. There was a visible peak shown in the water wash step, indicating a trace amount of the unspecified hydrophobic substance
  • Ultrafiltration/Diafiltration-(UFDF-2) This unit operation concentrates the product to the desired concentration and replaces the ammonium sulfate with the desirable buffer or water for conjugation. This step is performed using a 5-kDa molecular weight cutoff filter.
  • the HIC filtrate was concentrated ⁇ 10-folds, and then followed by diafiltration using water with ⁇ 20 numbers of diavolumes (DV).
  • the cross-flow rate and TMP for the UFDF-2 run were typically set at 200 LMH and 0.5 bars, respectively.
  • the retentate from the UFDF-2 was collected along with the rinse.
  • the final pool was filtered through a 0.2- ⁇ m filter.
  • the SEC-HPLC profiles for the final purified 08 O-Ag were analyzed. Table 6-1 below summerizes the quality attributes of the final purified 08 O-Ag.
  • the serotype 09 is also a short chain O-antigen, and the molecular weight is expected to be in the range of 10 - 15 kDa.
  • the purification process outlined was used. The process begins with acid hydrolysis after fermentation process to release the O-Ag from the lipopolysaccharides (LPS). Based on this DOE results conducted for the serotype 025b O-Ag (see Example 5), the conditions used for acid hydrolysis for all serotypes of O-antigens are pH 3.8 ⁇ 0.1 , temperature 95 ⁇ 5°C and incubation time of 2.0 hours. This step was performed in the fermentation tank.
  • the main purpose of this step is to precipitate cell debris, host cell proteins and nucleic acids from the broth that contains the product. It also enhances the efficiency of the downstream clarification process.
  • the flocculation was performed for the neutralized filtrate after the acid hydrolysis described in the Example 5 under Section of “Flocculation”.
  • the 10% Alum solution was added to the neutralized filtrate to the final concentration of 2% (w/v), and the pH was further adjusted to 3.2 using sulfuric acid.
  • the flocculated slurry is incubated at ambient temperature for 1.0 hour, followed by centrifugation at 12,000 - 14,000 g for 30 minutes.
  • the supernatant is filtered by a 0.2- ⁇ m filter or other suitable depth filter to remove any small particles that may skipped into the solution.
  • the depth filtrate was proceeded to the next step of UFDF-1.
  • the comparison of SEC-HPLC chromatographic profiles for the neutralized filtrate and the depth filtrate was analyzed.
  • Purification begins with the depth filtrate (from step 2 above) by ultrafiltration and diafiltration (UFDF) using 10-kDa Sartocon Hydrosart membrane cassette.
  • the amount of material processed is typically 20 - 30 liters per m 2 of membrane area.
  • the purposes of this operation are: (i) volume reduction by concentrating the solution 10 - 20 folds and (ii) buffer exchange by replacing the fermentation media with desired buffer through diafiltration.
  • the buffer used in this step is 20mM citrate / 0.1 M NaCI pH 6.0 followed by the second buffer of 20mM Tris / 20mM NaCI pH 7.2.
  • the numbers of diavolumes are 10 for each diafiltration step, respectively.
  • the SEC-HPLC chromatograms of retentate after the UFDF-1 were analyzed.
  • the 3M carbon filter is used at loading of approximately 100 - 150 g of O-Ag per m 2 of carbon filter area.
  • the carbon was first rinsed with water followed by the diafiltration buffer at approximately 20 liters of buffer per m 2 of membrane area.
  • the retentate from UFDF-1 was then filtered at a flow rate of 50 LMH (liters per m 2 per hour) in single pass mode.
  • the carbon filter was then rinsed with buffer. The filtrate and the buffer rinse that contained the product was collected.
  • This step was developed to remove the non-specific negatively charged impurity (see Section IEX membrane Chromatography in Example 5).
  • the IEX membrane used here is Millipure’s NatriFlo (HD-Q) cassette.
  • the Sartobind Q membrane from Sartorius Stedim can also be used.
  • the membrane was first equilibrated with the 20mM Tris / 20mM NaCI pH 7.2, typically 20 - 30 membrane volume (MV).
  • the carbon filtrate was then loaded onto the membrane at about 200 - 250 mg of O-Ag per mL of MV.
  • the flow through effluent or filtrate that contained the product was collected.
  • the membrane was rinsed with equilibration buffer and then washed with the high salt buffer, 20mM Tris / 1 0M NaCI pH 7.2.
  • the conductivity and UV profiles of the IEX membrane chromatographic run was analyzed.
  • the UV signal showed a peak during the high salt wash, indicating there was an unknown negatively charged impurity that was present in the carbon filtrate.
  • the SEC-HPLC chromatograms for the carbon filtrate, IEX filtrate and the high salt wash effluent indicate that the high salt elution sample showed a small peak with the similar retention time of the product.
  • This unit operation removes any impurities that had hydrophobic characteristics, such as residual lipid A left from the acid hydrolysis step.
  • the Sartobind Phenyl 150-mL membrane was used for the HIC step.
  • the IEX filtrate was treated with 4.0M ammonium sulfate (AS) soution to the final concentration of 2.0M.
  • the phenyl membrane was first equilibrated with the running buffer of 2.0M ammonium sulfate.
  • the AS treated IEX filtrate was pushed through the HIC membrane at flow rate of 40 - 60 mL/min.
  • the HIC membrane was then rinse with the running buffer, followed by the water wash.
  • the flow through effluent along with the buffer rinse was collected as HIC filtrate, and the water wash was also collected for analysis.
  • This unit operation concentrates the product to the desired concentration and replaces the ammonium sulfate with the desirable buffer or water for conjugation. This step is performed using a 5-kDa molecular weight cutoff filter.
  • the HIC filtrate was concentrated ⁇ 10-folds, and then followed by diafiltration using water with ⁇ 20 numbers of diavolumes (DV).
  • the cross-flow rate and TMP for the UFDF-2 run were typically set at 200 LMH and 0.5 bars, respectively.
  • the retentate from the UFDF-2 was collected along with the rinse.
  • the final pool was filtered through a 0.2- ⁇ m filter.
  • the SEC-HPLC profiles for the final purified 09 O-Ag were analyzed. Table 7-1 below summerizes the quality attributes of the final purified 09 O-Ag.
  • the process begins with acid hydrolysis after fermentation process to release the O-Ag from the lipopolysaccharides (LPS). Based on this DOE results conducted for the serotype 025b O-Ag (see Example 5), the conditions used for acid hydrolysis for all serotypes of O-antigens are pH 3.8 ⁇ 0.1 , temperature 95 ⁇ 5°C and incubation time of 2.0 hours. This step was performed in the fermentation tank.
  • the main purpose of this step is to precipitate cell debris, host cell proteins and nucleic acids from the broth that contains the product. It also enhances the efficiency of the downstream clarification process.
  • the flocculation was performed here for the neutralized filtrate after the acid hydrolysis described in the Example 5 under Section of “Flocculation”.
  • the 10% Alum solution was added to the neutralized filtrate to the final concentration of 2% (w/v), and the pH was further adjusted to 3.2 using sulfuric acid.
  • the flocculated slurry is incubated at ambient temperature for 1.0 hour, followed by centrifugation at 12,000 - 14,000 g for 30 minutes.
  • the supernatant is filtered by a 0.2- ⁇ m filter or other suitable depth filter to remove any small particles that may skipped into the solution.
  • the depth filtrate was proceeded to the next step of UFDF-1 .
  • Purification begins with the depth filtrate (from step 2 above) by ultrafiltration and diafiltration (UFDF) using 10-kDa Sartocon Hydrosart membrane cassette.
  • the amount of material processed is typically 20 - 30 liters per m 2 of membrane area.
  • the purposes of this operation are: (i) volume reduction by concentrating the solution 10 - 20 folds and (ii) buffer exchange by replacing the fermentation media with desired buffer through diafiltration.
  • the buffer used in this step is 20mM citrate / 0.1 M NaCI pH 6.0 followed by the second buffer of 25mM Tris/25mM NaCI pH 7.5.
  • the numbers of diavolumes are 18 for each diafiltration step, respectively.
  • the 3M R55SP carbon filter is used at loading of approximately 100 - 150 g of O-Ag per m 2 of carbon filter area.
  • the carbon was first rinsed with water followed by the diafiltration buffer at approximately 20 liters of buffer per m 2 of membrane area.
  • the retentate from UFDF-1 was then filtered at a flow rate of 50 LMH (liters per m 2 per hour) in single pass mode.
  • the carbon filter was then rinsed with buffer. The filtrate and the buffer rinse that contained the product was collected.
  • This step was developed to remove the non-specific negatively charged impurity (see Section IEX membrane Chromatography in Example 5).
  • the IEX membrane used here is Millipure’s NatriFlo cassette.
  • the Sartobind Q membrane from Sartorius Stedim can also be used.
  • the membrane was first equilibrated with the 25mM Tris / 25mM NaCI pH 7.5, typically 20 - 30 membrane volume (MV).
  • the carbon filtrate was then loaded onto the membrane at about 150 - 200 mg of O-Ag per mL of MV. The flow through effluent or filtrate that contained the product was collected.
  • the membrane was rinsed with equilibration buffer and two step washings, the first one with 25mM Tris / 25mM NaCI pH7.5 buffer and the second one with the high salt buffer, 25mM Tris / 1 0M NaCI pH 7.5.
  • This unit operation removes any impurities that had hydrophobic characteristics, such as residual lipid A left from the acid hydrolysis step.
  • the Sartobind Phenyl 150-mL membrane was used for the HIC step.
  • the IEX filtrate was treated with 4.0M ammonium sulfate (AS) soution to the final concentration of 2.0M.
  • the phenyl membrane was first equilibrated with the running buffer of 2.0M ammonium sulfate.
  • the AS treated IEX filtrate was pushed through the HIC membrane at flow rate of 40 - 60 mL/min.
  • the HIC membrane was then rinse with the running buffer, followed by the water wash.
  • the flow through effluent along with the buffer rinse was collected as HIC filtrate, and the water wash was also collected for analysis.
  • the SEC-HPLC chromatogram for the HIC filtrate were analyzed.
  • This unit operation concentrates the product to the desired concentration and replaces the ammonium sulfate with the desirable buffer or water for conjugation. This step is performed using a 5-kDa molecular weight cutoff filter.
  • the HIC filtrate was concentrated ⁇ 10-folds, and then followed by diafiltration using water with ⁇ 20 numbers of diavolumes (DV).
  • the cross-flow rate and TMP for the UFDF-2 run were typically set at 300 LMH and 0.5 - 1.0 bars, respectively.
  • the retentate from the UFDF-2 was collected along with the rinse.
  • the final pool was filtered through a 0.2- ⁇ m filter.
  • the SEC-HPLC profiles for the final purified 021 O-Ag were analyzed. Table 8-1 below summerizes the quality attributes of the final purified 021 O-Ag.
  • the process begins with acid hydrolysis after fermentation process to release the O-Ag from the lipopolysaccharides (LPS). Based on this DOE results conducted for the serotype 025b O-Ag (see Example 5), the conditions used for acid hydrolysis for all serotypes of O-antigens are pH 3.8 ⁇ 0.1 , temperature 95 ⁇ 5°C and incubation time of 2.0 hours. This step was performed in the fermentation tank. 2.
  • the main purpose of this step is to precipitate cell debris, host cell proteins and nucleic acids from the broth that contains the product. It also enhances the efficiency of the downstream clarification process.
  • the flocculation was performed here for the neutralized filtrate after the acid hydrolysis described in the Example 5 under Section of “Flocculation”.
  • the 10% Alum solution was added to the neutralized filtrate to the final concentration of 2% (w/v), and the pH was further adjusted to 3.2 using sulfuric acid.
  • the flocculated slurry is incubated at ambient temperature for 1.0 hour, followed by centrifugation at 12,000 - 14,000 g for 30 minutes.
  • the supernatant is filtered by a 0.2- ⁇ m filter or other suitable depth filter to remove any small particles that may skipped into the solution.
  • the depth filtrate was proceeded to the next step of UFDF-1 .
  • the SEC- HPLC chromatograms of neutralized filtrate and the depth filtrate were analyzed.
  • Purification begins with the depth filtrate (from step 2 above) by ultrafiltration and diafiltration (UFDF) using 10-kDa Sartocon Hydrosart membrane cassette.
  • the amount of material processed is typically 20 - 30 liters per m 2 of membrane area.
  • the purposes of this operation are: (i) volume reduction by concentrating the solution 10 - 20 folds and (ii) buffer exchange by replacing the fermentation media with desired buffer through diafiltration.
  • the buffer used in this step is 20mM citrate / 0.1 M NaCI pH 6.0 followed by the second buffer of 25mM Tris/25mM NaCI pH 7.5.
  • the numbers of diavolumes are 18 for each diafiltration step, respectively.
  • the SEC-HPLC chromatograms of retentate after the UFDF-1 were analyzed.
  • the 3M R55SP carbon filter is used at loading of approximately 100 - 150 g of O-Ag per m 2 of carbon filter area.
  • the carbon was first rinsed with water followed by the diafiltration buffer at approximately 20 liters of buffer per m 2 of membrane area.
  • the retentate from UFDF-1 was then filtered at a flow rate of 50 LMH (liters per m 2 per hour) in single pass mode.
  • the carbon filter was then rinsed with buffer. The filtrate and the buffer rinse that contained the product was collected.
  • IEX membrane Chromatography This step was developed to remove the non-specific negatively charged impurity (see Section IEX membrane Chromatography in Example 5).
  • the IEX membrane used here is Millipure’s NatriFlo (HD-Q) cassette.
  • the Sartobind Q membrane from Sartorius Stedim can also be used.
  • the membrane was first equilibrated with the 20mM Tris / 20mM NaCI pH 7.2, typically 20 - 30 membrane volume (MV).
  • the carbon filtrate was then loaded onto the membrane at about 150 - 200 mg of O-Ag per mL of MV. The flow through effluent or filtrate that contained the product was collected.
  • the membrane was rinsed with equilibration buffer and two step washings, the first one with 20mM Tris / 25mM NaCI pH7.5 buffer and the second one with the high salt buffer, 25mM Tris / 1 0M NaCI pH 7.5.
  • the SEC-HPLC chromatograms forthe carbon filtrate and the IEX filtrate were analyzed.
  • This unit operation removes any impurities that had hydrophobic characteristics, such as residual lipid A left from the acid hydrolysis step.
  • the Sartobind Phenyl 150-mL membrane was used for the HIC step.
  • the IEX filtrate was treated with 4.0M ammonium sulfate (AS) soution to the final concentration of 2.0M.
  • the phenyl membrane was first equilibrated with the running buffer of 2.0M ammonium sulfate.
  • the AS treated IEX filtrate was pushed through the HIC membrane at flow rate of 40 - 60 mL/min.
  • the HIC membrane was then rinse with the running buffer, followed by the water wash.
  • the flow through effluent was collected along with the rinse as HIC filtrate, and the water wash was also collected for analysis.
  • the conductivity and UV profiles for the HIC membrane chromatography run indicate that the hydrophobic related impurities were bound onto the HIC membrane and subsequently washed out by the water.
  • the SEC-HPLC chromatogram for the HIC filtrate and HIC wash was analyzed.
  • This unit operation concentrates the product to the desired concentration and replaces the ammonium sulfate with the desirable buffer or water for conjugation. This step is performed using a 5-kDa molecular weight cutoff filter.
  • the HIC filtrate was concentrated ⁇ 10-folds, and then followed by diafiltration using water with ⁇ 20 numbers of diavolumes (DV).
  • the cross-flow rate and TMP for the UFDF-2 run were typically set at 300 LMH and 0.5 - 1.0 bars, respectively.
  • the retentate from the UFDF-2 was collected along with the rinse.
  • the final pool was filtered through a 0.2- ⁇ m filter.
  • the SEC-HPLC profiles for the final purified 04 O-Ag were analyzed. Table 9-1 below summerizes the quality attributes of the final purified 04 O-Ag.
  • the process begins with acid hydrolysis after fermentation process to release the O-Ag from the lipopolysaccharides (LPS). Based on this DOE results conducted for the serotype 025b O-Ag (see Example 5), the conditions used for acid hydrolysis for all serotypes of O-antigens are pH 3.8 ⁇ 0.1 , temperature 95 ⁇ 5°C and incubation time of 2.0 hours. This step was performed in the fermentation tank.
  • the flocculation was performed from the neutralized filtrate after the acid hydrolysis described in the Example 5 under Section of “Flocculation”.
  • the 10% Alum solution was added to the neutralized filtrate to the final concentration of 2% (w/v), and the pH was further adjusted to 3.2 using sulfuric acid.
  • the flocculated slurry is incubated at ambient temperature for 1 .0 hour, followed by centrifugation at 12,000 - 14,000 g for 30 minutes.
  • the supernatant is filtered by a 0.2-mh ⁇ filter or other suitable depth filter to remove any small particles that may skipped into the solution.
  • the depth filtrate was proceeded to the next step of UFDF-1 .
  • Purification begins with the depth filtrate (from step 2 above) by ultrafiltration and diafiltration (UFDF) using 10-kDa Sartocon Hydrosart membrane cassette.
  • the amount of material processed is typically 20 - 30 liters per m 2 of membrane area.
  • the purposes of this operation are: (i) volume reduction by concentrating the solution 10 - 20 folds and (ii) buffer exchange by replacing the fermentation media with desired buffer through diafiltration.
  • the buffer used in this step is 20mM citrate / 0.1 M NaCI pH 6.0 followed by the second buffer of 25mM Tris / 25mM NaCI pH 7.5.
  • the numbers of diavolumes are 18 for each diafiltration step, respectively.
  • the 3M carbon filter is used at loading of approximately 75-125 g of O-Ag per m 2 of carbon filter area.
  • the carbon was first rinsed with water followed by the diafiltration buffer at approximately 20 liters of buffer per m 2 of membrane area.
  • the retentate from UFDF-1 was then filtered at a flow rate of 50 LMH (liters per m 2 per hour) in single pass mode.
  • the carbon filter was then rinsed with buffer. The filtrate and the buffer rinse that contained the product was collected.
  • This step was developed to remove the non-specific negatively charged impurity (see Section IEX membrane Chromatography in Example 5).
  • the IEX membrane used here is Millipure’s NatriFlo cassette.
  • the Sartobind Q membrane from Sartorius Stedim can also be used.
  • the membrane was first equilibrated with the 20mM Tris / 20mM NaCI pH 7.2, typically 20 - 30 membrane volume (MV).
  • the carbon filtrate was then loaded onto the membrane at about 50 - 100 mg of O-Ag per ml_ of MV. The flow through effluent or filtrate that contained the product was collected.
  • the membrane was rinsed with equilibration buffer and two step washings, the first one with 25mM Tris / 25mM NaCI pH7.5 buffer and the second one with the high salt buffer, 25mM Tris / 1.0M NaCI pH 7.5.
  • the UV and conductivity profiles for the IEX membrane chromatography were analyzed. As it delineared that there was a peak eluted out in the high salt wash cycle, indicating that there was small amount of impurities that were bound onto the membrane.
  • the SEC-HPLC chromatograms for the carbon filtrate and IEX filtrate were analyzed.
  • This unit operation removes any impurities that had hydrophobic characteristics, such as residual lipid A left from the acid hydrolysis step.
  • the Sartobind Phenyl 150-mL membrane was used for the HIC step.
  • the IEX filtrate was treated with 4.0M ammonium sulfate (AS) soution to the final concentration of 1.2M.
  • the phenyl membrane was first equilibrated with the running buffer of 2.0M ammonium sulfate.
  • the AS treated IEX filtrate was pushed through the HIC membrane at flow rate of 40 - 60 mL/min.
  • the HIC membrane was then rinse with the running buffer, followed by the water wash.
  • the flow through effluent was collected along with the rinse as HIC filtrate, and the water wash was also collected for analysis.
  • the SEC-HPLC chromatogram for the HIC filtrate is was analyzed.
  • This unit operation concentrates the product to the desired concentration and replaces the ammonium sulfate with water for conjugation. This step is performed using a 5-kDa molecular weight cutoff filter.
  • the HIC filtrate was concentrated ⁇ 10-folds, and then followed by diafiltration using water with ⁇ 20 numbers of diavolumes (DV).
  • the cross-flow rate and TMP for the UFDF-2 run were typically set at 300 LMH and 0.5 - 1.0 bars, respectively.
  • the retentate from the UFDF-2 was collected along with the rinse.
  • the final pool was filtered through a 0.2- ⁇ m filter.
  • the SEC-HPLC profiles for the final purified 02 O-Ag were analyzed. Table 10-1 below summerizes the quality attributes of the final purified 02 O-Ag.
  • the process begins with acid hydrolysis after fermentation process to release the O-Ag from the lipopolysaccharides (LPS). Based on this DOE results conducted for the serotype 025b O-Ag (see Example 5), the conditions used for acid hydrolysis for all serotypes of O-antigens are pH 3.8 ⁇ 0.1 , temperature 95 ⁇ 5°C and incubation time of 2.0 hours. This step was performed in the fermentation tank.
  • the flocculation was performed from the neutralized filtrate after the acid hydrolysis described in the Example 5 under Section of “Flocculation”.
  • the 10% Alum solution was added to the neutralized filtrate to the final concentration of 2% (w/v), and the pH was further adjusted to 3.2 using sulfuric acid.
  • the flocculated slurry is incubated at ambient temperature for 1 .0 hour, followed by centrifugation at 12,000 - 14,000 g for 30 minutes.
  • the supernatant is filtered by a 0.2-mh ⁇ filter or other suitable depth filter to remove any small particles that may skipped into the solution.
  • the depth filtrate was proceeded to the next step of UFDF-1 .
  • Purification begins with the depth filtrate (from step 2 above) by ultrafiltration and diafiltration (UFDF) using 10-kDa Sartocon Hydrosart membrane cassette.
  • the amount of material processed is typically 20 - 30 liters per m 2 of membrane area.
  • the purposes of this operation are: (i) volume reduction by concentrating the solution 10 - 20 folds and (ii) buffer exchange by replacing the fermentation media with desired buffer through diafiltration.
  • the buffer used in this step is 20mM citrate / 0.1 M NaCI pH 6.0 followed by the second buffer of 25mM Tris / 25mM NaCI pH 7.5.
  • the numbers of diavolumes are 18 for each diafiltration step, respectively.
  • the UV and conductivity profiles for the UFDF-1 indicate that most UV related small molecular weight impurities were removed during the first diafiltration.
  • the SEC-HPLC chromatograms of retentate after the UFDF-1 were analyzed.
  • the 3M R55SP carbon filter is used at loading of approximately 100 - 150 g of O-Ag per m 2 of carbon filter area.
  • the carbon was first rinsed with water followed by the diafiltration buffer at approximately 20 liters of buffer per m 2 of membrane area.
  • the retentate from UFDF-1 was then filtered at a flow rate of 50 LMH (liters per m 2 per hour) in single pass mode.
  • the carbon filter was then rinsed with buffer.
  • the filtrate and the buffer rinse that contained the product was collected.
  • the SEC-HPLC chromatograms for the UFDF retentate and the carbon filtrate and carbon bulk which included rinseindicate that carbon filtration was very effective in removing the residual color and small MW impurities.
  • This step was developed to remove the non-specific negatively charged impurity (see Section IEX membrane Chromatography in Example 5).
  • the IEX membrane used here is Millipure’s NatriFlo cassette.
  • the Sartobind Q membrane from Sartorius Stedim can also be used.
  • the membrane was first equilibrated with the 25mM Tris / 25mM NaCI pH 7.5, typically 20 - 30 membrane volume (MV).
  • the carbon filtrate was then loaded onto the membrane at about 100 - 125 mg of O-Ag per mL of MV. The flow through effluent or filtrate that contained the product was collected.
  • the membrane was rinsed with equilibration buffer and two step washings, the first one with 25mM Tris / 25mM NaCI pH7.5 buffer and the second one with the high salt buffer, 25mM Tris / 1.0M NaCI pH 7.5.
  • the UV and conductivity profiles for the IEX membrane chromatography were analyzed. As it delineared that there was a peak eluted out in the high salt wash step, indicating that there was unknown impurity bound onto the membrane.
  • the SEC-HPLC chromatograms for the carbon filtrate, IEX filtrate and 2 high salt wash samples were analyzed.
  • This unit operation removes any impurities that had hydrophobic characteristics, such as residual lipid A left from the acid hydrolysis step.
  • the Sartobind Phenyl 150-mL membrane was used for the HIC step.
  • the IEX filtrate was treated with 4.0M ammonium sulfate (AS) soution to the final concentration of 2.0M.
  • the phenyl membrane was first equilibrated with the running buffer of 2.0M ammonium sulfate.
  • the AS treated IEX filtrate was pushed through the HIC membrane at flow rate of 40 - 60 mL/min.
  • the HIC membrane was then rinse with the running buffer, followed by the water wash.
  • the flow through effluent was collected along with the rinse as HIC filtrate, and the water wash was also collected for analysis.
  • the SEC-HPLC chromatogram for the HIC filtrate was analyzed.
  • This unit operation concentrates the product to the desired concentration and replaces the ammonium sulfate with water for conjugation. This step is performed using a 5-kDa molecular weight cutoff filter.
  • the HIC filtrate was concentrated ⁇ 10-folds and followed by diafiltration into water with ⁇ 20 numbers of diavolumes (DV).
  • the retentate from the UFDF-2 was collected along with the rinse.
  • the final pool was filtered through a 0.2- ⁇ m filter.
  • the SEC-HPLC profiles for the final purified 011 O-Ag were analyzed. Table 11-1 below summerizes the quality attributes of the final purified 011 O-Ag.
  • the process begins with acid hydrolysis after fermentation process to release the O-Ag from the lipopolysaccharides (LPS). Based on this DOE results conducted for the serotype 025b O-Ag (see Example 5), the conditions used for acid hydrolysis for all serotypes of O-antigens are pH 3.8 ⁇ 0.1 , temperature 95 ⁇ 5°C and incubation time of 2.0 hours. This step was performed in the fermentation tank.
  • the flocculation was performed from the neutralized filtrate after the acid hydrolysis described in the Example 5 under Section of “Flocculation”.
  • the 10% Alum solution was added to the neutralized filtrate to the final concentration of 2% (w/v), and the pH was further adjusted to 3.2 using sulfuric acid.
  • the flocculated slurry is incubated at ambient temperature for 1.0 hour, followed by centrifugation at 12,000 - 14,000 g for 30 minutes.
  • the supernatant is filtered by a 0.2-mh ⁇ filter or other suitable depth filter to remove any small particles that may skipped into the solution.
  • the depth filtrate was proceeded to the next step of UFDF-1.
  • 12-1 shows the SEC- HPLC chromatograms of the neutralized filtrate and the depth filtrate after the flocculation.
  • Purification begins with the depth filtrate (from step 2 above) by ultrafiltration and diafiltration (UFDF) using 10-kDa Sartocon Hydrosart membrane cassette.
  • the amount of material processed is typically 20 - 30 liters per m 2 of membrane area.
  • the purposes of this operation are: (i) volume reduction by concentrating the solution 10 - 20 folds and (ii) buffer exchange by replacing the fermentation media with desired buffer through diafiltration.
  • the buffer used in this step is 20mM citrate / 0.1 M NaCI pH 6.0 followed by the second buffer of 25mM Tris / 25mM NaCI pH 7.5.
  • the numbers of diavolumes are 18 for each diafiltration step, respectively.
  • the comparison of SEC-HPLC chromatograms for the depth filtrate and the retentate after the UFDF-1 was analyzed.
  • the 3M R55SP carbon filter is used at loading of approximately 200 - 250 g of O-Ag per m 2 of carbon filter area.
  • the carbon was first rinsed with water followed by the diafiltration buffer at approximately 20 liters of buffer per m 2 of membrane area.
  • the retentate from UFDF-1 was then filtered at a flow rate of 50 LMH (liters per m 2 per hour) in single pass mode.
  • the carbon filter was then rinsed with buffer. The filtrate and the buffer rinse that contained the product was collected.
  • This step was developed to remove the non-specific negatively charged impurity (see Section IEX membrane Chromatography in Example 5).
  • the IEX membrane used here is Millipure’s NatriFlo cassette.
  • the Sartobind Q membrane from Sartorius Stedim can also be used.
  • the membrane was first equilibrated with the 20mM Tris / 20mM NaCI pH 7.2, typically 20 - 30 membrane volume (MV).
  • the carbon filtrate was then loaded onto the membrane at about 100 - 150 mg of O-Ag per ml_ of MV. The flow through effluent or filtrate that contained the product was collected.
  • the membrane was rinsed with equilibration buffer and two step washings, the first one with 25mM Tris / 25mM NaCI pH7.4 buffer and the second one with the high salt buffer, 25mM Tris / 1 0M NaCI pH 7.4.
  • the SEC-HPLC chromatograms for the IEX filtrate were analyzed.
  • This unit operation removes any impurities that had hydrophobic characteristics, such as residual lipid A left from the acid hydrolysis step.
  • the Sartobind Phenyl 150-mL membrane was used for the HIC step.
  • the IEX filtrate was treated with 4.0M ammonium sulfate (AS) soution to the final concentration of 2.0M.
  • the phenyl membrane was first equilibrated with the running buffer of 2.0M ammonium sulfate.
  • the AS treated IEX filtrate was pushed through the HIC membrane at flow rate of 40 - 60 mL/min.
  • the HIC membrane was then rinse with the running buffer, followed by the water wash.
  • the flow through effluent was collected along with the rinse as HIC filtrate, and the water wash was also collected for analysis.
  • the conductivity and UV280 profiles of the HIC chromatographic run were analyzed. A small amount of the hydrophobic substances bound onto the HIC membrane and it was subsequently washed out by the water. The SEC-HPLC chromatogram for the HIC filtrate and the HIC wash was analyzed.
  • This unit operation concentrates the product to the desired concentration and replaces the ammonium sulfate with water for conjugation.
  • This step is performed using a 5-kDa molecular weight cutoff filter.
  • the HIC filtrate was concentrated ⁇ 10-folds, and then followed by diafiltration using water with ⁇ 20 numbers of diavolumes (DV).
  • the cross-flow rate and TMP for the UFDF-2 run were typically set at 300 LMH and 0.5 - 1.0 bars, respectively.
  • the retentate from the UFDF-2 was collected along with the rinse.
  • the final pool was filtered through a 0.2- ⁇ m filter.
  • the SEC-HPLC profiles for the final purified 018 O-Ag were analyzed. Table 12-1 below summerizes the quality attributes of the final purified 018 O-Ag.
  • the process begins with acid hydrolysis after fermentation process to release the O-Ag from the lipopolysaccharides (LPS). Based on this DOE results conducted for the serotype 025b O-Ag (see Example 5), the conditions used for acid hydrolysis for all serotypes of O-antigens are pH 3.8 ⁇ 0.1 , temperature 95 ⁇ 5°C and incubation time of 2.0 hours. This step was performed in the fermentation tank.
  • the batch was cooled to the ambient temperature.
  • the pH was further adjusted to 3.2 using sulfuric acid, and the batch was incubated at ambient temperature for 1.0 hour, followed by centrifugation at 12,000 - 14,000 g for 30 minutes.
  • the supernatant showed slight haziness as opposed to that of flocculated batch, and hazy supernatant was then filtered by a 0.2- ⁇ m filter.
  • the resulting depth filtrate was visually clear and proceeded to the subsequent purification processing steps which include UFDF-1 , carbon filtration, IEX membrane chromatography, HIC filtration and UFDF-2 described in the Examples 5 - 16.
  • Table 13-1 shows the comparison of quality attributes for 025b O-Ag purified with and without Alum flocculation step.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • Materials Engineering (AREA)
  • Medicinal Chemistry (AREA)
  • Water Supply & Treatment (AREA)
  • Sustainable Development (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Saccharide Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PCT/IB2021/051330 2020-02-21 2021-02-17 Purification of saccharides WO2021165847A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CA3171864A CA3171864A1 (en) 2020-02-21 2021-02-17 Purification of saccharides
IL295713A IL295713A (en) 2020-02-21 2021-02-17 Isolation of saccharides
BR112022015796A BR112022015796A2 (pt) 2020-02-21 2021-02-17 Purificação de sacarídeos
KR1020227032647A KR20220144393A (ko) 2020-02-21 2021-02-17 당류의 정제
CN202180021155.1A CN115362177A (zh) 2020-02-21 2021-02-17 糖类的纯化
AU2021224078A AU2021224078B2 (en) 2020-02-21 2021-02-17 Purification of saccharides
MX2022010355A MX2022010355A (es) 2020-02-21 2021-02-17 Purificacion de sacaridos.
EP21711029.5A EP4107192A1 (en) 2020-02-21 2021-02-17 Purification of saccharides
US17/799,992 US20230085173A1 (en) 2020-02-21 2021-02-17 Purification of saccharides

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202062980134P 2020-02-21 2020-02-21
US62/980,134 2020-02-21
US202063068338P 2020-08-20 2020-08-20
US63/068,338 2020-08-20
US202163143795P 2021-01-30 2021-01-30
US63/143,795 2021-01-30

Publications (1)

Publication Number Publication Date
WO2021165847A1 true WO2021165847A1 (en) 2021-08-26

Family

ID=74867574

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2021/051330 WO2021165847A1 (en) 2020-02-21 2021-02-17 Purification of saccharides

Country Status (11)

Country Link
US (1) US20230085173A1 (es)
EP (1) EP4107192A1 (es)
JP (1) JP2021132644A (es)
KR (1) KR20220144393A (es)
CN (1) CN115362177A (es)
AU (1) AU2021224078B2 (es)
BR (1) BR112022015796A2 (es)
CA (1) CA3171864A1 (es)
IL (1) IL295713A (es)
MX (1) MX2022010355A (es)
WO (1) WO2021165847A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117512031B (zh) * 2023-10-16 2024-06-25 江苏金迪克生物技术股份有限公司 一种肺炎球菌荚膜多糖的纯化方法

Citations (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
GB2220221A (en) 1988-07-02 1990-01-04 Bkl Extrusions Ltd Glazing bead
EP0372501A2 (de) 1988-12-07 1990-06-13 BEHRINGWERKE Aktiengesellschaft Synthetische Antigene, Verfahren zu ihrer Herstellung und ihre Verwendung
EP0378881A1 (en) 1989-01-17 1990-07-25 ENIRICERCHE S.p.A. Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
US4950740A (en) 1987-03-17 1990-08-21 Cetus Corporation Recombinant diphtheria vaccines
WO1991001146A1 (en) 1989-07-14 1991-02-07 Praxis Biologics, Inc. Cytokine and hormone carriers for conjugate vaccines
EP0427347A1 (en) 1989-11-10 1991-05-15 ENIRICERCHE S.p.A. Synthetic peptides useful as universal carriers for the preparation of immunogenic conjugates and their use in the development of synthetic vaccines
EP0471177A2 (en) 1990-08-13 1992-02-19 American Cyanamid Company Filamentous hemagglutinin of bordetella pertussis as a carrier molecule for conjugate vaccines
WO1993015760A1 (en) 1992-02-11 1993-08-19 U.S. Government, As Represented By The Secretary Of The Army Dual carrier immunogenic construct
WO1993017712A2 (en) 1992-03-06 1993-09-16 Biocine Spa Conjugates formed from heat shock proteins and oligo- or polysaccharides
WO1994003208A1 (en) 1992-07-30 1994-02-17 Yeda Research And Development Company Ltd. Conjugates of poorly immunogenic antigens and synthetic peptide carriers and vaccines comprising them
WO1995008348A1 (en) 1993-09-22 1995-03-30 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method of activating soluble carbohydrate using novel cyanylating reagents for the production of immunogenic constructs
EP0689454A1 (en) 1993-03-23 1996-01-03 Smithkline Beecham Biolog VACCINE COMPOSITIONS CONTAINING 3-O DESACETYL MONOPHOSPHORYLIC LIPID
WO1996029094A1 (en) 1995-03-22 1996-09-26 Andrew Lees Producing immunogenic constructs using soluble carbohydrates activated via organic cyanylating reagents
EP0735898A1 (en) 1993-12-23 1996-10-09 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccines
EP0761231A1 (en) 1992-06-25 1997-03-12 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine composition containing adjuvants
US5614382A (en) 1993-03-05 1997-03-25 American Cyanamid Company Plasmid for production of CRM protein and diphtheria toxin
EP0835318A2 (en) 1995-06-29 1998-04-15 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccines against hepatitis c
EP0594610B1 (en) 1990-05-31 1998-09-02 Arne Forsgren PROTEIN D - AN IgD-BINDING PROTEIN OF HAEMOPHILUS INFLUENZAE
US5843711A (en) 1992-05-06 1998-12-01 The Regents Of The University Of California Diphtheria toxin receptor-binding region
WO1998057659A1 (en) 1997-06-14 1998-12-23 Smithkline Beecham Biologicals S.A. Adjuvant compositions for vaccines
WO1998058668A2 (en) 1997-06-20 1998-12-30 Microbiological Research Authority Bordetella pertussis antigens as carriers in vaccinating conjugates and oral vaccines comprising bordetella pertussis fimbriae
WO1999011241A1 (en) 1997-09-05 1999-03-11 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
US5917017A (en) 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
WO1999044636A2 (en) 1998-03-05 1999-09-10 The Medical College Of Ohio Il-12 enhancement of immune responses to t-independent antigens
WO1999052549A1 (en) 1998-04-09 1999-10-21 Smithkline Beecham Biologicals S.A. Adjuvant compositions
WO2000007621A2 (en) 1998-08-05 2000-02-17 Smithkline Beecham Biologicals S.A. Vaccine comprising an iscom consisting of sterol and saponin which is free of additional detergent
WO2000010599A2 (en) 1998-08-19 2000-03-02 North American Vaccine, Inc. IMMUNOGENIC β-PROPIONAMIDO-LINKED POLYSACCHARIDE PROTEIN CONJUGATE USEFUL AS A VACCINE PRODUCED USING AN N-ACRYLOYLATED POLYSACCHARIDE
WO2000023105A2 (en) 1998-10-16 2000-04-27 Smithkline Beecham Biologicals S.A. Adjuvant systems and vaccines
WO2000037105A2 (en) 1998-12-21 2000-06-29 Medimmune, Inc. Streptococcus pneumoniae proteins and immunogenic fragments for vaccines
WO2000039299A2 (en) 1998-12-23 2000-07-06 Shire Biochem Inc. Streptococcus antigens
WO2000056358A2 (en) 1999-03-19 2000-09-28 Smithkline Beecham Biologicals S.A. Vaccine against streptococcus pneumoniae capsular polysaccharides
WO2000061761A2 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
WO2000062800A2 (en) 1999-04-19 2000-10-26 Smithkline Beecham Biologicals Sa Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
WO2001021207A2 (en) 1999-09-24 2001-03-29 Smithkline Beecham Biologicals S.A. Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
WO2001021152A1 (en) 1999-09-24 2001-03-29 Smithkline Beecham Biologicals S.A. Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant
WO2001072337A1 (en) 2000-03-27 2001-10-04 Microbiological Research Authority Proteins for use as carriers in conjugate vaccines
WO2001098334A2 (en) 2000-06-20 2001-12-27 Shire Biochem Inc. Streptococcus antigens
US6455673B1 (en) 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
WO2002091998A2 (en) 2001-05-11 2002-11-21 Aventis Pasteur, Inc. Novel meningitis conjugate vaccine
WO2003054007A2 (en) 2001-12-20 2003-07-03 Shire Biochem Inc. Streptococcus antigens
WO2004081515A2 (en) 2003-03-13 2004-09-23 Glaxosmithkline Biologicals S.A. Purification process for bacterial cytolysin
WO2004083251A2 (en) 2003-03-17 2004-09-30 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
WO2006032499A1 (en) 2004-09-22 2006-03-30 Glaxosmithkline Biologicals S.A. Purification process for bacterial cytolysin
WO2006110381A1 (en) 2005-04-08 2006-10-19 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
WO2007052168A2 (en) 2005-11-01 2007-05-10 Novartis Vaccines And Diagnostics Srl Fed batch culture methods for streptococci
WO2007084856A2 (en) 2006-01-13 2007-07-26 Baxter International Inc. Method for purifying polysaccharides
WO2007116028A2 (en) 2006-04-07 2007-10-18 Glaxosmithkline Biologicals S.A. Conjugate vaccines
WO2008118752A2 (en) 2007-03-23 2008-10-02 Wyeth Shortened purification process for the production of capsular streptococcus pneumoniae polysaccharides
WO2009000826A1 (en) 2007-06-26 2008-12-31 Glaxosmithkline Biologicals S.A. Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
WO2009081276A2 (en) 2007-12-20 2009-07-02 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
WO2010151544A1 (en) 2009-06-22 2010-12-29 Wyeth Llc Immunogenic compositions of staphylococcus aureus antigens
WO2011041003A2 (en) 2009-06-22 2011-04-07 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
WO2011051917A1 (en) 2009-10-30 2011-05-05 Novartis Ag Purification of staphylococcus aureus type 5 and type 8 capsular saccharides
CN103495161A (zh) 2013-10-08 2014-01-08 江苏康泰生物医学技术有限公司 一种多元肺炎球菌荚膜多糖-蛋白质结合物的混合物及其制备方法
WO2014027302A1 (en) 2012-08-16 2014-02-20 Pfizer Inc. Glycoconjugation processes and compositions
WO2014097099A2 (en) 2012-12-20 2014-06-26 Pfizer Inc. Glycoconjugation process
WO2015110940A2 (en) 2014-01-21 2015-07-30 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
WO2015110941A2 (en) 2014-01-21 2015-07-30 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2015121783A1 (en) 2014-02-14 2015-08-20 Pfizer Inc. Immunogenic glycoprotein conjugates
US20190231810A1 (en) * 2012-05-22 2019-08-01 Gnosis S.P.A. Low polydispersity, low molecular weight biotechnological chondroitin sulfate with anti-inflammatory and antiarthritis activity and use thereof in the prevention of osteoarthritis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102660601B (zh) * 2012-04-17 2015-10-28 江苏康泰生物医学技术有限公司 快速纯化细菌荚膜多糖的方法
WO2019050814A1 (en) * 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. ANTI-PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC CONJUGATES POLYSACCHARIDE-PROTEIN CARRIER
CN110172087B (zh) * 2019-05-31 2021-05-11 中国科学院过程工程研究所 一种o抗原亲和介质及其制备方法和应用

Patent Citations (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
US4950740A (en) 1987-03-17 1990-08-21 Cetus Corporation Recombinant diphtheria vaccines
GB2220221A (en) 1988-07-02 1990-01-04 Bkl Extrusions Ltd Glazing bead
EP0372501A2 (de) 1988-12-07 1990-06-13 BEHRINGWERKE Aktiengesellschaft Synthetische Antigene, Verfahren zu ihrer Herstellung und ihre Verwendung
EP0378881A1 (en) 1989-01-17 1990-07-25 ENIRICERCHE S.p.A. Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
WO1991001146A1 (en) 1989-07-14 1991-02-07 Praxis Biologics, Inc. Cytokine and hormone carriers for conjugate vaccines
EP0427347A1 (en) 1989-11-10 1991-05-15 ENIRICERCHE S.p.A. Synthetic peptides useful as universal carriers for the preparation of immunogenic conjugates and their use in the development of synthetic vaccines
EP0594610B1 (en) 1990-05-31 1998-09-02 Arne Forsgren PROTEIN D - AN IgD-BINDING PROTEIN OF HAEMOPHILUS INFLUENZAE
EP0471177A2 (en) 1990-08-13 1992-02-19 American Cyanamid Company Filamentous hemagglutinin of bordetella pertussis as a carrier molecule for conjugate vaccines
WO1993015760A1 (en) 1992-02-11 1993-08-19 U.S. Government, As Represented By The Secretary Of The Army Dual carrier immunogenic construct
WO1993017712A2 (en) 1992-03-06 1993-09-16 Biocine Spa Conjugates formed from heat shock proteins and oligo- or polysaccharides
US5843711A (en) 1992-05-06 1998-12-01 The Regents Of The University Of California Diphtheria toxin receptor-binding region
EP0761231A1 (en) 1992-06-25 1997-03-12 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine composition containing adjuvants
WO1994003208A1 (en) 1992-07-30 1994-02-17 Yeda Research And Development Company Ltd. Conjugates of poorly immunogenic antigens and synthetic peptide carriers and vaccines comprising them
US5614382A (en) 1993-03-05 1997-03-25 American Cyanamid Company Plasmid for production of CRM protein and diphtheria toxin
EP0689454A1 (en) 1993-03-23 1996-01-03 Smithkline Beecham Biolog VACCINE COMPOSITIONS CONTAINING 3-O DESACETYL MONOPHOSPHORYLIC LIPID
WO1995008348A1 (en) 1993-09-22 1995-03-30 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method of activating soluble carbohydrate using novel cyanylating reagents for the production of immunogenic constructs
EP0735898A1 (en) 1993-12-23 1996-10-09 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccines
US6455673B1 (en) 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
US5917017A (en) 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
WO1996029094A1 (en) 1995-03-22 1996-09-26 Andrew Lees Producing immunogenic constructs using soluble carbohydrates activated via organic cyanylating reagents
EP0835318A2 (en) 1995-06-29 1998-04-15 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccines against hepatitis c
WO1998057659A1 (en) 1997-06-14 1998-12-23 Smithkline Beecham Biologicals S.A. Adjuvant compositions for vaccines
WO1998058668A2 (en) 1997-06-20 1998-12-30 Microbiological Research Authority Bordetella pertussis antigens as carriers in vaccinating conjugates and oral vaccines comprising bordetella pertussis fimbriae
WO1999011241A1 (en) 1997-09-05 1999-03-11 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
WO1999044636A2 (en) 1998-03-05 1999-09-10 The Medical College Of Ohio Il-12 enhancement of immune responses to t-independent antigens
WO1999052549A1 (en) 1998-04-09 1999-10-21 Smithkline Beecham Biologicals S.A. Adjuvant compositions
WO2000007621A2 (en) 1998-08-05 2000-02-17 Smithkline Beecham Biologicals S.A. Vaccine comprising an iscom consisting of sterol and saponin which is free of additional detergent
WO2000010599A2 (en) 1998-08-19 2000-03-02 North American Vaccine, Inc. IMMUNOGENIC β-PROPIONAMIDO-LINKED POLYSACCHARIDE PROTEIN CONJUGATE USEFUL AS A VACCINE PRODUCED USING AN N-ACRYLOYLATED POLYSACCHARIDE
WO2000023105A2 (en) 1998-10-16 2000-04-27 Smithkline Beecham Biologicals S.A. Adjuvant systems and vaccines
WO2000037105A2 (en) 1998-12-21 2000-06-29 Medimmune, Inc. Streptococcus pneumoniae proteins and immunogenic fragments for vaccines
WO2000039299A2 (en) 1998-12-23 2000-07-06 Shire Biochem Inc. Streptococcus antigens
WO2000056358A2 (en) 1999-03-19 2000-09-28 Smithkline Beecham Biologicals S.A. Vaccine against streptococcus pneumoniae capsular polysaccharides
WO2000061761A2 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
WO2000062800A2 (en) 1999-04-19 2000-10-26 Smithkline Beecham Biologicals Sa Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
WO2001021207A2 (en) 1999-09-24 2001-03-29 Smithkline Beecham Biologicals S.A. Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
WO2001021152A1 (en) 1999-09-24 2001-03-29 Smithkline Beecham Biologicals S.A. Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant
WO2001072337A1 (en) 2000-03-27 2001-10-04 Microbiological Research Authority Proteins for use as carriers in conjugate vaccines
WO2001098334A2 (en) 2000-06-20 2001-12-27 Shire Biochem Inc. Streptococcus antigens
WO2002091998A2 (en) 2001-05-11 2002-11-21 Aventis Pasteur, Inc. Novel meningitis conjugate vaccine
WO2003054007A2 (en) 2001-12-20 2003-07-03 Shire Biochem Inc. Streptococcus antigens
WO2004081515A2 (en) 2003-03-13 2004-09-23 Glaxosmithkline Biologicals S.A. Purification process for bacterial cytolysin
WO2004083251A2 (en) 2003-03-17 2004-09-30 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
WO2006032499A1 (en) 2004-09-22 2006-03-30 Glaxosmithkline Biologicals S.A. Purification process for bacterial cytolysin
WO2006110381A1 (en) 2005-04-08 2006-10-19 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
WO2007052168A2 (en) 2005-11-01 2007-05-10 Novartis Vaccines And Diagnostics Srl Fed batch culture methods for streptococci
WO2007084856A2 (en) 2006-01-13 2007-07-26 Baxter International Inc. Method for purifying polysaccharides
WO2007116028A2 (en) 2006-04-07 2007-10-18 Glaxosmithkline Biologicals S.A. Conjugate vaccines
WO2008118752A2 (en) 2007-03-23 2008-10-02 Wyeth Shortened purification process for the production of capsular streptococcus pneumoniae polysaccharides
WO2009000826A1 (en) 2007-06-26 2008-12-31 Glaxosmithkline Biologicals S.A. Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
WO2009081276A2 (en) 2007-12-20 2009-07-02 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
WO2011041003A2 (en) 2009-06-22 2011-04-07 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
WO2010151544A1 (en) 2009-06-22 2010-12-29 Wyeth Llc Immunogenic compositions of staphylococcus aureus antigens
WO2011051917A1 (en) 2009-10-30 2011-05-05 Novartis Ag Purification of staphylococcus aureus type 5 and type 8 capsular saccharides
US20190231810A1 (en) * 2012-05-22 2019-08-01 Gnosis S.P.A. Low polydispersity, low molecular weight biotechnological chondroitin sulfate with anti-inflammatory and antiarthritis activity and use thereof in the prevention of osteoarthritis
WO2014027302A1 (en) 2012-08-16 2014-02-20 Pfizer Inc. Glycoconjugation processes and compositions
WO2014097099A2 (en) 2012-12-20 2014-06-26 Pfizer Inc. Glycoconjugation process
CN103495161A (zh) 2013-10-08 2014-01-08 江苏康泰生物医学技术有限公司 一种多元肺炎球菌荚膜多糖-蛋白质结合物的混合物及其制备方法
WO2015110940A2 (en) 2014-01-21 2015-07-30 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
WO2015110941A2 (en) 2014-01-21 2015-07-30 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2015121783A1 (en) 2014-02-14 2015-08-20 Pfizer Inc. Immunogenic glycoprotein conjugates

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BARALDOI ET AL., INFECT IMMUN, vol. 72, 2004, pages 4884 - 4887
CAS, no. 9002-93-1
DOUGLAS ET AL., J. BACTERIOL., vol. 169, no. 11, 1987, pages 4967 - 4971
FALUGI ET AL., EUR J IMMUNOL, vol. 31, 2001, pages 3816 - 3824
FATTOM ET AL., INFECT IMMUN., vol. 58, no. 7, 1990, pages 2367 - 74
KUO ET AL., INFECT IMMUN, vol. 63, 1995, pages 2706 - 2713
NICHOLLSYOULE: "Genetically Engineered Toxins", 1992, MAECEL DEKKER INC.
UCHIDA ET AL., J. BIOL. CHEM., vol. 218, 1973, pages 3838 - 3844
UCHIDA ET AL., NATURE NEW BIOLOGY, vol. 233, 1971, pages 8 - 11

Also Published As

Publication number Publication date
MX2022010355A (es) 2022-09-21
JP2021132644A (ja) 2021-09-13
AU2021224078B2 (en) 2024-01-18
EP4107192A1 (en) 2022-12-28
KR20220144393A (ko) 2022-10-26
CN115362177A (zh) 2022-11-18
AU2021224078A1 (en) 2022-09-08
CA3171864A1 (en) 2021-08-26
IL295713A (en) 2022-10-01
US20230085173A1 (en) 2023-03-16
BR112022015796A2 (pt) 2022-10-11

Similar Documents

Publication Publication Date Title
AU2020225578C1 (en) Methods for purifying bacterial polysaccharides
US20240026405A1 (en) Method for Removal of Impurities from Bacterial Capsular Polysaccharide Based Preparations
US7582459B2 (en) Process for producing a capsular polysaccharide for use in conjugate vaccines
AU2021224078B2 (en) Purification of saccharides
RU2816593C1 (ru) Очистка сахаридов
TW202337491A (zh) 包含結合之莢膜醣抗原的免疫原組合物及其用途
RU2817197C2 (ru) Способы очистки бактериальных полисахаридов
US20230383324A1 (en) Methods for purifying bacterial polysaccharides
WO2023161817A1 (en) Methods for incorporating azido groups in bacterial capsular polysaccharides
EA041065B1 (ru) Способ удаления примесей из препаратов на основе бактериальных капсулярных полисахаридов

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21711029

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 202217044502

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2021224078

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 3171864

Country of ref document: CA

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112022015796

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2021224078

Country of ref document: AU

Date of ref document: 20210217

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20227032647

Country of ref document: KR

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021711029

Country of ref document: EP

Effective date: 20220921

ENP Entry into the national phase

Ref document number: 112022015796

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20220810

WWE Wipo information: entry into national phase

Ref document number: 522440229

Country of ref document: SA